Motif 922 (n=204)
Position-wise Probabilities
Download
| uniprot | genes | site | source | protein | function |
|---|---|---|---|---|---|
| A6NE02 | BTBD17 | S42 | ochoa | BTB/POZ domain-containing protein 17 (Galectin-3-binding protein-like) | None |
| O00273 | DFFA | S107 | ochoa | DNA fragmentation factor subunit alpha (DNA fragmentation factor 45 kDa subunit) (DFF-45) (Inhibitor of CAD) (ICAD) | Inhibitor of the caspase-activated DNase (DFF40). |
| O00443 | PIK3C2A | S60 | ochoa | Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PI3K-C2-alpha) (PtdIns-3-kinase C2 subunit alpha) (EC 2.7.1.137) (EC 2.7.1.153) (EC 2.7.1.154) (Phosphoinositide 3-kinase-C2-alpha) | Generates phosphatidylinositol 3-phosphate (PtdIns3P) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as second messengers. Has a role in several intracellular trafficking events. Functions in insulin signaling and secretion. Required for translocation of the glucose transporter SLC2A4/GLUT4 to the plasma membrane and glucose uptake in response to insulin-mediated RHOQ activation. Regulates insulin secretion through two different mechanisms: involved in glucose-induced insulin secretion downstream of insulin receptor in a pathway that involves AKT1 activation and TBC1D4/AS160 phosphorylation, and participates in the late step of insulin granule exocytosis probably in insulin granule fusion. Synthesizes PtdIns3P in response to insulin signaling. Functions in clathrin-coated endocytic vesicle formation and distribution. Regulates dynamin-independent endocytosis, probably by recruiting EEA1 to internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on large dense core vesicles. Participates in calcium induced contraction of vascular smooth muscle by regulating myosin light chain (MLC) phosphorylation through a mechanism involving Rho kinase-dependent phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role in the EGF signaling cascade. May be involved in mitosis and UV-induced damage response. Required for maintenance of normal renal structure and function by supporting normal podocyte function. Involved in the regulation of ciliogenesis and trafficking of ciliary components (PubMed:31034465). {ECO:0000269|PubMed:10766823, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232, ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:31034465, ECO:0000269|PubMed:9337861}. |
| O14958 | CASQ2 | S36 | ochoa | Calsequestrin-2 (Calsequestrin, cardiac muscle isoform) | Calsequestrin is a high-capacity, moderate affinity, calcium-binding protein and thus acts as an internal calcium store in muscle. Calcium ions are bound by clusters of acidic residues at the protein surface, especially at the interface between subunits. Can bind around 60 Ca(2+) ions. Regulates the release of lumenal Ca(2+) via the calcium release channel RYR2; this plays an important role in triggering muscle contraction. Plays a role in excitation-contraction coupling in the heart and in regulating the rate of heart beats. {ECO:0000269|PubMed:16908766, ECO:0000269|PubMed:17881003, ECO:0000269|PubMed:18399795, ECO:0000269|PubMed:21416293}. |
| O15063 | GARRE1 | S359 | ochoa | Granule associated Rac and RHOG effector protein 1 (GARRE1) | Acts as an effector of RAC1 (PubMed:31871319). Associates with CCR4-NOT complex which is one of the major cellular mRNA deadenylases and is linked to various cellular processes including bulk mRNA degradation, miRNA-mediated repression, translational repression during translational initiation and general transcription regulation (PubMed:29395067). May also play a role in miRNA silencing machinery (PubMed:29395067). {ECO:0000269|PubMed:29395067, ECO:0000269|PubMed:31871319}. |
| O15194 | CTDSPL | S28 | ochoa | CTD small phosphatase-like protein (CTDSP-like) (EC 3.1.3.16) (Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 3) (NIF-like protein) (Nuclear LIM interactor-interacting factor 1) (NLI-interacting factor 1) (Protein YA22) (hYA22) (RBSP3) (Small C-terminal domain phosphatase 3) (SCP3) (Small CTD phosphatase 3) | Recruited by REST to neuronal genes that contain RE-1 elements, leading to neuronal gene silencing in non-neuronal cells (By similarity). Preferentially catalyzes the dephosphorylation of 'Ser-5' within the tandem 7 residue repeats in the C-terminal domain (CTD) of the largest RNA polymerase II subunit POLR2A. Negatively regulates RNA polymerase II transcription, possibly by controlling the transition from initiation/capping to processive transcript elongation. {ECO:0000250, ECO:0000269|PubMed:12721286}. |
| O43182 | ARHGAP6 | S366 | ochoa | Rho GTPase-activating protein 6 (Rho-type GTPase-activating protein 6) (Rho-type GTPase-activating protein RhoGAPX-1) | GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Could regulate the interactions of signaling molecules with the actin cytoskeleton. Promotes continuous elongation of cytoplasmic processes during cell motility and simultaneous retraction of the cell body changing the cell morphology. {ECO:0000269|PubMed:10699171}. |
| O60331 | PIP5K1C | S476 | ochoa | Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma (PIP5K1gamma) (PtdIns(4)P-5-kinase 1 gamma) (EC 2.7.1.68) (Type I phosphatidylinositol 4-phosphate 5-kinase gamma) | Catalyzes the phosphorylation of phosphatidylinositol 4-phosphate (PtdIns(4)P/PI4P) to form phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2/PIP2), a lipid second messenger that regulates several cellular processes such as signal transduction, vesicle trafficking, actin cytoskeleton dynamics, cell adhesion, and cell motility (PubMed:12422219, PubMed:22942276). PtdIns(4,5)P2 can directly act as a second messenger or can be utilized as a precursor to generate other second messengers: inositol 1,4,5-trisphosphate (IP3), diacylglycerol (DAG) or phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3/PIP3) (Probable). PIP5K1A-mediated phosphorylation of PtdIns(4)P is the predominant pathway for PtdIns(4,5)P2 synthesis (By similarity). Together with PIP5K1A, is required for phagocytosis, both enzymes regulating different types of actin remodeling at sequential steps (By similarity). Promotes particle attachment by generating the pool of PtdIns(4,5)P2 that induces controlled actin depolymerization to facilitate Fc-gamma-R clustering. Mediates RAC1-dependent reorganization of actin filaments. Required for synaptic vesicle transport (By similarity). Controls the plasma membrane pool of PtdIns(4,5)P2 implicated in synaptic vesicle endocytosis and exocytosis (PubMed:12847086). Plays a role in endocytosis mediated by clathrin and AP-2 (adaptor protein complex 2) (PubMed:12847086). Required for clathrin-coated pits assembly at the synapse (PubMed:17261850). Participates in cell junction assembly (PubMed:17261850). Modulates adherens junctions formation by facilitating CDH1/cadherin trafficking (PubMed:17261850). Required for focal adhesion dynamics. Modulates the targeting of talins (TLN1 and TLN2) to the plasma membrane and their efficient assembly into focal adhesions (PubMed:12422219). Regulates the interaction between talins (TLN1 and TLN2) and beta-integrins (PubMed:12422219). Required for uropodium formation and retraction of the cell rear during directed migration (By similarity). Has a role in growth factor-stimulated directional cell migration and adhesion (By similarity). Required for talin assembly into nascent adhesions forming at the leading edge toward the direction of the growth factor (PubMed:17635937). Negative regulator of T-cell activation and adhesion (By similarity). Negatively regulates integrin alpha-L/beta-2 (LFA-1) polarization and adhesion induced by T-cell receptor (By similarity). Together with PIP5K1A has a role during embryogenesis and together with PIP5K1B may have a role immediately after birth (By similarity). {ECO:0000250|UniProtKB:O70161, ECO:0000250|UniProtKB:P70182, ECO:0000269|PubMed:12422219, ECO:0000269|PubMed:12847086, ECO:0000269|PubMed:17261850, ECO:0000269|PubMed:17635937, ECO:0000269|PubMed:22942276, ECO:0000305|PubMed:19889969}. |
| O60356 | NUPR1 | S22 | ochoa | Nuclear protein 1 (Candidate of metastasis 1) (Protein p8) | Transcription regulator that converts stress signals into a program of gene expression that empowers cells with resistance to the stress induced by a change in their microenvironment. Thereby participates in the regulation of many processes namely cell-cycle, apoptosis, autophagy and DNA repair responses (PubMed:11056169, PubMed:11940591, PubMed:16300740, PubMed:16478804, PubMed:18690848, PubMed:19650074, PubMed:19723804, PubMed:20181828, PubMed:22565310, PubMed:22858377, PubMed:30451898). Controls cell cycle progression and protects cells from genotoxic stress induced by doxorubicin through the complex formation with TP53 and EP300 that binds CDKN1A promoter leading to transcriptional induction of CDKN1A (PubMed:18690848). Protects pancreatic cancer cells from stress-induced cell death by binding the RELB promoter and activating its transcription, leading to IER3 transactivation (PubMed:22565310). Negatively regulates apoptosis through interaction with PTMA (PubMed:16478804). Inhibits autophagy-induced apoptosis in cardiac cells through FOXO3 interaction, inducing cytoplasmic translocation of FOXO3 thereby preventing the FOXO3 association with the pro-autophagic BNIP3 promoter (PubMed:20181828). Inhibits cell growth and facilitates programmed cell death by apoptosis after adriamycin-induced DNA damage through transactivation of TP53 (By similarity). Regulates methamphetamine-induced apoptosis and autophagy through DDIT3-mediated endoplasmic reticulum stress pathway (By similarity). Participates in DNA repair following gamma-irradiation by facilitating DNA access of the transcription machinery through interaction with MSL1 leading to inhibition of histone H4' Lys-16' acetylation (H4K16ac) (PubMed:19650074). Coactivator of PAX2 transcription factor activity, both by recruiting EP300 to increase PAX2 transcription factor activity and by binding PAXIP1 to suppress PAXIP1-induced inhibition on PAX2 (PubMed:11940591). Positively regulates cell cycle progression through interaction with COPS5 inducing cytoplasmic translocation of CDKN1B leading to the CDKN1B degradation (PubMed:16300740). Coordinates, through its interaction with EP300, the assiociation of MYOD1, EP300 and DDX5 to the MYOG promoter, leading to inhibition of cell-cycle progression and myogenic differentiation promotion (PubMed:19723804). Negatively regulates beta cell proliferation via inhibition of cell-cycle regulatory genes expression through the suppression of their promoter activities (By similarity). Also required for LHB expression and ovarian maturation (By similarity). Exacerbates CNS inflammation and demyelination upon cuprizone treatment (By similarity). {ECO:0000250|UniProtKB:O54842, ECO:0000250|UniProtKB:Q9WTK0, ECO:0000269|PubMed:11056169, ECO:0000269|PubMed:11940591, ECO:0000269|PubMed:16300740, ECO:0000269|PubMed:16478804, ECO:0000269|PubMed:18690848, ECO:0000269|PubMed:19650074, ECO:0000269|PubMed:19723804, ECO:0000269|PubMed:20181828, ECO:0000269|PubMed:22565310, ECO:0000269|PubMed:22858377, ECO:0000269|PubMed:30451898}. |
| O60701 | UGDH | S349 | ochoa | UDP-glucose 6-dehydrogenase (UDP-Glc dehydrogenase) (UDP-GlcDH) (UDPGDH) (EC 1.1.1.22) | Catalyzes the formation of UDP-alpha-D-glucuronate, a constituent of complex glycosaminoglycans (PubMed:21502315, PubMed:21961565, PubMed:22123821, PubMed:23106432, PubMed:25478983, PubMed:27966912, PubMed:30420606, PubMed:30457329). Required for the biosynthesis of chondroitin sulfate and heparan sulfate. Required for embryonic development via its role in the biosynthesis of glycosaminoglycans (By similarity). Required for proper brain and neuronal development (PubMed:32001716). {ECO:0000250|UniProtKB:O70475, ECO:0000269|PubMed:21502315, ECO:0000269|PubMed:21961565, ECO:0000269|PubMed:22123821, ECO:0000269|PubMed:23106432, ECO:0000269|PubMed:25478983, ECO:0000269|PubMed:27966912, ECO:0000269|PubMed:30420606, ECO:0000269|PubMed:30457329, ECO:0000269|PubMed:32001716}. |
| O60869 | EDF1 | S53 | ochoa | Endothelial differentiation-related factor 1 (EDF-1) (Multiprotein-bridging factor 1) (MBF1) | Transcriptional coactivator stimulating NR5A1 and ligand-dependent NR1H3/LXRA and PPARG transcriptional activities. Enhances the DNA-binding activity of ATF1, ATF2, CREB1 and NR5A1. Regulates nitric oxid synthase activity probably by sequestering calmodulin in the cytoplasm. May function in endothelial cells differentiation, hormone-induced cardiomyocytes hypertrophy and lipid metabolism. {ECO:0000269|PubMed:10567391, ECO:0000269|PubMed:12040021, ECO:0000269|PubMed:15112053, ECO:0000269|PubMed:9813014}. |
| O75955 | FLOT1 | Y149 | psp | Flotillin-1 | May act as a scaffolding protein within caveolar membranes, functionally participating in formation of caveolae or caveolae-like vesicles. |
| O95677 | EYA4 | S361 | ochoa | Protein phosphatase EYA4 (EC 3.1.3.48) (Eyes absent homolog 4) | Tyrosine phosphatase that specifically dephosphorylates 'Tyr-142' of histone H2AX (H2AXY142ph). 'Tyr-142' phosphorylation of histone H2AX plays a central role in DNA repair and acts as a mark that distinguishes between apoptotic and repair responses to genotoxic stress. Promotes efficient DNA repair by dephosphorylating H2AX, promoting the recruitment of DNA repair complexes containing MDC1. Its function as histone phosphatase probably explains its role in transcription regulation during organogenesis. May be involved in development of the eye (By similarity). {ECO:0000250|UniProtKB:Q99502}. |
| O95831 | AIFM1 | S268 | ochoa | Apoptosis-inducing factor 1, mitochondrial (EC 1.6.99.-) (Programmed cell death protein 8) | Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nucleus induces 'parthanatos' i.e. caspase-independent fragmentation of chromosomal DNA (PubMed:20362274). Binds to DNA in a sequence-independent manner (PubMed:27178839). Interacts with EIF3G, and thereby inhibits the EIF3 machinery and protein synthesis, and activates caspase-7 to amplify apoptosis (PubMed:17094969). Plays a critical role in caspase-independent, pyknotic cell death in hydrogen peroxide-exposed cells (PubMed:19418225). In contrast, participates in normal mitochondrial metabolism. Plays an important role in the regulation of respiratory chain biogenesis by interacting with CHCHD4 and controlling CHCHD4 mitochondrial import (PubMed:26004228). {ECO:0000250|UniProtKB:Q9Z0X1, ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225, ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327, ECO:0000269|PubMed:26004228, ECO:0000269|PubMed:27178839, ECO:0000269|PubMed:33168626}.; FUNCTION: [Isoform 4]: Has NADH oxidoreductase activity. Does not induce nuclear apoptosis. {ECO:0000269|PubMed:16644725}.; FUNCTION: [Isoform 5]: Pro-apoptotic isoform. {ECO:0000269|PubMed:16365034}. |
| P00519 | ABL1 | S683 | ochoa | Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150) | Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9 (PubMed:22810897). Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. In response to oxidative stress, phosphorylates serine/threonine kinase PRKD2 at 'Tyr-717' (PubMed:28428613). ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage-induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 also acts as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin-associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1. Regulates T-cell differentiation in a TBX21-dependent manner (By similarity). Positively regulates chemokine-mediated T-cell migration, polarization, and homing to lymph nodes and immune-challenged tissues, potentially via activation of NEDD9/HEF1 and RAP1 (By similarity). Phosphorylates TBX21 on tyrosine residues leading to an enhancement of its transcriptional activator activity (By similarity). {ECO:0000250|UniProtKB:P00520, ECO:0000269|PubMed:10391250, ECO:0000269|PubMed:11971963, ECO:0000269|PubMed:12379650, ECO:0000269|PubMed:12531427, ECO:0000269|PubMed:12672821, ECO:0000269|PubMed:15031292, ECO:0000269|PubMed:15556646, ECO:0000269|PubMed:15657060, ECO:0000269|PubMed:15886098, ECO:0000269|PubMed:16424036, ECO:0000269|PubMed:16678104, ECO:0000269|PubMed:16943190, ECO:0000269|PubMed:17306540, ECO:0000269|PubMed:17623672, ECO:0000269|PubMed:18328268, ECO:0000269|PubMed:18945674, ECO:0000269|PubMed:19891780, ECO:0000269|PubMed:20357770, ECO:0000269|PubMed:20417104, ECO:0000269|PubMed:22810897, ECO:0000269|PubMed:28428613, ECO:0000269|PubMed:9037071, ECO:0000269|PubMed:9144171, ECO:0000269|PubMed:9461559}. |
| P05230 | FGF1 | S131 | psp | Fibroblast growth factor 1 (FGF-1) (Acidic fibroblast growth factor) (aFGF) (Endothelial cell growth factor) (ECGF) (Heparin-binding growth factor 1) (HBGF-1) | Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as a potent mitogen in vitro. Acts as a ligand for FGFR1 and integrins. Binds to FGFR1 in the presence of heparin leading to FGFR1 dimerization and activation via sequential autophosphorylation on tyrosine residues which act as docking sites for interacting proteins, leading to the activation of several signaling cascades. Binds to integrin ITGAV:ITGB3. Its binding to integrin, subsequent ternary complex formation with integrin and FGFR1, and the recruitment of PTPN11 to the complex are essential for FGF1 signaling. Induces the phosphorylation and activation of FGFR1, FRS2, MAPK3/ERK1, MAPK1/ERK2 and AKT1 (PubMed:18441324, PubMed:20422052). Can induce angiogenesis (PubMed:23469107). {ECO:0000269|PubMed:16597617, ECO:0000269|PubMed:18441324, ECO:0000269|PubMed:20145243, ECO:0000269|PubMed:20422052, ECO:0000269|PubMed:23469107, ECO:0000269|PubMed:8663044}. |
| P06213 | INSR | S1217 | psp | Insulin receptor (IR) (EC 2.7.10.1) (CD antigen CD220) [Cleaved into: Insulin receptor subunit alpha; Insulin receptor subunit beta] | Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosine residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity). {ECO:0000250|UniProtKB:P15208, ECO:0000269|PubMed:12138094, ECO:0000269|PubMed:16314505, ECO:0000269|PubMed:16831875, ECO:0000269|PubMed:8257688, ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8452530, ECO:0000269|PubMed:9428692}. |
| P06493 | CDK1 | Y160 | ochoa | Cyclin-dependent kinase 1 (CDK1) (EC 2.7.11.22) (EC 2.7.11.23) (Cell division control protein 2 homolog) (Cell division protein kinase 1) (p34 protein kinase) | Plays a key role in the control of the eukaryotic cell cycle by modulating the centrosome cycle as well as mitotic onset; promotes G2-M transition via association with multiple interphase cyclins (PubMed:16407259, PubMed:16933150, PubMed:17459720, PubMed:18356527, PubMed:19509060, PubMed:19917720, PubMed:20171170, PubMed:20935635, PubMed:20937773, PubMed:21063390, PubMed:2188730, PubMed:23355470, PubMed:2344612, PubMed:23601106, PubMed:23602554, PubMed:25556658, PubMed:26829474, PubMed:27814491, PubMed:30139873, PubMed:30704899). Phosphorylates PARVA/actopaxin, APC, AMPH, APC, BARD1, Bcl-xL/BCL2L1, BRCA2, CALD1, CASP8, CDC7, CDC20, CDC25A, CDC25C, CC2D1A, CENPA, CSNK2 proteins/CKII, FZR1/CDH1, CDK7, CEBPB, CHAMP1, DMD/dystrophin, EEF1 proteins/EF-1, EZH2, KIF11/EG5, EGFR, FANCG, FOS, GFAP, GOLGA2/GM130, GRASP1, UBE2A/hHR6A, HIST1H1 proteins/histone H1, HMGA1, HIVEP3/KRC, KAT5, LMNA, LMNB, LBR, MKI67, LATS1, MAP1B, MAP4, MARCKS, MCM2, MCM4, MKLP1, MLST8, MYB, NEFH, NFIC, NPC/nuclear pore complex, PITPNM1/NIR2, NPM1, NCL, NUCKS1, NPM1/numatrin, ORC1, PRKAR2A, EEF1E1/p18, EIF3F/p47, p53/TP53, NONO/p54NRB, PAPOLA, PLEC/plectin, RB1, TPPP, UL40/R2, RAB4A, RAP1GAP, RBBP8/CtIP, RCC1, RPS6KB1/S6K1, KHDRBS1/SAM68, ESPL1, SKI, BIRC5/survivin, STIP1, TEX14, beta-tubulins, MAPT/TAU, NEDD1, VIM/vimentin, TK1, FOXO1, RUNX1/AML1, SAMHD1, SIRT2, CGAS and RUNX2 (PubMed:16407259, PubMed:16933150, PubMed:17459720, PubMed:18356527, PubMed:19202191, PubMed:19509060, PubMed:19917720, PubMed:20171170, PubMed:20935635, PubMed:20937773, PubMed:21063390, PubMed:2188730, PubMed:23355470, PubMed:2344612, PubMed:23601106, PubMed:23602554, PubMed:25012651, PubMed:25556658, PubMed:26829474, PubMed:27814491, PubMed:30704899, PubMed:32351706, PubMed:34741373). CDK1/CDC2-cyclin-B controls pronuclear union in interphase fertilized eggs (PubMed:18480403, PubMed:20360007). Essential for early stages of embryonic development (PubMed:18480403, PubMed:20360007). During G2 and early mitosis, CDC25A/B/C-mediated dephosphorylation activates CDK1/cyclin complexes which phosphorylate several substrates that trigger at least centrosome separation, Golgi dynamics, nuclear envelope breakdown and chromosome condensation (PubMed:18480403, PubMed:20360007, PubMed:2188730, PubMed:2344612, PubMed:30139873). Once chromosomes are condensed and aligned at the metaphase plate, CDK1 activity is switched off by WEE1- and PKMYT1-mediated phosphorylation to allow sister chromatid separation, chromosome decondensation, reformation of the nuclear envelope and cytokinesis (PubMed:18480403, PubMed:20360007). Phosphorylates KRT5 during prometaphase and metaphase (By similarity). Inactivated by PKR/EIF2AK2- and WEE1-mediated phosphorylation upon DNA damage to stop cell cycle and genome replication at the G2 checkpoint thus facilitating DNA repair (PubMed:20360007). Reactivated after successful DNA repair through WIP1-dependent signaling leading to CDC25A/B/C-mediated dephosphorylation and restoring cell cycle progression (PubMed:20395957). Catalyzes lamin (LMNA, LMNB1 and LMNB2) phosphorylation at the onset of mitosis, promoting nuclear envelope breakdown (PubMed:2188730, PubMed:2344612, PubMed:37788673). In proliferating cells, CDK1-mediated FOXO1 phosphorylation at the G2-M phase represses FOXO1 interaction with 14-3-3 proteins and thereby promotes FOXO1 nuclear accumulation and transcription factor activity, leading to cell death of postmitotic neurons (PubMed:18356527). The phosphorylation of beta-tubulins regulates microtubule dynamics during mitosis (PubMed:16371510). NEDD1 phosphorylation promotes PLK1-mediated NEDD1 phosphorylation and subsequent targeting of the gamma-tubulin ring complex (gTuRC) to the centrosome, an important step for spindle formation (PubMed:19509060). In addition, CC2D1A phosphorylation regulates CC2D1A spindle pole localization and association with SCC1/RAD21 and centriole cohesion during mitosis (PubMed:20171170). The phosphorylation of Bcl-xL/BCL2L1 after prolongated G2 arrest upon DNA damage triggers apoptosis (PubMed:19917720). In contrast, CASP8 phosphorylation during mitosis prevents its activation by proteolysis and subsequent apoptosis (PubMed:20937773). This phosphorylation occurs in cancer cell lines, as well as in primary breast tissues and lymphocytes (PubMed:20937773). EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing (PubMed:20935635). CALD1 phosphorylation promotes Schwann cell migration during peripheral nerve regeneration (By similarity). CDK1-cyclin-B complex phosphorylates NCKAP5L and mediates its dissociation from centrosomes during mitosis (PubMed:26549230). Regulates the amplitude of the cyclic expression of the core clock gene BMAL1 by phosphorylating its transcriptional repressor NR1D1, and this phosphorylation is necessary for SCF(FBXW7)-mediated ubiquitination and proteasomal degradation of NR1D1 (PubMed:27238018). Phosphorylates EML3 at 'Thr-881' which is essential for its interaction with HAUS augmin-like complex and TUBG1 (PubMed:30723163). Phosphorylates CGAS during mitosis, leading to its inhibition, thereby preventing CGAS activation by self DNA during mitosis (PubMed:32351706). Phosphorylates SKA3 on multiple sites during mitosis which promotes SKA3 binding to the NDC80 complex and anchoring of the SKA complex to kinetochores, to enable stable attachment of mitotic spindle microtubules to kinetochores (PubMed:28479321, PubMed:31804178, PubMed:32491969). {ECO:0000250|UniProtKB:P11440, ECO:0000250|UniProtKB:P39951, ECO:0000269|PubMed:16371510, ECO:0000269|PubMed:16407259, ECO:0000269|PubMed:16933150, ECO:0000269|PubMed:17459720, ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:18480403, ECO:0000269|PubMed:19202191, ECO:0000269|PubMed:19509060, ECO:0000269|PubMed:19917720, ECO:0000269|PubMed:20171170, ECO:0000269|PubMed:20360007, ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:20937773, ECO:0000269|PubMed:21063390, ECO:0000269|PubMed:2188730, ECO:0000269|PubMed:23355470, ECO:0000269|PubMed:2344612, ECO:0000269|PubMed:23601106, ECO:0000269|PubMed:23602554, ECO:0000269|PubMed:25012651, ECO:0000269|PubMed:25556658, ECO:0000269|PubMed:26549230, ECO:0000269|PubMed:26829474, ECO:0000269|PubMed:27238018, ECO:0000269|PubMed:27814491, ECO:0000269|PubMed:28479321, ECO:0000269|PubMed:30139873, ECO:0000269|PubMed:30704899, ECO:0000269|PubMed:30723163, ECO:0000269|PubMed:31804178, ECO:0000269|PubMed:32351706, ECO:0000269|PubMed:32491969, ECO:0000269|PubMed:34741373, ECO:0000269|PubMed:37788673}.; FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. {ECO:0000269|PubMed:21516087}. |
| P08047 | SP1 | S728 | psp | Transcription factor Sp1 | Transcription factor that can activate or repress transcription in response to physiological and pathological stimuli. Binds with high affinity to GC-rich motifs and regulates the expression of a large number of genes involved in a variety of processes such as cell growth, apoptosis, differentiation and immune responses. Highly regulated by post-translational modifications (phosphorylations, sumoylation, proteolytic cleavage, glycosylation and acetylation). Also binds the PDGFR-alpha G-box promoter. May have a role in modulating the cellular response to DNA damage. Implicated in chromatin remodeling. Plays an essential role in the regulation of FE65 gene expression. In complex with ATF7IP, maintains telomerase activity in cancer cells by inducing TERT and TERC gene expression. Isoform 3 is a stronger activator of transcription than isoform 1. Positively regulates the transcription of the core clock component BMAL1 (PubMed:10391891, PubMed:11371615, PubMed:11904305, PubMed:14593115, PubMed:16377629, PubMed:16478997, PubMed:16943418, PubMed:17049555, PubMed:18171990, PubMed:18199680, PubMed:18239466, PubMed:18513490, PubMed:18619531, PubMed:19193796, PubMed:20091743, PubMed:21046154, PubMed:21798247). Plays a role in the recruitment of SMARCA4/BRG1 on the c-FOS promoter. Plays a role in protecting cells against oxidative stress following brain injury by regulating the expression of RNF112 (By similarity). {ECO:0000250|UniProtKB:O89090, ECO:0000250|UniProtKB:Q01714, ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:11371615, ECO:0000269|PubMed:11904305, ECO:0000269|PubMed:14593115, ECO:0000269|PubMed:16377629, ECO:0000269|PubMed:16478997, ECO:0000269|PubMed:16943418, ECO:0000269|PubMed:17049555, ECO:0000269|PubMed:18171990, ECO:0000269|PubMed:18199680, ECO:0000269|PubMed:18239466, ECO:0000269|PubMed:18513490, ECO:0000269|PubMed:18619531, ECO:0000269|PubMed:19193796, ECO:0000269|PubMed:20091743, ECO:0000269|PubMed:21046154, ECO:0000269|PubMed:21798247}. |
| P08621 | SNRNP70 | S320 | ochoa | U1 small nuclear ribonucleoprotein 70 kDa (U1 snRNP 70 kDa) (U1-70K) (snRNP70) | Component of the spliceosomal U1 snRNP, which is essential for recognition of the pre-mRNA 5' splice-site and the subsequent assembly of the spliceosome (PubMed:19325628, PubMed:25555158). SNRNP70 binds to the loop I region of U1-snRNA (PubMed:19325628, PubMed:2467746, PubMed:25555158). {ECO:0000269|PubMed:19325628, ECO:0000269|PubMed:2467746, ECO:0000269|PubMed:25555158}.; FUNCTION: [Isoform 3]: Truncated isoforms that lack the RRM domain cannot bind U1-snRNA. {ECO:0000269|PubMed:2467746}.; FUNCTION: [Isoform 4]: Truncated isoforms that lack the RRM domain cannot bind U1-snRNA. {ECO:0000269|PubMed:2467746}. |
| P0C7M8 | CLEC2L | S55 | ochoa | C-type lectin domain family 2 member L | None |
| P10243 | MYBL1 | S626 | ochoa | Myb-related protein A (A-Myb) (Myb-like protein 1) | Transcription factor that specifically recognizes the sequence 5'-YAAC[GT]G-3' (PubMed:7987850, PubMed:8058310). Acts as a master regulator of male meiosis by promoting expression of piRNAs: activates expression of both piRNA precursor RNAs and expression of protein-coding genes involved in piRNA metabolism (By similarity). The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and governs the methylation and subsequent repression of transposons, which is essential for the germline integrity (By similarity). Transcriptional activator of SOX30 (By similarity). {ECO:0000250|UniProtKB:P51960, ECO:0000269|PubMed:7987850, ECO:0000269|PubMed:8058310}. |
| P12956 | XRCC6 | S314 | ochoa | X-ray repair cross-complementing protein 6 (EC 3.6.4.-) (EC 4.2.99.-) (5'-deoxyribose-5-phosphate lyase Ku70) (5'-dRP lyase Ku70) (70 kDa subunit of Ku antigen) (ATP-dependent DNA helicase 2 subunit 1) (ATP-dependent DNA helicase II 70 kDa subunit) (CTC box-binding factor 75 kDa subunit) (CTC75) (CTCBF) (DNA repair protein XRCC6) (Lupus Ku autoantigen protein p70) (Ku70) (Thyroid-lupus autoantigen) (TLAA) (X-ray repair complementing defective repair in Chinese hamster cells 6) | Single-stranded DNA-dependent ATP-dependent helicase that plays a key role in DNA non-homologous end joining (NHEJ) by recruiting DNA-PK to DNA (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Required for double-strand break repair and V(D)J recombination (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Also has a role in chromosome translocation (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Has a role in chromosome translocation (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). The DNA helicase II complex binds preferentially to fork-like ends of double-stranded DNA in a cell cycle-dependent manner (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). It works in the 3'-5' direction (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). During NHEJ, the XRCC5-XRRC6 dimer performs the recognition step: it recognizes and binds to the broken ends of the DNA and protects them from further resection (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Binding to DNA may be mediated by XRCC6 (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). The XRCC5-XRRC6 dimer acts as a regulatory subunit of the DNA-dependent protein kinase complex DNA-PK by increasing the affinity of the catalytic subunit PRKDC to DNA by 100-fold (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). The XRCC5-XRRC6 dimer is probably involved in stabilizing broken DNA ends and bringing them together (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). The assembly of the DNA-PK complex to DNA ends is required for the NHEJ ligation step (PubMed:11493912, PubMed:12145306, PubMed:20493174, PubMed:2466842, PubMed:7957065, PubMed:8621488, PubMed:9742108). Probably also acts as a 5'-deoxyribose-5-phosphate lyase (5'-dRP lyase), by catalyzing the beta-elimination of the 5' deoxyribose-5-phosphate at an abasic site near double-strand breaks (PubMed:20383123). 5'-dRP lyase activity allows to 'clean' the termini of abasic sites, a class of nucleotide damage commonly associated with strand breaks, before such broken ends can be joined (PubMed:20383123). The XRCC5-XRRC6 dimer together with APEX1 acts as a negative regulator of transcription (PubMed:8621488). In association with NAA15, the XRCC5-XRRC6 dimer binds to the osteocalcin promoter and activates osteocalcin expression (PubMed:12145306). Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728). Negatively regulates apoptosis by interacting with BAX and sequestering it from the mitochondria (PubMed:15023334). Might have deubiquitination activity, acting on BAX (PubMed:18362350). {ECO:0000269|PubMed:11493912, ECO:0000269|PubMed:12145306, ECO:0000269|PubMed:15023334, ECO:0000269|PubMed:18362350, ECO:0000269|PubMed:20383123, ECO:0000269|PubMed:20493174, ECO:0000269|PubMed:2466842, ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:7957065, ECO:0000269|PubMed:8621488, ECO:0000269|PubMed:9742108}. |
| P14923 | JUP | S98 | ochoa | Junction plakoglobin (Catenin gamma) (Desmoplakin III) (Desmoplakin-3) | Common junctional plaque protein. The membrane-associated plaques are architectural elements in an important strategic position to influence the arrangement and function of both the cytoskeleton and the cells within the tissue. The presence of plakoglobin in both the desmosomes and in the intermediate junctions suggests that it plays a central role in the structure and function of submembranous plaques. Acts as a substrate for VE-PTP and is required by it to stimulate VE-cadherin function in endothelial cells. Can replace beta-catenin in E-cadherin/catenin adhesion complexes which are proposed to couple cadherins to the actin cytoskeleton (By similarity). {ECO:0000250}. |
| P15408 | FOSL2 | S211 | ochoa | Fos-related antigen 2 (FRA-2) | Controls osteoclast survival and size (By similarity). As a dimer with JUN, activates LIF transcription (By similarity). Activates CEBPB transcription in PGE2-activated osteoblasts (By similarity). {ECO:0000250|UniProtKB:P47930, ECO:0000250|UniProtKB:P51145}. |
| P17931 | LGALS3 | S188 | ochoa | Galectin-3 (Gal-3) (35 kDa lectin) (Carbohydrate-binding protein 35) (CBP 35) (Galactose-specific lectin 3) (Galactoside-binding protein) (GALBP) (IgE-binding protein) (L-31) (Laminin-binding protein) (Lectin L-29) (Mac-2 antigen) | Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis (By similarity). In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells. Together with TRIM16, coordinates the recognition of membrane damage with mobilization of the core autophagy regulators ATG16L1 and BECN1 in response to damaged endomembranes. {ECO:0000250, ECO:0000269|PubMed:15181153, ECO:0000269|PubMed:19594635, ECO:0000269|PubMed:19616076, ECO:0000269|PubMed:27693506}. |
| P18206 | VCL | S288 | ochoa | Vinculin (Metavinculin) (MV) | Actin filament (F-actin)-binding protein involved in cell-matrix adhesion and cell-cell adhesion. Regulates cell-surface E-cadherin expression and potentiates mechanosensing by the E-cadherin complex. May also play important roles in cell morphology and locomotion. {ECO:0000269|PubMed:20484056}. |
| P19174 | PLCG1 | S1224 | ochoa | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (EC 3.1.4.11) (PLC-148) (Phosphoinositide phospholipase C-gamma-1) (Phospholipase C-II) (PLC-II) (Phospholipase C-gamma-1) (PLC-gamma-1) | Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, EGFR, FGFR1, FGFR2, FGFR3 and FGFR4 (By similarity). Plays a role in actin reorganization and cell migration (PubMed:17229814). Guanine nucleotide exchange factor that binds the GTPase DNM1 and catalyzes the dissociation of GDP, allowing a GTP molecule to bind in its place, therefore enhancing DNM1-dependent endocytosis (By similarity). {ECO:0000250|UniProtKB:P10686, ECO:0000269|PubMed:17229814, ECO:0000269|PubMed:37422272}. |
| P19525 | EIF2AK2 | S456 | ochoa|psp | Interferon-induced, double-stranded RNA-activated protein kinase (EC 2.7.11.1) (Eukaryotic translation initiation factor 2-alpha kinase 2) (eIF-2A protein kinase 2) (Interferon-inducible RNA-dependent protein kinase) (P1/eIF-2A protein kinase) (Protein kinase RNA-activated) (PKR) (Protein kinase R) (Tyrosine-protein kinase EIF2AK2) (EC 2.7.10.2) (p68 kinase) | IFN-induced dsRNA-dependent serine/threonine-protein kinase that phosphorylates the alpha subunit of eukaryotic translation initiation factor 2 (EIF2S1/eIF-2-alpha) and plays a key role in the innate immune response to viral infection (PubMed:18835251, PubMed:19189853, PubMed:19507191, PubMed:21072047, PubMed:21123651, PubMed:22381929, PubMed:22948139, PubMed:23229543). Inhibits viral replication via the integrated stress response (ISR): EIF2S1/eIF-2-alpha phosphorylation in response to viral infection converts EIF2S1/eIF-2-alpha in a global protein synthesis inhibitor, resulting to a shutdown of cellular and viral protein synthesis, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activator ATF4 (PubMed:19189853, PubMed:21123651, PubMed:22948139, PubMed:23229543). Exerts its antiviral activity on a wide range of DNA and RNA viruses including hepatitis C virus (HCV), hepatitis B virus (HBV), measles virus (MV) and herpes simplex virus 1 (HHV-1) (PubMed:11836380, PubMed:19189853, PubMed:19840259, PubMed:20171114, PubMed:21710204, PubMed:23115276, PubMed:23399035). Also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation: phosphorylates other substrates including p53/TP53, PPP2R5A, DHX9, ILF3, IRS1 and the HHV-1 viral protein US11 (PubMed:11836380, PubMed:19229320, PubMed:22214662). In addition to serine/threonine-protein kinase activity, also has tyrosine-protein kinase activity and phosphorylates CDK1 at 'Tyr-4' upon DNA damage, facilitating its ubiquitination and proteasomal degradation (PubMed:20395957). Either as an adapter protein and/or via its kinase activity, can regulate various signaling pathways (p38 MAP kinase, NF-kappa-B and insulin signaling pathways) and transcription factors (JUN, STAT1, STAT3, IRF1, ATF3) involved in the expression of genes encoding pro-inflammatory cytokines and IFNs (PubMed:22948139, PubMed:23084476, PubMed:23372823). Activates the NF-kappa-B pathway via interaction with IKBKB and TRAF family of proteins and activates the p38 MAP kinase pathway via interaction with MAP2K6 (PubMed:10848580, PubMed:15121867, PubMed:15229216). Can act as both a positive and negative regulator of the insulin signaling pathway (ISP) (PubMed:20685959). Negatively regulates ISP by inducing the inhibitory phosphorylation of insulin receptor substrate 1 (IRS1) at 'Ser-312' and positively regulates ISP via phosphorylation of PPP2R5A which activates FOXO1, which in turn up-regulates the expression of insulin receptor substrate 2 (IRS2) (PubMed:20685959). Can regulate NLRP3 inflammasome assembly and the activation of NLRP3, NLRP1, AIM2 and NLRC4 inflammasomes (PubMed:22801494). Plays a role in the regulation of the cytoskeleton by binding to gelsolin (GSN), sequestering the protein in an inactive conformation away from actin (By similarity). {ECO:0000250|UniProtKB:Q03963, ECO:0000269|PubMed:10848580, ECO:0000269|PubMed:11836380, ECO:0000269|PubMed:15121867, ECO:0000269|PubMed:15229216, ECO:0000269|PubMed:18835251, ECO:0000269|PubMed:19189853, ECO:0000269|PubMed:19229320, ECO:0000269|PubMed:19507191, ECO:0000269|PubMed:19840259, ECO:0000269|PubMed:20171114, ECO:0000269|PubMed:20395957, ECO:0000269|PubMed:20685959, ECO:0000269|PubMed:21072047, ECO:0000269|PubMed:21123651, ECO:0000269|PubMed:21710204, ECO:0000269|PubMed:22214662, ECO:0000269|PubMed:22381929, ECO:0000269|PubMed:22801494, ECO:0000269|PubMed:22948139, ECO:0000269|PubMed:23084476, ECO:0000269|PubMed:23115276, ECO:0000269|PubMed:23229543, ECO:0000269|PubMed:23372823, ECO:0000269|PubMed:23399035, ECO:0000269|PubMed:32197074}. |
| P20618 | PSMB1 | S162 | ochoa | Proteasome subunit beta type-1 (Macropain subunit C5) (Multicatalytic endopeptidase complex subunit C5) (Proteasome component C5) (Proteasome gamma chain) (Proteasome subunit beta-6) (beta-6) | Non-catalytic component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). {ECO:0000269|PubMed:15244466, ECO:0000269|PubMed:27176742, ECO:0000269|PubMed:8610016}. |
| P20701 | ITGAL | S1140 | ochoa | Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a) | Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin ITGAL/ITGB2 is a receptor for F11R (PubMed:11812992, PubMed:15528364). Integrin ITGAL/ITGB2 is a receptor for the secreted form of ubiquitin-like protein ISG15; the interaction is mediated by ITGAL (PubMed:29100055). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992). Acts as a platform at the immunological synapse to translate TCR engagement and density of the ITGAL ligand ICAM1 into graded adhesion (PubMed:38195629). Required for generation of common lymphoid progenitor cells in bone marrow, indicating a role in lymphopoiesis (By similarity). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). {ECO:0000250|UniProtKB:P24063, ECO:0000269|PubMed:11812992, ECO:0000269|PubMed:15356110, ECO:0000269|PubMed:15528364, ECO:0000269|PubMed:23775590, ECO:0000269|PubMed:29100055, ECO:0000269|PubMed:38195629}. |
| P20963 | CD247 | S146 | ochoa | T-cell surface glycoprotein CD3 zeta chain (T-cell receptor T3 zeta chain) (CD antigen CD247) | Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine kinases LCK and FYN, resulting in the activation of downstream signaling pathways (PubMed:1384049, PubMed:1385158, PubMed:2470098, PubMed:7509083). CD3Z ITAMs phosphorylation creates multiple docking sites for the protein kinase ZAP70 leading to ZAP70 phosphorylation and its conversion into a catalytically active enzyme (PubMed:7509083). Plays an important role in intrathymic T-cell differentiation. Additionally, participates in the activity-dependent synapse formation of retinal ganglion cells (RGCs) in both the retina and dorsal lateral geniculate nucleus (dLGN) (By similarity). {ECO:0000250|UniProtKB:P24161, ECO:0000269|PubMed:1384049, ECO:0000269|PubMed:1385158, ECO:0000269|PubMed:16027224, ECO:0000269|PubMed:2470098, ECO:0000269|PubMed:28465009, ECO:0000269|PubMed:7509083}. |
| P21127 | CDK11B | Y594 | ochoa | Cyclin-dependent kinase 11B (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 1) (CLK-1) (Cell division protein kinase 11B) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L1) (p58 CLK-1) | Plays multiple roles in cell cycle progression, cytokinesis and apoptosis. Involved in pre-mRNA splicing in a kinase activity-dependent manner. Isoform 7 may act as a negative regulator of normal cell cycle progression. {ECO:0000269|PubMed:12501247, ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:18216018, ECO:0000269|PubMed:2217177}. |
| P21291 | CSRP1 | Y73 | ochoa | Cysteine and glycine-rich protein 1 (Cysteine-rich protein 1) (CRP) (CRP1) (Epididymis luminal protein 141) (HEL-141) | Could play a role in neuronal development. |
| P21796 | VDAC1 | S193 | psp | Non-selective voltage-gated ion channel VDAC1 (Outer mitochondrial membrane protein porin 1) (Plasmalemmal porin) (Porin 31HL) (Porin 31HM) (Voltage-dependent anion-selective channel protein 1) (VDAC-1) (hVDAC1) | Non-selective voltage-gated ion channel that mediates the transport of anions and cations through the mitochondrion outer membrane and plasma membrane (PubMed:10661876, PubMed:11845315, PubMed:18755977, PubMed:30061676, PubMed:8420959). The channel at the outer mitochondrial membrane allows diffusion of small hydrophilic molecules; in the plasma membrane it is involved in cell volume regulation and apoptosis (PubMed:10661876, PubMed:11845315, PubMed:18755977, PubMed:8420959). It adopts an open conformation at low or zero membrane potential and a closed conformation at potentials above 30-40 mV (PubMed:10661876, PubMed:18755977, PubMed:8420959). The open state has a weak anion selectivity whereas the closed state is cation-selective (PubMed:18755977, PubMed:8420959). Binds various signaling molecules, including the sphingolipid ceramide, the phospholipid phosphatidylcholine, and the sterols cholesterol and oxysterol (PubMed:18755977, PubMed:31015432). In depolarized mitochondria, acts downstream of PRKN and PINK1 to promote mitophagy or prevent apoptosis; polyubiquitination by PRKN promotes mitophagy, while monoubiquitination by PRKN decreases mitochondrial calcium influx which ultimately inhibits apoptosis (PubMed:32047033). May participate in the formation of the permeability transition pore complex (PTPC) responsible for the release of mitochondrial products that triggers apoptosis (PubMed:15033708, PubMed:25296756). May mediate ATP export from cells (PubMed:30061676). Part of a complex composed of HSPA9, ITPR1 and VDAC1 that regulates mitochondrial calcium-dependent apoptosis by facilitating calcium transport from the ER lumen to the mitochondria intermembrane space thus providing calcium for the downstream calcium channel MCU that directly releases it into mitochondria matrix (By similarity). Mediates cytochrome c efflux (PubMed:20230784). {ECO:0000250|UniProtKB:Q60932, ECO:0000269|PubMed:10661876, ECO:0000269|PubMed:11845315, ECO:0000269|PubMed:15033708, ECO:0000269|PubMed:18755977, ECO:0000269|PubMed:20230784, ECO:0000269|PubMed:25296756, ECO:0000269|PubMed:30061676, ECO:0000269|PubMed:31015432, ECO:0000269|PubMed:32047033, ECO:0000269|PubMed:8420959}.; FUNCTION: Catalyzes the scrambling of phospholipids across the outer mitochondrial membrane; the mechanism is unrelated to channel activity and is capable of translocating both anionic and zwitterionic phospholipids. {ECO:0000269|PubMed:38065946}. |
| P22681 | CBL | S452 | ochoa | E3 ubiquitin-protein ligase CBL (EC 2.3.2.27) (Casitas B-lineage lymphoma proto-oncogene) (Proto-oncogene c-Cbl) (RING finger protein 55) (RING-type E3 ubiquitin transferase CBL) (Signal transduction protein CBL) | E3 ubiquitin-protein ligase that acts as a negative regulator of many signaling pathways by mediating ubiquitination of cell surface receptors (PubMed:10514377, PubMed:11896602, PubMed:14661060, PubMed:14739300, PubMed:15190072, PubMed:17509076, PubMed:18374639, PubMed:19689429, PubMed:21596750, PubMed:28381567). Accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome (PubMed:10514377, PubMed:14661060, PubMed:14739300, PubMed:17094949, PubMed:17509076, PubMed:17974561). Recognizes activated receptor tyrosine kinases, including KIT, FLT1, FGFR1, FGFR2, PDGFRA, PDGFRB, CSF1R, EPHA8 and KDR and mediates their ubiquitination to terminate signaling (PubMed:15190072, PubMed:18374639, PubMed:21596750). Recognizes membrane-bound HCK, SRC and other kinases of the SRC family and mediates their ubiquitination and degradation (PubMed:11896602). Ubiquitinates EGFR and SPRY2 (PubMed:17094949, PubMed:17974561). Ubiquitinates NECTIN1 following association between NECTIN1 and herpes simplex virus 1/HHV-1 envelope glycoprotein D, leading to NECTIN1 removal from cell surface (PubMed:28381567). Participates in signal transduction in hematopoietic cells. Plays an important role in the regulation of osteoblast differentiation and apoptosis (PubMed:15190072, PubMed:18374639). Essential for osteoclastic bone resorption (PubMed:14739300). The 'Tyr-731' phosphorylated form induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function (PubMed:14739300). May be functionally coupled with the E2 ubiquitin-protein ligase UB2D3. In association with CBLB, required for proper feedback inhibition of ciliary platelet-derived growth factor receptor-alpha (PDGFRA) signaling pathway via ubiquitination and internalization of PDGFRA (By similarity). {ECO:0000250|UniProtKB:P22682, ECO:0000269|PubMed:10514377, ECO:0000269|PubMed:11896602, ECO:0000269|PubMed:14661060, ECO:0000269|PubMed:14739300, ECO:0000269|PubMed:15190072, ECO:0000269|PubMed:17094949, ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17974561, ECO:0000269|PubMed:18374639, ECO:0000269|PubMed:19689429, ECO:0000269|PubMed:21596750, ECO:0000269|PubMed:28381567}. |
| P24941 | CDK2 | Y159 | ochoa | Cyclin-dependent kinase 2 (EC 2.7.11.22) (Cell division protein kinase 2) (p33 protein kinase) | Serine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis (PubMed:10499802, PubMed:10884347, PubMed:10995386, PubMed:10995387, PubMed:11051553, PubMed:11113184, PubMed:12944431, PubMed:15800615, PubMed:17495531, PubMed:19966300, PubMed:20935635, PubMed:21262353, PubMed:21596315, PubMed:28216226, PubMed:28666995). Phosphorylates CABLES1, CTNNB1, CDK2AP2, ERCC6, NBN, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, NPAT, EZH2 (PubMed:10499802, PubMed:10995386, PubMed:10995387, PubMed:11051553, PubMed:11113184, PubMed:12944431, PubMed:15800615, PubMed:19966300, PubMed:20935635, PubMed:21262353, PubMed:21596315, PubMed:28216226). Triggers duplication of centrosomes and DNA (PubMed:11051553). Acts at the G1-S transition to promote the E2F transcriptional program and the initiation of DNA synthesis, and modulates G2 progression; controls the timing of entry into mitosis/meiosis by controlling the subsequent activation of cyclin B/CDK1 by phosphorylation, and coordinates the activation of cyclin B/CDK1 at the centrosome and in the nucleus (PubMed:18372919, PubMed:19238148, PubMed:19561645). Crucial role in orchestrating a fine balance between cellular proliferation, cell death, and DNA repair in embryonic stem cells (ESCs) (PubMed:18372919, PubMed:19238148, PubMed:19561645). Activity of CDK2 is maximal during S phase and G2; activated by interaction with cyclin E during the early stages of DNA synthesis to permit G1-S transition, and subsequently activated by cyclin A2 (cyclin A1 in germ cells) during the late stages of DNA replication to drive the transition from S phase to mitosis, the G2 phase (PubMed:18372919, PubMed:19238148, PubMed:19561645). EZH2 phosphorylation promotes H3K27me3 maintenance and epigenetic gene silencing (PubMed:20935635). Cyclin E/CDK2 prevents oxidative stress-mediated Ras-induced senescence by phosphorylating MYC (PubMed:19966300). Involved in G1-S phase DNA damage checkpoint that prevents cells with damaged DNA from initiating mitosis; regulates homologous recombination-dependent repair by phosphorylating BRCA2, this phosphorylation is low in S phase when recombination is active, but increases as cells progress towards mitosis (PubMed:15800615, PubMed:20195506, PubMed:21319273). In response to DNA damage, double-strand break repair by homologous recombination a reduction of CDK2-mediated BRCA2 phosphorylation (PubMed:15800615). Involved in regulation of telomere repair by mediating phosphorylation of NBN (PubMed:28216226). Phosphorylation of RB1 disturbs its interaction with E2F1 (PubMed:10499802). NPM1 phosphorylation by cyclin E/CDK2 promotes its dissociates from unduplicated centrosomes, thus initiating centrosome duplication (PubMed:11051553). Cyclin E/CDK2-mediated phosphorylation of NPAT at G1-S transition and until prophase stimulates the NPAT-mediated activation of histone gene transcription during S phase (PubMed:10995386, PubMed:10995387). Required for vitamin D-mediated growth inhibition by being itself inactivated (PubMed:20147522). Involved in the nitric oxide- (NO) mediated signaling in a nitrosylation/activation-dependent manner (PubMed:20079829). USP37 is activated by phosphorylation and thus triggers G1-S transition (PubMed:21596315). CTNNB1 phosphorylation regulates insulin internalization (PubMed:21262353). Phosphorylates FOXP3 and negatively regulates its transcriptional activity and protein stability (By similarity). Phosphorylates ERCC6 which is essential for its chromatin remodeling activity at DNA double-strand breaks (PubMed:29203878). Acts as a regulator of the phosphatidylinositol 3-kinase/protein kinase B signal transduction by mediating phosphorylation of the C-terminus of protein kinase B (PKB/AKT1 and PKB/AKT2), promoting its activation (PubMed:24670654). {ECO:0000250|UniProtKB:P97377, ECO:0000269|PubMed:10499802, ECO:0000269|PubMed:10884347, ECO:0000269|PubMed:10995386, ECO:0000269|PubMed:10995387, ECO:0000269|PubMed:11051553, ECO:0000269|PubMed:11113184, ECO:0000269|PubMed:12944431, ECO:0000269|PubMed:15800615, ECO:0000269|PubMed:17495531, ECO:0000269|PubMed:18372919, ECO:0000269|PubMed:19966300, ECO:0000269|PubMed:20079829, ECO:0000269|PubMed:20147522, ECO:0000269|PubMed:20195506, ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:21262353, ECO:0000269|PubMed:21319273, ECO:0000269|PubMed:21596315, ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:28216226, ECO:0000269|PubMed:28666995, ECO:0000269|PubMed:29203878, ECO:0000303|PubMed:19238148, ECO:0000303|PubMed:19561645}. |
| P25100 | ADRA1D | S323 | psp | Alpha-1D adrenergic receptor (Alpha-1A adrenergic receptor) (Alpha-1D adrenoreceptor) (Alpha-1D adrenoceptor) (Alpha-adrenergic receptor 1a) | This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium. |
| P25705 | ATP5F1A | S184 | ochoa | ATP synthase F(1) complex subunit alpha, mitochondrial (ATP synthase F1 subunit alpha) | Subunit alpha, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1) region and a stationary peripheral stalk (PubMed:37244256). During catalysis, ATP synthesis in the catalytic domain of F(1) is coupled via a rotary mechanism of the central stalk subunits to proton translocation (Probable). In vivo, can only synthesize ATP although its ATP hydrolase activity can be activated artificially in vitro (By similarity). With the catalytic subunit beta (ATP5F1B), forms the catalytic core in the F(1) domain (PubMed:37244256). Subunit alpha does not bear the catalytic high-affinity ATP-binding sites (Probable). Binds the bacterial siderophore enterobactin and can promote mitochondrial accumulation of enterobactin-derived iron ions (PubMed:30146159). {ECO:0000250|UniProtKB:P19483, ECO:0000269|PubMed:30146159, ECO:0000269|PubMed:37244256, ECO:0000305|PubMed:37244256}. |
| P29350 | PTPN6 | S26 | ochoa | Tyrosine-protein phosphatase non-receptor type 6 (EC 3.1.3.48) (Hematopoietic cell protein-tyrosine phosphatase) (Protein-tyrosine phosphatase 1C) (PTP-1C) (Protein-tyrosine phosphatase SHP-1) (SH-PTP1) | Tyrosine phosphatase enzyme that plays important roles in controlling immune signaling pathways and fundamental physiological processes such as hematopoiesis (PubMed:14739280, PubMed:29925997). Dephosphorylates and negatively regulate several receptor tyrosine kinases (RTKs) such as EGFR, PDGFR and FGFR, thereby modulating their signaling activities (PubMed:21258366, PubMed:9733788). When recruited to immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptors such as immunoglobulin-like transcript 2/LILRB1, programmed cell death protein 1/PDCD1, CD3D, CD22, CLEC12A and other receptors involved in immune regulation, initiates their dephosphorylation and subsequently inhibits downstream signaling events (PubMed:11907092, PubMed:14739280, PubMed:37932456, PubMed:38166031). Modulates the signaling of several cytokine receptors including IL-4 receptor (PubMed:9065461). Additionally, targets multiple cytoplasmic signaling molecules including STING1, LCK or STAT1 among others involved in diverse cellular processes including modulation of T-cell activation or cGAS-STING signaling (PubMed:34811497, PubMed:38532423). Within the nucleus, negatively regulates the activity of some transcription factors such as NFAT5 via direct dephosphorylation. Also acts as a key transcriptional regulator of hepatic gluconeogenesis by controlling recruitment of RNA polymerase II to the PCK1 promoter together with STAT5A (PubMed:37595871). {ECO:0000269|PubMed:10574931, ECO:0000269|PubMed:11266449, ECO:0000269|PubMed:11907092, ECO:0000269|PubMed:14739280, ECO:0000269|PubMed:21258366, ECO:0000269|PubMed:29925997, ECO:0000269|PubMed:34811497, ECO:0000269|PubMed:37595871, ECO:0000269|PubMed:37932456, ECO:0000269|PubMed:38166031, ECO:0000269|PubMed:38532423, ECO:0000269|PubMed:9065461, ECO:0000269|PubMed:9733788}. |
| P30085 | CMPK1 | S141 | ochoa | UMP-CMP kinase (EC 2.7.4.14) (Deoxycytidylate kinase) (CK) (dCMP kinase) (Nucleoside-diphosphate kinase) (EC 2.7.4.6) (Uridine monophosphate/cytidine monophosphate kinase) (UMP/CMP kinase) (UMP/CMPK) | Catalyzes the phosphorylation of pyrimidine nucleoside monophosphates at the expense of ATP. Plays an important role in de novo pyrimidine nucleotide biosynthesis. Has preference for UMP and CMP as phosphate acceptors. Also displays broad nucleoside diphosphate kinase activity. {ECO:0000255|HAMAP-Rule:MF_03172, ECO:0000269|PubMed:10462544, ECO:0000269|PubMed:11912132, ECO:0000269|PubMed:23416111}. |
| P31937 | HIBADH | S88 | ochoa | 3-hydroxyisobutyrate dehydrogenase, mitochondrial (HIBADH) (EC 1.1.1.31) | None |
| P35568 | IRS1 | S350 | ochoa | Insulin receptor substrate 1 (IRS-1) | Signaling adapter protein that participates in the signal transduction from two prominent receptor tyrosine kinases, insulin receptor/INSR and insulin-like growth factor I receptor/IGF1R (PubMed:7541045, PubMed:33991522, PubMed:38625937). Plays therefore an important role in development, growth, glucose homeostasis as well as lipid metabolism (PubMed:19639489). Upon phosphorylation by the insulin receptor, functions as a signaling scaffold that propagates insulin action through binding to SH2 domain-containing proteins including the p85 regulatory subunit of PI3K, NCK1, NCK2, GRB2 or SHP2 (PubMed:11171109, PubMed:8265614). Recruitment of GRB2 leads to the activation of the guanine nucleotide exchange factor SOS1 which in turn triggers the Ras/Raf/MEK/MAPK signaling cascade (By similarity). Activation of the PI3K/AKT pathway is responsible for most of insulin metabolic effects in the cell, and the Ras/Raf/MEK/MAPK is involved in the regulation of gene expression and in cooperation with the PI3K pathway regulates cell growth and differentiation. Acts a positive regulator of the Wnt/beta-catenin signaling pathway through suppression of DVL2 autophagy-mediated degradation leading to cell proliferation (PubMed:24616100). {ECO:0000250|UniProtKB:P35570, ECO:0000269|PubMed:11171109, ECO:0000269|PubMed:16878150, ECO:0000269|PubMed:19639489, ECO:0000269|PubMed:38625937, ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:8265614}. |
| P35580 | MYH10 | S1938 | ochoa|psp | Myosin-10 (Cellular myosin heavy chain, type B) (Myosin heavy chain 10) (Myosin heavy chain, non-muscle IIb) (Non-muscle myosin heavy chain B) (NMMHC-B) (Non-muscle myosin heavy chain IIb) (NMMHC II-b) (NMMHC-IIB) | Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping. Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2. During cell spreading, plays an important role in cytoskeleton reorganization, focal contacts formation (in the central part but not the margins of spreading cells), and lamellipodial extension; this function is mechanically antagonized by MYH9. {ECO:0000269|PubMed:20052411, ECO:0000269|PubMed:20603131}.; FUNCTION: (Microbial infection) Acts as a receptor for herpes simplex virus 1/HHV-1 envelope glycoprotein B. {ECO:0000305|PubMed:25428876, ECO:0000305|PubMed:39048823}. |
| P37837 | TALDO1 | S75 | ochoa | Transaldolase (EC 2.2.1.2) | Catalyzes the rate-limiting step of the non-oxidative phase in the pentose phosphate pathway. Catalyzes the reversible conversion of sedheptulose-7-phosphate and D-glyceraldehyde 3-phosphate into erythrose-4-phosphate and beta-D-fructose 6-phosphate (PubMed:18687684, PubMed:8955144). Not only acts as a pentose phosphate pathway enzyme, but also affects other metabolite pathways by altering its subcellular localization between the nucleus and the cytoplasm (By similarity). {ECO:0000250|UniProtKB:Q93092, ECO:0000269|PubMed:18687684, ECO:0000269|PubMed:8955144}. |
| P42166 | TMPO | S459 | ochoa | Lamina-associated polypeptide 2, isoform alpha (Thymopoietin isoform alpha) (TP alpha) (Thymopoietin-related peptide isoform alpha) (TPRP isoform alpha) [Cleaved into: Thymopoietin (TP) (Splenin); Thymopentin (TP5)] | May be involved in the structural organization of the nucleus and in the post-mitotic nuclear assembly. Plays an important role, together with LMNA, in the nuclear anchorage of RB1.; FUNCTION: TP and TP5 may play a role in T-cell development and function. TP5 is an immunomodulating pentapeptide. |
| P42345 | MTOR | S2478 | ochoa | Serine/threonine-protein kinase mTOR (EC 2.7.11.1) (FK506-binding protein 12-rapamycin complex-associated protein 1) (FKBP12-rapamycin complex-associated protein) (Mammalian target of rapamycin) (mTOR) (Mechanistic target of rapamycin) (Rapamycin and FKBP12 target 1) (Rapamycin target protein 1) (Tyrosine-protein kinase mTOR) (EC 2.7.10.2) | Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, PubMed:31601708, PubMed:32561715, PubMed:34519269, PubMed:37751742). MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins (PubMed:15268862, PubMed:15467718, PubMed:17517883, PubMed:18372248, PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, PubMed:30171069, PubMed:29236692, PubMed:37751742). Functions as part of 2 structurally and functionally distinct signaling complexes mTORC1 and mTORC2 (mTOR complex 1 and 2) (PubMed:15268862, PubMed:15467718, PubMed:18497260, PubMed:18925875, PubMed:20516213, PubMed:21576368, PubMed:21659604, PubMed:23429704, PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to nutrients, growth factors or amino acids, mTORC1 is recruited to the lysosome membrane and promotes protein, lipid and nucleotide synthesis by phosphorylating key regulators of mRNA translation and ribosome synthesis (PubMed:12087098, PubMed:12150925, PubMed:12150926, PubMed:12231510, PubMed:12718876, PubMed:14651849, PubMed:15268862, PubMed:15467718, PubMed:15545625, PubMed:15718470, PubMed:18497260, PubMed:18762023, PubMed:18925875, PubMed:20516213, PubMed:20537536, PubMed:21659604, PubMed:23429703, PubMed:23429704, PubMed:25799227, PubMed:26018084, PubMed:29150432, PubMed:29236692, PubMed:31112131, PubMed:34519269). This includes phosphorylation of EIF4EBP1 and release of its inhibition toward the elongation initiation factor 4E (eiF4E) (PubMed:24403073, PubMed:29236692). Moreover, phosphorylates and activates RPS6KB1 and RPS6KB2 that promote protein synthesis by modulating the activity of their downstream targets including ribosomal protein S6, eukaryotic translation initiation factor EIF4B, and the inhibitor of translation initiation PDCD4 (PubMed:12087098, PubMed:12150925, PubMed:18925875, PubMed:29150432, PubMed:29236692). Stimulates the pyrimidine biosynthesis pathway, both by acute regulation through RPS6KB1-mediated phosphorylation of the biosynthetic enzyme CAD, and delayed regulation, through transcriptional enhancement of the pentose phosphate pathway which produces 5-phosphoribosyl-1-pyrophosphate (PRPP), an allosteric activator of CAD at a later step in synthesis, this function is dependent on the mTORC1 complex (PubMed:23429703, PubMed:23429704). Regulates ribosome synthesis by activating RNA polymerase III-dependent transcription through phosphorylation and inhibition of MAF1 an RNA polymerase III-repressor (PubMed:20516213). Activates dormant ribosomes by mediating phosphorylation of SERBP1, leading to SERBP1 inactivation and reactivation of translation (PubMed:36691768). In parallel to protein synthesis, also regulates lipid synthesis through SREBF1/SREBP1 and LPIN1 (PubMed:23426360). To maintain energy homeostasis mTORC1 may also regulate mitochondrial biogenesis through regulation of PPARGC1A (By similarity). In the same time, mTORC1 inhibits catabolic pathways: negatively regulates autophagy through phosphorylation of ULK1 (PubMed:32561715). Under nutrient sufficiency, phosphorylates ULK1 at 'Ser-758', disrupting the interaction with AMPK and preventing activation of ULK1 (PubMed:32561715). Also prevents autophagy through phosphorylation of the autophagy inhibitor DAP (PubMed:20537536). Also prevents autophagy by phosphorylating RUBCNL/Pacer under nutrient-rich conditions (PubMed:30704899). Prevents autophagy by mediating phosphorylation of AMBRA1, thereby inhibiting AMBRA1 ability to mediate ubiquitination of ULK1 and interaction between AMBRA1 and PPP2CA (PubMed:23524951, PubMed:25438055). mTORC1 exerts a feedback control on upstream growth factor signaling that includes phosphorylation and activation of GRB10 a INSR-dependent signaling suppressor (PubMed:21659604). Among other potential targets mTORC1 may phosphorylate CLIP1 and regulate microtubules (PubMed:12231510). The mTORC1 complex is inhibited in response to starvation and amino acid depletion (PubMed:12150925, PubMed:12150926, PubMed:24403073, PubMed:31695197). The non-canonical mTORC1 complex, which acts independently of RHEB, specifically mediates phosphorylation of MiT/TFE factors MITF, TFEB and TFE3 in the presence of nutrients, promoting their cytosolic retention and inactivation (PubMed:22343943, PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670, PubMed:36697823). Upon starvation or lysosomal stress, inhibition of mTORC1 induces dephosphorylation and nuclear translocation of TFEB and TFE3, promoting their transcription factor activity (PubMed:22343943, PubMed:22576015, PubMed:22692423, PubMed:24448649, PubMed:32612235, PubMed:36608670). The mTORC1 complex regulates pyroptosis in macrophages by promoting GSDMD oligomerization (PubMed:34289345). MTOR phosphorylates RPTOR which in turn inhibits mTORC1 (By similarity). As part of the mTORC2 complex, MTOR transduces signals from growth factors to pathways involved in proliferation, cytoskeletal organization, lipogenesis and anabolic output (PubMed:15268862, PubMed:15467718, PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In response to growth factors, mTORC2 phosphorylates and activates AGC protein kinase family members, including AKT (AKT1, AKT2 and AKT3), PKC (PRKCA, PRKCB and PRKCE) and SGK1 (PubMed:15268862, PubMed:15467718, PubMed:21376236, PubMed:24670654, PubMed:29424687, PubMed:29567957, PubMed:35926713). In contrast to mTORC1, mTORC2 is nutrient-insensitive (PubMed:15467718). mTORC2 plays a critical role in AKT1 activation by mediating phosphorylation of different sites depending on the context, such as 'Thr-450', 'Ser-473', 'Ser-477' or 'Thr-479', facilitating the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDPK1/PDK1 which is a prerequisite for full activation (PubMed:15718470, PubMed:21376236, PubMed:24670654, PubMed:29424687, PubMed:29567957). mTORC2 also regulates the phosphorylation of SGK1 at 'Ser-422' (PubMed:18925875). mTORC2 may regulate the actin cytoskeleton, through phosphorylation of PRKCA, PXN and activation of the Rho-type guanine nucleotide exchange factors RHOA and RAC1A or RAC1B (PubMed:15268862). The mTORC2 complex also phosphorylates various proteins involved in insulin signaling, such as FBXW8 and IGF2BP1 (By similarity). May also regulate insulin signaling by acting as a tyrosine protein kinase that catalyzes phosphorylation of IGF1R and INSR; additional evidence are however required to confirm this result in vivo (PubMed:26584640). Regulates osteoclastogenesis by adjusting the expression of CEBPB isoforms (By similarity). Plays an important regulatory role in the circadian clock function; regulates period length and rhythm amplitude of the suprachiasmatic nucleus (SCN) and liver clocks (By similarity). {ECO:0000250|UniProtKB:Q9JLN9, ECO:0000269|PubMed:12087098, ECO:0000269|PubMed:12150925, ECO:0000269|PubMed:12150926, ECO:0000269|PubMed:12231510, ECO:0000269|PubMed:12718876, ECO:0000269|PubMed:14651849, ECO:0000269|PubMed:15268862, ECO:0000269|PubMed:15467718, ECO:0000269|PubMed:15545625, ECO:0000269|PubMed:15718470, ECO:0000269|PubMed:17517883, ECO:0000269|PubMed:18372248, ECO:0000269|PubMed:18497260, ECO:0000269|PubMed:18762023, ECO:0000269|PubMed:18925875, ECO:0000269|PubMed:20516213, ECO:0000269|PubMed:20537536, ECO:0000269|PubMed:21376236, ECO:0000269|PubMed:21576368, ECO:0000269|PubMed:21659604, ECO:0000269|PubMed:22343943, ECO:0000269|PubMed:22576015, ECO:0000269|PubMed:22692423, ECO:0000269|PubMed:23426360, ECO:0000269|PubMed:23429703, ECO:0000269|PubMed:23429704, ECO:0000269|PubMed:23524951, ECO:0000269|PubMed:24403073, ECO:0000269|PubMed:24448649, ECO:0000269|PubMed:24670654, ECO:0000269|PubMed:25438055, ECO:0000269|PubMed:25799227, ECO:0000269|PubMed:26018084, ECO:0000269|PubMed:26584640, ECO:0000269|PubMed:29150432, ECO:0000269|PubMed:29236692, ECO:0000269|PubMed:29424687, ECO:0000269|PubMed:29567957, ECO:0000269|PubMed:30171069, ECO:0000269|PubMed:30704899, ECO:0000269|PubMed:31112131, ECO:0000269|PubMed:31601708, ECO:0000269|PubMed:31695197, ECO:0000269|PubMed:32561715, ECO:0000269|PubMed:32612235, ECO:0000269|PubMed:34289345, ECO:0000269|PubMed:34519269, ECO:0000269|PubMed:35926713, ECO:0000269|PubMed:36608670, ECO:0000269|PubMed:36691768, ECO:0000269|PubMed:36697823, ECO:0000269|PubMed:37751742}. |
| P43243 | MATR3 | S501 | ochoa | Matrin-3 | May play a role in transcription or may interact with other nuclear matrix proteins to form the internal fibrogranular network. In association with the SFPQ-NONO heteromer may play a role in nuclear retention of defective RNAs. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:28712728). Binds to N6-methyladenosine (m6A)-containing mRNAs and contributes to MYC stability by binding to m6A-containing MYC mRNAs (PubMed:32245947). May bind to specific miRNA hairpins (PubMed:28431233). {ECO:0000269|PubMed:11525732, ECO:0000269|PubMed:28431233, ECO:0000269|PubMed:28712728, ECO:0000269|PubMed:32245947}. |
| P48730 | CSNK1D | S331 | ochoa | Casein kinase I isoform delta (CKI-delta) (CKId) (EC 2.7.11.1) (Tau-protein kinase CSNK1D) (EC 2.7.11.26) | Essential serine/threonine-protein kinase that regulates diverse cellular growth and survival processes including Wnt signaling, DNA repair and circadian rhythms. It can phosphorylate a large number of proteins. Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. Phosphorylates connexin-43/GJA1, MAP1A, SNAPIN, MAPT/TAU, TOP2A, DCK, HIF1A, EIF6, p53/TP53, DVL2, DVL3, ESR1, AIB1/NCOA3, DNMT1, PKD2, YAP1, PER1 and PER2. Central component of the circadian clock. In balance with PP1, determines the circadian period length through the regulation of the speed and rhythmicity of PER1 and PER2 phosphorylation. Controls PER1 and PER2 nuclear transport and degradation. YAP1 phosphorylation promotes its SCF(beta-TRCP) E3 ubiquitin ligase-mediated ubiquitination and subsequent degradation. DNMT1 phosphorylation reduces its DNA-binding activity. Phosphorylation of ESR1 and AIB1/NCOA3 stimulates their activity and coactivation. Phosphorylation of DVL2 and DVL3 regulates WNT3A signaling pathway that controls neurite outgrowth. Phosphorylates NEDD9/HEF1 (By similarity). EIF6 phosphorylation promotes its nuclear export. Triggers down-regulation of dopamine receptors in the forebrain. Activates DCK in vitro by phosphorylation. TOP2A phosphorylation favors DNA cleavable complex formation. May regulate the formation of the mitotic spindle apparatus in extravillous trophoblast. Modulates connexin-43/GJA1 gap junction assembly by phosphorylation. Probably involved in lymphocyte physiology. Regulates fast synaptic transmission mediated by glutamate. {ECO:0000250|UniProtKB:Q9DC28, ECO:0000269|PubMed:10606744, ECO:0000269|PubMed:12270943, ECO:0000269|PubMed:14761950, ECO:0000269|PubMed:16027726, ECO:0000269|PubMed:17562708, ECO:0000269|PubMed:17962809, ECO:0000269|PubMed:19043076, ECO:0000269|PubMed:20041275, ECO:0000269|PubMed:20048001, ECO:0000269|PubMed:20407760, ECO:0000269|PubMed:20637175, ECO:0000269|PubMed:20696890, ECO:0000269|PubMed:20699359, ECO:0000269|PubMed:21084295, ECO:0000269|PubMed:21422228, ECO:0000269|PubMed:23636092}. |
| P48735 | IDH2 | S423 | ochoa | Isocitrate dehydrogenase [NADP], mitochondrial (IDH) (EC 1.1.1.42) (ICD-M) (IDP) (NADP(+)-specific ICDH) (Oxalosuccinate decarboxylase) | Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140). {ECO:0000269|PubMed:19228619, ECO:0000269|PubMed:22416140}. |
| P49326 | FMO5 | S401 | ochoa | Flavin-containing monooxygenase 5 (FMO 5) (Baeyer-Villiger monooxygenase 1) (hBVMO1) (EC 1.14.13.-) (Dimethylaniline monooxygenase [N-oxide-forming] 5) (EC 1.14.13.8) (Dimethylaniline oxidase 5) (NADPH oxidase) (EC 1.6.3.1) | Acts as a Baeyer-Villiger monooxygenase on a broad range of substrates. Catalyzes the insertion of an oxygen atom into a carbon-carbon bond adjacent to a carbonyl, which converts ketones to esters (PubMed:20947616, PubMed:26771671, PubMed:28783300). Active on diverse carbonyl compounds, whereas soft nucleophiles are mostly non- or poorly reactive (PubMed:26771671, PubMed:7872795). In contrast with other forms of FMO it is non- or poorly active on 'classical' substrates such as drugs, pesticides, and dietary components containing soft nucleophilic heteroatoms (Probable) (PubMed:7872795). Able to oxidize drug molecules bearing a carbonyl group on an aliphatic chain, such as nabumetone and pentoxifylline (PubMed:28783300). Also, in the absence of substrates, shows slow but yet significant NADPH oxidase activity (PubMed:26771671). Acts as a positive modulator of cholesterol biosynthesis as well as glucose homeostasis, promoting metabolic aging via pleiotropic effects (By similarity). {ECO:0000250|UniProtKB:P97872, ECO:0000269|PubMed:20947616, ECO:0000269|PubMed:26771671, ECO:0000269|PubMed:28783300, ECO:0000269|PubMed:7872795, ECO:0000305|PubMed:26771671}. |
| P50613 | CDK7 | Y169 | ochoa | Cyclin-dependent kinase 7 (EC 2.7.11.22) (EC 2.7.11.23) (39 kDa protein kinase) (p39 Mo15) (CDK-activating kinase 1) (Cell division protein kinase 7) (Serine/threonine-protein kinase 1) (TFIIH basal transcription factor complex kinase subunit) | Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription (PubMed:9852112, PubMed:19136461, PubMed:26257281, PubMed:28768201). Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11 (PubMed:9372954, PubMed:9840937, PubMed:19136461, PubMed:26257281, PubMed:28768201). Initiates transcription by RNA polymerase II by mediating phosphorylation of POLR2A at 'Ser-5' of the repetitive C-terminal domain (CTD) when POLR2A is in complex with DNA, promoting dissociation from DNA and initiation (PubMed:19136461, PubMed:26257281, PubMed:28768201). CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the CTD of POLR2A, allowing its escape from the promoter and elongation of the transcripts (PubMed:9852112). Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition. {ECO:0000269|PubMed:10024882, ECO:0000269|PubMed:11113184, ECO:0000269|PubMed:16327805, ECO:0000269|PubMed:17373709, ECO:0000269|PubMed:17386261, ECO:0000269|PubMed:17901130, ECO:0000269|PubMed:19015234, ECO:0000269|PubMed:19071173, ECO:0000269|PubMed:19136461, ECO:0000269|PubMed:19450536, ECO:0000269|PubMed:19667075, ECO:0000269|PubMed:20360007, ECO:0000269|PubMed:26257281, ECO:0000269|PubMed:28768201, ECO:0000269|PubMed:9372954, ECO:0000269|PubMed:9840937, ECO:0000269|PubMed:9852112}. |
| P51003 | PAPOLA | S27 | ochoa | Poly(A) polymerase alpha (PAP-alpha) (EC 2.7.7.19) (Polynucleotide adenylyltransferase alpha) | Polymerase that creates the 3'-poly(A) tail of mRNA's. Also required for the endoribonucleolytic cleavage reaction at some polyadenylation sites. May acquire specificity through interaction with a cleavage and polyadenylation specificity factor (CPSF) at its C-terminus. {ECO:0000269|PubMed:19224921}. |
| P51116 | FXR2 | S404 | ochoa | RNA-binding protein FXR2 (FXR2P) (FMR1 autosomal homolog 2) | mRNA-binding protein that acts as a regulator of mRNAs translation and/or stability, and which is required for adult hippocampal neurogenesis (By similarity). Specifically binds to AU-rich elements (AREs) in the 3'-UTR of target mRNAs (By similarity). Promotes formation of some phase-separated membraneless compartment by undergoing liquid-liquid phase separation upon binding to AREs-containing mRNAs: mRNAs storage into membraneless compartments regulates their translation and/or stability (By similarity). Acts as a regulator of adult hippocampal neurogenesis by regulating translation and/or stability of NOG mRNA, thereby preventing NOG protein expression in the dentate gyrus (By similarity). {ECO:0000250|UniProtKB:Q61584, ECO:0000250|UniProtKB:Q9WVR4}. |
| P54198 | HIRA | S650 | ochoa | Protein HIRA (TUP1-like enhancer of split protein 1) | Cooperates with ASF1A to promote replication-independent chromatin assembly. Required for the periodic repression of histone gene transcription during the cell cycle. Required for the formation of senescence-associated heterochromatin foci (SAHF) and efficient senescence-associated cell cycle exit. {ECO:0000269|PubMed:12370293, ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:15621527}. |
| P60709 | ACTB | S52 | ochoa | Actin, cytoplasmic 1 (EC 3.6.4.-) (Beta-actin) [Cleaved into: Actin, cytoplasmic 1, N-terminally processed] | Actin is a highly conserved protein that polymerizes to produce filaments that form cross-linked networks in the cytoplasm of cells (PubMed:25255767, PubMed:29581253). Actin exists in both monomeric (G-actin) and polymeric (F-actin) forms, both forms playing key functions, such as cell motility and contraction (PubMed:29581253). In addition to their role in the cytoplasmic cytoskeleton, G- and F-actin also localize in the nucleus, and regulate gene transcription and motility and repair of damaged DNA (PubMed:29925947). Plays a role in the assembly of the gamma-tubulin ring complex (gTuRC), which regulates the minus-end nucleation of alpha-beta tubulin heterodimers that grow into microtubule protafilaments (PubMed:39321809, PubMed:38609661). Part of the ACTR1A/ACTB filament around which the dynactin complex is built (By similarity). The dynactin multiprotein complex activates the molecular motor dynein for ultra-processive transport along microtubules (By similarity). {ECO:0000250|UniProtKB:Q6QAQ1, ECO:0000269|PubMed:25255767, ECO:0000269|PubMed:29581253, ECO:0000269|PubMed:29925947, ECO:0000269|PubMed:38609661, ECO:0000269|PubMed:39321809}. |
| P62736 | ACTA2 | S54 | ochoa | Actin, aortic smooth muscle (EC 3.6.4.-) (Alpha-actin-2) (Cell growth-inhibiting gene 46 protein) [Cleaved into: Actin, aortic smooth muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| P62753 | RPS6 | S53 | ochoa | Small ribosomal subunit protein eS6 (40S ribosomal protein S6) (Phosphoprotein NP33) | Component of the 40S small ribosomal subunit (PubMed:23636399, PubMed:8706699). Plays an important role in controlling cell growth and proliferation through the selective translation of particular classes of mRNA (PubMed:17220279). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). {ECO:0000269|PubMed:17220279, ECO:0000269|PubMed:23636399, ECO:0000269|PubMed:34516797, ECO:0000269|PubMed:8706699}. |
| P62805 | H4C1 | S48 | ochoa | Histone H4 | Core component of nucleosome. Nucleosomes wrap and compact DNA into chromatin, limiting DNA accessibility to the cellular machineries which require DNA as a template. Histones thereby play a central role in transcription regulation, DNA repair, DNA replication and chromosomal stability. DNA accessibility is regulated via a complex set of post-translational modifications of histones, also called histone code, and nucleosome remodeling. |
| P63261 | ACTG1 | S52 | ochoa | Actin, cytoplasmic 2 (EC 3.6.4.-) (Gamma-actin) [Cleaved into: Actin, cytoplasmic 2, N-terminally processed] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. May play a role in the repair of noise-induced stereocilia gaps thereby maintains hearing sensitivity following loud noise damage (By similarity). {ECO:0000250|UniProtKB:P63260, ECO:0000305|PubMed:29581253}. |
| P63267 | ACTG2 | S53 | ochoa | Actin, gamma-enteric smooth muscle (EC 3.6.4.-) (Alpha-actin-3) (Gamma-2-actin) (Smooth muscle gamma-actin) [Cleaved into: Actin, gamma-enteric smooth muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| P68032 | ACTC1 | S54 | ochoa | Actin, alpha cardiac muscle 1 (EC 3.6.4.-) (Alpha-cardiac actin) [Cleaved into: Actin, alpha cardiac muscle 1, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| P68133 | ACTA1 | S54 | ochoa | Actin, alpha skeletal muscle (EC 3.6.4.-) (Alpha-actin-1) [Cleaved into: Actin, alpha skeletal muscle, intermediate form] | Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells. |
| P85299 | PRR5 | S338 | ochoa | Proline-rich protein 5 (Protein observed with Rictor-1) (Protor-1) | Associated subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals (PubMed:17461779, PubMed:17599906, PubMed:29424687). mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive (PubMed:17461779, PubMed:17599906, PubMed:29424687). mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors (PubMed:17461779, PubMed:17599906, PubMed:29424687). PRR5 plays an important role in regulation of PDGFRB expression and in modulation of platelet-derived growth factor signaling (PubMed:17599906). May act as a tumor suppressor in breast cancer (PubMed:15718101). {ECO:0000269|PubMed:15718101, ECO:0000269|PubMed:17461779, ECO:0000269|PubMed:17599906, ECO:0000269|PubMed:29424687}. |
| Q09666 | AHNAK | S3326 | ochoa | Neuroblast differentiation-associated protein AHNAK (Desmoyokin) | May be required for neuronal cell differentiation. |
| Q09666 | AHNAK | S5418 | ochoa | Neuroblast differentiation-associated protein AHNAK (Desmoyokin) | May be required for neuronal cell differentiation. |
| Q12778 | FOXO1 | S153 | psp | Forkhead box protein O1 (Forkhead box protein O1A) (Forkhead in rhabdomyosarcoma) | Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress (PubMed:10358076, PubMed:12228231, PubMed:15220471, PubMed:15890677, PubMed:18356527, PubMed:19221179, PubMed:20543840, PubMed:21245099). Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3' (PubMed:10358076). Activity suppressed by insulin (PubMed:10358076). Main regulator of redox balance and osteoblast numbers and controls bone mass (By similarity). Orchestrates the endocrine function of the skeleton in regulating glucose metabolism (By similarity). Also acts as a key regulator of chondrogenic commitment of skeletal progenitor cells in response to lipid availability: when lipids levels are low, translocates to the nucleus and promotes expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation (By similarity). Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity (By similarity). Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP (By similarity). Acts as an inhibitor of glucose sensing in pancreatic beta cells by acting as a transcription repressor and suppressing expression of PDX1 (By similarity). In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC1 and PCK1 (By similarity). Also promotes gluconeogenesis by directly promoting expression of PPARGC1A and G6PC1 (PubMed:17024043). Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1 (PubMed:18356527, PubMed:19221179). Promotes neural cell death (PubMed:18356527). Mediates insulin action on adipose tissue (By similarity). Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake (By similarity). Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells (By similarity). Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner (PubMed:20543840). Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By similarity). Positive regulator of apoptosis in cardiac smooth muscle cells as a result of its transcriptional activation of pro-apoptotic genes (PubMed:19483080). Regulates endothelial cell (EC) viability and apoptosis in a PPIA/CYPA-dependent manner via transcription of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis (PubMed:31063815). {ECO:0000250|UniProtKB:A4L7N3, ECO:0000250|UniProtKB:G3V7R4, ECO:0000250|UniProtKB:Q9R1E0, ECO:0000269|PubMed:10358076, ECO:0000269|PubMed:12228231, ECO:0000269|PubMed:15220471, ECO:0000269|PubMed:15890677, ECO:0000269|PubMed:17024043, ECO:0000269|PubMed:18356527, ECO:0000269|PubMed:19221179, ECO:0000269|PubMed:19483080, ECO:0000269|PubMed:20543840, ECO:0000269|PubMed:21245099, ECO:0000269|PubMed:31063815}. |
| Q13232 | NME3 | S142 | ochoa | Nucleoside diphosphate kinase 3 (NDK 3) (NDP kinase 3) (EC 2.7.4.6) (DR-nm23) (Nucleoside diphosphate kinase C) (NDPKC) (nm23-H3) | Catalyzes the phosphorylation of ribonucleosides and deoxyribonucleoside diphosphates, other than ATP, into the corresponding triphosphates with ATP as the major phosphate donor (PubMed:11277919, PubMed:30587587). The ATP gamma phosphate is transferred to the nucleoside diphosphate beta phosphate via a ping-pong mechanism, using a phosphorylated active-site intermediate. Through the catalyzed exchange of gamma-phosphate between di- and triphosphonucleosides participates in regulation of intracellular nucleotide homeostasis (PubMed:11277919, PubMed:30587587). Inhibits granulocyte differentiation (PubMed:7638209). May be required for ciliary function during renal development (By similarity). {ECO:0000250|UniProtKB:Q9PTF3, ECO:0000269|PubMed:11277919, ECO:0000269|PubMed:30587587, ECO:0000269|PubMed:7638209}.; FUNCTION: Independently of its kinase activity, facilitates mitochondrial tethering prior to membrane fusion through its direct membrane-binding and hexamerization (PubMed:30587587, PubMed:37584589). Implicated in repair of both single- and double-stranded breaks in DNA through its association with the ribonucleotide reductase complex (RNR complex) via its interaction with the histone acetyltransferase KAT5, this interaction enables recruitment of NME3 at DNA damage sites where it plays a role in the repair of DNA, independently of its kinase activity (PubMed:37584589). {ECO:0000269|PubMed:30587587, ECO:0000269|PubMed:37584589}. |
| Q13330 | MTA1 | S458 | ochoa | Metastasis-associated protein MTA1 | Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator (PubMed:16617102, PubMed:17671180, PubMed:17922032, PubMed:21965678, PubMed:24413532). Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin (PubMed:16428440, PubMed:28977666). In the NuRD complex, regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA (PubMed:17671180). In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A (PubMed:17922032, PubMed:24413532). Acts as a transcriptional coactivator of BCAS3, and SUMO2, independent of the NuRD complex (PubMed:16617102, PubMed:17671180, PubMed:21965678). Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3 (By similarity). Regulates p53-dependent and -independent DNA repair processes following genotoxic stress (PubMed:19837670). Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair (PubMed:19837670). Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles (By similarity). Positively regulates the CLOCK-BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1 (By similarity). Regulates deacetylation of BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression (By similarity). With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation (By similarity). {ECO:0000250|UniProtKB:Q8K4B0, ECO:0000269|PubMed:16428440, ECO:0000269|PubMed:16617102, ECO:0000269|PubMed:17671180, ECO:0000269|PubMed:17922032, ECO:0000269|PubMed:19837670, ECO:0000269|PubMed:21965678, ECO:0000269|PubMed:24413532}.; FUNCTION: [Isoform Short]: Binds to ESR1 and sequesters it in the cytoplasm and enhances its non-genomic responses. {ECO:0000269|PubMed:15077195}. |
| Q13421 | MSLN | S200 | ochoa | Mesothelin (CAK1 antigen) (Pre-pro-megakaryocyte-potentiating factor) [Cleaved into: Megakaryocyte-potentiating factor (MPF); Mesothelin, cleaved form] | Membrane-anchored forms may play a role in cellular adhesion.; FUNCTION: Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro. |
| Q14151 | SAFB2 | S274 | ochoa | Scaffold attachment factor B2 (SAF-B2) | Binds to scaffold/matrix attachment region (S/MAR) DNA. Can function as an estrogen receptor corepressor and can also inhibit cell proliferation. |
| Q14157 | UBAP2L | S360 | ochoa | Ubiquitin-associated protein 2-like (Protein NICE-4) (RNA polymerase II degradation factor UBAP2L) | Recruits the ubiquitination machinery to RNA polymerase II for polyubiquitination, removal and degradation, when the transcription-coupled nucleotide excision repair (TC-NER) machinery fails to resolve DNA damage (PubMed:35633597). Plays an important role in the activity of long-term repopulating hematopoietic stem cells (LT-HSCs) (By similarity). Is a regulator of stress granule assembly, required for their efficient formation (PubMed:29395067, PubMed:35977029). Required for proper brain development and neocortex lamination (By similarity). {ECO:0000250|UniProtKB:Q80X50, ECO:0000269|PubMed:29395067, ECO:0000269|PubMed:35633597}. |
| Q14432 | PDE3A | S438 | ochoa|psp | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (EC 3.1.4.17) (Cyclic GMP-inhibited phosphodiesterase A) (CGI-PDE A) (cGMP-inhibited cAMP phosphodiesterase) (cGI-PDE) | Cyclic nucleotide phosphodiesterase with specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes (PubMed:1315035, PubMed:25961942, PubMed:8155697, PubMed:8695850). Also has activity toward cUMP (PubMed:27975297). Independently of its catalytic activity it is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling (PubMed:31420216, PubMed:34707099). {ECO:0000269|PubMed:1315035, ECO:0000269|PubMed:25961942, ECO:0000269|PubMed:27975297, ECO:0000269|PubMed:31420216, ECO:0000269|PubMed:34707099, ECO:0000269|PubMed:8155697, ECO:0000269|PubMed:8695850}. |
| Q14527 | HLTF | Y195 | psp | Helicase-like transcription factor (EC 2.3.2.27) (EC 3.6.4.-) (DNA-binding protein/plasminogen activator inhibitor 1 regulator) (HIP116) (RING finger protein 80) (RING-type E3 ubiquitin transferase HLTF) (SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 3) (Sucrose nonfermenting protein 2-like 3) | Has both helicase and E3 ubiquitin ligase activities. Possesses intrinsic ATP-dependent nucleosome-remodeling activity; This activity may be required for transcriptional activation or repression of specific target promoters (By similarity). These may include the SERPINE1 and HIV-1 promoters and the SV40 enhancer, to which this protein can bind directly. Plays a role in error-free postreplication repair (PRR) of damaged DNA and maintains genomic stability through acting as a ubiquitin ligase for 'Lys-63'-linked polyubiquitination of chromatin-bound PCNA. {ECO:0000250, ECO:0000269|PubMed:10391891, ECO:0000269|PubMed:18316726, ECO:0000269|PubMed:18719106, ECO:0000269|PubMed:7876228, ECO:0000269|PubMed:8672239, ECO:0000269|PubMed:9126292}. |
| Q14814 | MEF2D | S98 | ochoa|psp | Myocyte-specific enhancer factor 2D | Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific, growth factor- and stress-induced genes. Mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. Plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signaling in muscle-specific and/or growth factor-related transcription. Plays a critical role in the regulation of neuronal apoptosis (By similarity). {ECO:0000250, ECO:0000269|PubMed:10849446, ECO:0000269|PubMed:11904443, ECO:0000269|PubMed:12691662, ECO:0000269|PubMed:15743823, ECO:0000269|PubMed:15834131}. |
| Q15424 | SAFB | S275 | ochoa | Scaffold attachment factor B1 (SAF-B) (SAF-B1) (HSP27 estrogen response element-TATA box-binding protein) (HSP27 ERE-TATA-binding protein) | Binds to scaffold/matrix attachment region (S/MAR) DNA and forms a molecular assembly point to allow the formation of a 'transcriptosomal' complex (consisting of SR proteins and RNA polymerase II) coupling transcription and RNA processing (PubMed:9671816). Functions as an estrogen receptor corepressor and can also bind to the HSP27 promoter and decrease its transcription (PubMed:12660241). Thereby acts as a negative regulator of cell proliferation (PubMed:12660241). When associated with RBMX, binds to and stimulates transcription from the SREBF1 promoter (By similarity). {ECO:0000250|UniProtKB:D3YXK2, ECO:0000269|PubMed:12660241, ECO:0000269|PubMed:9671816}. |
| Q15527 | SURF2 | S166 | ochoa | Surfeit locus protein 2 (Surf-2) | None |
| Q16891 | IMMT | S113 | ochoa | MICOS complex subunit MIC60 (Cell proliferation-inducing gene 4/52 protein) (Mitochondrial inner membrane protein) (Mitofilin) (p87/89) | Component of the MICOS complex, a large protein complex of the mitochondrial inner membrane that plays crucial roles in the maintenance of crista junctions, inner membrane architecture, and formation of contact sites to the outer membrane (PubMed:22114354, PubMed:25781180, PubMed:32567732, PubMed:33130824). Plays an important role in the maintenance of the MICOS complex stability and the mitochondrial cristae morphology (PubMed:22114354, PubMed:25781180, PubMed:32567732, PubMed:33130824). {ECO:0000269|PubMed:22114354, ECO:0000269|PubMed:25781180, ECO:0000269|PubMed:32567732, ECO:0000269|PubMed:33130824}. |
| Q2M3G4 | SHROOM1 | S250 | ochoa | Protein Shroom1 (Apical protein 2) | May be involved in the assembly of microtubule arrays during cell elongation. {ECO:0000250}. |
| Q4KMP7 | TBC1D10B | S318 | ochoa | TBC1 domain family member 10B (Rab27A-GAP-beta) | Acts as a GTPase-activating protein for RAB3A, RAB22A, RAB27A, and RAB35. Does not act on RAB2A and RAB6A. {ECO:0000269|PubMed:16923811, ECO:0000269|PubMed:19077034}. |
| Q4V9L6 | TMEM119 | S151 | ochoa | Transmembrane protein 119 (Osteoblast induction factor) (OBIF) | Plays an important role in bone formation and normal bone mineralization. Promotes the differentiation of myoblasts into osteoblasts (PubMed:20025746). May induce the commitment and differentiation of myoblasts into osteoblasts through an enhancement of BMP2 production and interaction with the BMP-RUNX2 pathway. Up-regulates the expression of ATF4, a transcription factor which plays a central role in osteoblast differentiation. Essential for normal spermatogenesis and late testicular differentiation (By similarity). {ECO:0000250|UniProtKB:Q8R138, ECO:0000269|PubMed:20025746}. |
| Q53F19 | NCBP3 | S530 | ochoa | Nuclear cap-binding protein subunit 3 (Protein ELG) | Associates with NCBP1/CBP80 to form an alternative cap-binding complex (CBC) which plays a key role in mRNA export. NCBP3 serves as adapter protein linking the capped RNAs (m7GpppG-capped RNA) to NCBP1/CBP80. Unlike the conventional CBC with NCBP2 which binds both small nuclear RNA (snRNA) and messenger (mRNA) and is involved in their export from the nucleus, the alternative CBC with NCBP3 does not bind snRNA and associates only with mRNA thereby playing a role in only mRNA export. The alternative CBC is particularly important in cellular stress situations such as virus infections and the NCBP3 activity is critical to inhibit virus growth (PubMed:26382858). {ECO:0000269|PubMed:26382858}. |
| Q53HL2 | CDCA8 | S224 | ochoa | Borealin (Cell division cycle-associated protein 8) (Dasra-B) (hDasra-B) (Pluripotent embryonic stem cell-related gene 3 protein) | Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Major effector of the TTK kinase in the control of attachment-error-correction and chromosome alignment. {ECO:0000269|PubMed:15249581, ECO:0000269|PubMed:15260989, ECO:0000269|PubMed:16571674, ECO:0000269|PubMed:18243099}. |
| Q5KSL6 | DGKK | S828 | ochoa | Diacylglycerol kinase kappa (DAG kinase kappa) (DGK-kappa) (EC 2.7.1.107) (142 kDa diacylglycerol kinase) (Diglyceride kinase kappa) | Diacylglycerol kinase that converts diacylglycerol/DAG into phosphatidic acid/phosphatidate/PA and regulates the respective levels of these two bioactive lipids (PubMed:16210324, PubMed:23949095). Thereby, acts as a central switch between the signaling pathways activated by these second messengers with different cellular targets and opposite effects in numerous biological processes (Probable). {ECO:0000269|PubMed:16210324, ECO:0000269|PubMed:23949095, ECO:0000305}. |
| Q5SYE7 | NHSL1 | S1555 | ochoa | NHS-like protein 1 | None |
| Q5T1M5 | FKBP15 | S1093 | ochoa | FK506-binding protein 15 (FKBP-15) (133 kDa FK506-binding protein) (133 kDa FKBP) (FKBP-133) (WASP- and FKBP-like protein) (WAFL) | May be involved in the cytoskeletal organization of neuronal growth cones. Seems to be inactive as a PPIase (By similarity). Involved in the transport of early endosomes at the level of transition between microfilament-based and microtubule-based movement. {ECO:0000250, ECO:0000269|PubMed:19121306}. |
| Q5T5P2 | KIAA1217 | S169 | ochoa | Sickle tail protein homolog | Required for normal development of intervertebral disks. {ECO:0000250|UniProtKB:A2AQ25}. |
| Q5XG99 | LYSMD4 | S58 | ochoa | LysM and putative peptidoglycan-binding domain-containing protein 4 | None |
| Q63HN8 | RNF213 | S226 | ochoa | E3 ubiquitin-protein ligase RNF213 (EC 2.3.2.27) (EC 3.6.4.-) (ALK lymphoma oligomerization partner on chromosome 17) (E3 ubiquitin-lipopolysaccharide ligase RNF213) (EC 2.3.2.-) (Mysterin) (RING finger protein 213) | Atypical E3 ubiquitin ligase that can catalyze ubiquitination of both proteins and lipids, and which is involved in various processes, such as lipid metabolism, angiogenesis and cell-autonomous immunity (PubMed:21799892, PubMed:26126547, PubMed:26278786, PubMed:26766444, PubMed:30705059, PubMed:32139119, PubMed:34012115). Acts as a key immune sensor by catalyzing ubiquitination of the lipid A moiety of bacterial lipopolysaccharide (LPS) via its RZ-type zinc-finger: restricts the proliferation of cytosolic bacteria, such as Salmonella, by generating the bacterial ubiquitin coat through the ubiquitination of LPS (PubMed:34012115). Also acts indirectly by mediating the recruitment of the LUBAC complex, which conjugates linear polyubiquitin chains (PubMed:34012115). Ubiquitination of LPS triggers cell-autonomous immunity, such as antibacterial autophagy, leading to degradation of the microbial invader (PubMed:34012115). Involved in lipid metabolism by regulating fat storage and lipid droplet formation; act by inhibiting the lipolytic process (PubMed:30705059). Also regulates lipotoxicity by inhibiting desaturation of fatty acids (PubMed:30846318). Also acts as an E3 ubiquitin-protein ligase via its RING-type zinc finger: mediates 'Lys-63'-linked ubiquitination of target proteins (PubMed:32139119, PubMed:33842849). Involved in the non-canonical Wnt signaling pathway in vascular development: acts by mediating ubiquitination and degradation of FLNA and NFATC2 downstream of RSPO3, leading to inhibit the non-canonical Wnt signaling pathway and promoting vessel regression (PubMed:26766444). Also has ATPase activity; ATPase activity is required for ubiquitination of LPS (PubMed:34012115). {ECO:0000269|PubMed:21799892, ECO:0000269|PubMed:26126547, ECO:0000269|PubMed:26278786, ECO:0000269|PubMed:26766444, ECO:0000269|PubMed:30705059, ECO:0000269|PubMed:30846318, ECO:0000269|PubMed:32139119, ECO:0000269|PubMed:33842849, ECO:0000269|PubMed:34012115}. |
| Q66K74 | MAP1S | S472 | ochoa | Microtubule-associated protein 1S (MAP-1S) (BPY2-interacting protein 1) (Microtubule-associated protein 8) (Variable charge Y chromosome 2-interacting protein 1) (VCY2-interacting protein 1) (VCY2IP-1) [Cleaved into: MAP1S heavy chain; MAP1S light chain] | Microtubule-associated protein that mediates aggregation of mitochondria resulting in cell death and genomic destruction (MAGD). Plays a role in anchoring the microtubule organizing center to the centrosomes. Binds to DNA. Plays a role in apoptosis. Involved in the formation of microtubule bundles (By similarity). {ECO:0000250, ECO:0000269|PubMed:15899810, ECO:0000269|PubMed:17234756}. |
| Q68DK7 | MSL1 | S217 | ochoa | Male-specific lethal 1 homolog (MSL-1) (Male-specific lethal 1-like 1) (MSL1-like 1) (Male-specific lethal-1 homolog 1) | Non-catalytic component of the MSL histone acetyltransferase complex, a multiprotein complex that mediates the majority of histone H4 acetylation at 'Lys-16' (H4K16ac), an epigenetic mark that prevents chromatin compaction (PubMed:16227571, PubMed:16543150, PubMed:33837287). The MSL complex is required for chromosome stability and genome integrity by maintaining homeostatic levels of H4K16ac (PubMed:33837287). The MSL complex is also involved in gene dosage by promoting up-regulation of genes expressed by the X chromosome (By similarity). X up-regulation is required to compensate for autosomal biallelic expression (By similarity). The MSL complex also participates in gene dosage compensation by promoting expression of Tsix non-coding RNA (By similarity). Within the MSL complex, acts as a scaffold to tether MSL3 and KAT8 together for enzymatic activity regulation (PubMed:22547026). Greatly enhances MSL2 E3 ubiquitin ligase activity, promoting monoubiquitination of histone H2B at 'Lys-34' (H2BK34Ub) (PubMed:21726816, PubMed:30930284). This modification in turn stimulates histone H3 methylation at 'Lys-4' (H3K4me) and 'Lys-79' (H3K79me) and leads to gene activation, including that of HOXA9 and MEIS1 (PubMed:21726816). {ECO:0000250|UniProtKB:Q6PDM1, ECO:0000269|PubMed:16227571, ECO:0000269|PubMed:16543150, ECO:0000269|PubMed:21726816, ECO:0000269|PubMed:22547026, ECO:0000269|PubMed:30930284, ECO:0000269|PubMed:33837287}. |
| Q6P2E9 | EDC4 | S33 | ochoa | Enhancer of mRNA-decapping protein 4 (Autoantigen Ge-1) (Autoantigen RCD-8) (Human enhancer of decapping large subunit) (Hedls) | In the process of mRNA degradation, seems to play a role in mRNA decapping. Component of a complex containing DCP2 and DCP1A which functions in decapping of ARE-containing mRNAs. Promotes complex formation between DCP1A and DCP2. Enhances the catalytic activity of DCP2 (in vitro). {ECO:0000269|PubMed:16364915}. |
| Q6ZRV2 | FAM83H | S667 | ochoa | Protein FAM83H | May play a major role in the structural organization and calcification of developing enamel (PubMed:18252228). May play a role in keratin cytoskeleton disassembly by recruiting CSNK1A1 to keratin filaments. Thereby, it may regulate epithelial cell migration (PubMed:23902688). {ECO:0000269|PubMed:18252228, ECO:0000269|PubMed:23902688}. |
| Q6ZV70 | LANCL3 | Y302 | ochoa | LanC-like protein 3 | None |
| Q7Z401 | DENND4A | S1606 | ochoa | C-myc promoter-binding protein (DENN domain-containing protein 4A) | Probable guanine nucleotide exchange factor (GEF) which may activate RAB10. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. According to PubMed:8056341, it may bind to ISRE-like element (interferon-stimulated response element) of MYC P2 promoter. {ECO:0000269|PubMed:20937701, ECO:0000269|PubMed:8056341}. |
| Q7Z5K2 | WAPL | S443 | ochoa | Wings apart-like protein homolog (Friend of EBNA2 protein) (WAPL cohesin release factor) | Regulator of sister chromatid cohesion in mitosis which negatively regulates cohesin association with chromatin (PubMed:26299517). Involved in both sister chromatid cohesion during interphase and sister-chromatid resolution during early stages of mitosis. Couples DNA replication to sister chromatid cohesion. Cohesion ensures that chromosome partitioning is accurate in both meiotic and mitotic cells and plays an important role in DNA repair. {ECO:0000269|PubMed:15150110, ECO:0000269|PubMed:17112726, ECO:0000269|PubMed:17113138, ECO:0000269|PubMed:19696148, ECO:0000269|PubMed:19907496, ECO:0000269|PubMed:21111234, ECO:0000269|PubMed:23776203, ECO:0000269|PubMed:26299517}. |
| Q7Z6Z7 | HUWE1 | S1368 | ochoa | E3 ubiquitin-protein ligase HUWE1 (EC 2.3.2.26) (ARF-binding protein 1) (ARF-BP1) (HECT, UBA and WWE domain-containing protein 1) (HECT-type E3 ubiquitin transferase HUWE1) (Homologous to E6AP carboxyl terminus homologous protein 9) (HectH9) (Large structure of UREB1) (LASU1) (Mcl-1 ubiquitin ligase E3) (Mule) (Upstream regulatory element-binding protein 1) (URE-B1) (URE-binding protein 1) | E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:15567145, PubMed:15767685, PubMed:15989957, PubMed:17567951, PubMed:18488021, PubMed:19037095, PubMed:19713937, PubMed:20534529, PubMed:30217973). Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1 (PubMed:15989957). Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair (PubMed:19713937). Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4 (PubMed:15567145, PubMed:15767685, PubMed:15989956). Ubiquitinates MFN2 to negatively regulate mitochondrial fusion in response to decreased stearoylation of TFRC (PubMed:26214738). Ubiquitination of MFN2 also takes place following induction of mitophagy; AMBRA1 acts as a cofactor for HUWE1-mediated ubiquitination (PubMed:30217973). Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN (PubMed:18488021). May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation (PubMed:17567951). Mediates polyubiquitination of isoform 2 of PA2G4 (PubMed:19037095). Acts in concert with MYCBP2 to regulate the circadian clock gene expression by promoting the lithium-induced ubiquination and degradation of NR1D1 (PubMed:20534529). Binds to an upstream initiator-like sequence in the preprodynorphin gene (By similarity). Mediates HAPSTR1 degradation, but is also a required cofactor in the pathway by which HAPSTR1 governs stress signaling (PubMed:35776542). Acts as a regulator of the JNK and NF-kappa-B signaling pathways by mediating assembly of heterotypic 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains that are then recognized by TAB2: HUWE1 mediates branching of 'Lys-48'-linked chains of substrates initially modified with 'Lys-63'-linked conjugates by TRAF6 (PubMed:27746020). 'Lys-63'-/'Lys-48'-linked branched ubiquitin chains protect 'Lys-63'-linkages from CYLD deubiquitination (PubMed:27746020). Ubiquitinates PPARA in hepatocytes (By similarity). {ECO:0000250|UniProtKB:P51593, ECO:0000250|UniProtKB:Q7TMY8, ECO:0000269|PubMed:15567145, ECO:0000269|PubMed:15767685, ECO:0000269|PubMed:15989956, ECO:0000269|PubMed:15989957, ECO:0000269|PubMed:17567951, ECO:0000269|PubMed:18488021, ECO:0000269|PubMed:19037095, ECO:0000269|PubMed:19713937, ECO:0000269|PubMed:20534529, ECO:0000269|PubMed:26214738, ECO:0000269|PubMed:27746020, ECO:0000269|PubMed:30217973, ECO:0000269|PubMed:35776542}. |
| Q86V48 | LUZP1 | S531 | ochoa | Leucine zipper protein 1 (Filamin mechanobinding actin cross-linking protein) (Fimbacin) | F-actin cross-linking protein (PubMed:30990684). Stabilizes actin and acts as a negative regulator of primary cilium formation (PubMed:32496561). Positively regulates the phosphorylation of both myosin II and protein phosphatase 1 regulatory subunit PPP1R12A/MYPT1 and promotes the assembly of myosin II stacks within actin stress fibers (PubMed:38832964). Inhibits the phosphorylation of myosin light chain MYL9 by DAPK3 and suppresses the constriction velocity of the contractile ring during cytokinesis (PubMed:38009294). Binds to microtubules and promotes epithelial cell apical constriction by up-regulating levels of diphosphorylated myosin light chain (MLC) through microtubule-dependent inhibition of MLC dephosphorylation by myosin phosphatase (By similarity). Involved in regulation of cell migration, nuclear size and centriole number, probably through regulation of the actin cytoskeleton (By similarity). Component of the CERF-1 and CERF-5 chromatin remodeling complexes in embryonic stem cells where it acts to stabilize the complexes (By similarity). Plays a role in embryonic brain and cardiovascular development (By similarity). {ECO:0000250|UniProtKB:Q8R4U7, ECO:0000269|PubMed:30990684, ECO:0000269|PubMed:32496561, ECO:0000269|PubMed:38009294, ECO:0000269|PubMed:38832964}. |
| Q86WV1 | SKAP1 | Y298 | psp | Src kinase-associated phosphoprotein 1 (Src family-associated phosphoprotein 1) (Src kinase-associated phosphoprotein of 55 kDa) (SKAP-55) (pp55) | Positively regulates T-cell receptor signaling by enhancing the MAP kinase pathway. Required for optimal conjugation between T-cells and antigen-presenting cells by promoting the clustering of integrin ITGAL on the surface of T-cells. May be involved in high affinity immunoglobulin epsilon receptor signaling in mast cells. {ECO:0000269|PubMed:10856234, ECO:0000269|PubMed:11909961, ECO:0000269|PubMed:12652296, ECO:0000269|PubMed:15939789, ECO:0000269|PubMed:16980616}. |
| Q8IV36 | HID1 | S598 | ochoa | Protein HID1 (Down-regulated in multiple cancers 1) (HID1 domain-containing protein) (Protein hid-1 homolog) | May play an important role in the development of cancers in a broad range of tissues. {ECO:0000269|PubMed:11281419}. |
| Q8IWZ3 | ANKHD1 | S93 | ochoa | Ankyrin repeat and KH domain-containing protein 1 (HIV-1 Vpr-binding ankyrin repeat protein) (Multiple ankyrin repeats single KH domain) (hMASK) | May play a role as a scaffolding protein that may be associated with the abnormal phenotype of leukemia cells. Isoform 2 may possess an antiapoptotic effect and protect cells during normal cell survival through its regulation of caspases. {ECO:0000269|PubMed:16098192}. |
| Q8IYI6 | EXOC8 | S151 | ochoa | Exocyst complex component 8 (Exocyst complex 84 kDa subunit) | Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. |
| Q8IZD4 | DCP1B | S147 | ochoa | mRNA-decapping enzyme 1B (EC 3.6.1.62) | May play a role in the degradation of mRNAs, both in normal mRNA turnover and in nonsense-mediated mRNA decay. May remove the 7-methyl guanine cap structure from mRNA molecules, yielding a 5'-phosphorylated mRNA fragment and 7m-GDP (By similarity). {ECO:0000250|UniProtKB:Q9NPI6}. |
| Q8N3J3 | HROB | S46 | ochoa | Homologous recombination OB-fold protein | DNA-binding protein involved in homologous recombination that acts by recruiting the MCM8-MCM9 helicase complex to sites of DNA damage to promote DNA repair synthesis. {ECO:0000269|PubMed:31467087}. |
| Q8N3K9 | CMYA5 | S155 | ochoa | Cardiomyopathy-associated protein 5 (Dystrobrevin-binding protein 2) (Genethonin-3) (Myospryn) (SPRY domain-containing protein 2) (Tripartite motif-containing protein 76) | May serve as an anchoring protein that mediates the subcellular compartmentation of protein kinase A (PKA) via binding to PRKAR2A (By similarity). May function as a repressor of calcineurin-mediated transcriptional activity. May attenuate calcineurin ability to induce slow-fiber gene program in muscle and may negatively modulate skeletal muscle regeneration (By similarity). Plays a role in the assembly of ryanodine receptor (RYR2) clusters in striated muscle (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:Q70KF4}. |
| Q8N8K9 | KIAA1958 | S249 | ochoa | Uncharacterized protein KIAA1958 | None |
| Q8NEY1 | NAV1 | S695 | ochoa | Neuron navigator 1 (Pore membrane and/or filament-interacting-like protein 3) (Steerin-1) (Unc-53 homolog 1) (unc53H1) | May be involved in neuronal migration. {ECO:0000250}. |
| Q8NFH5 | NUP35 | S93 | ochoa | Nucleoporin NUP35 (35 kDa nucleoporin) (Mitotic phosphoprotein 44) (MP-44) (Nuclear pore complex protein Nup53) (Nucleoporin NUP53) | Functions as a component of the nuclear pore complex (NPC). NPC components, collectively referred to as nucleoporins (NUPs), can play the role of both NPC structural components and of docking or interaction partners for transiently associated nuclear transport factors. May play a role in the association of MAD1 with the NPC. {ECO:0000269|PubMed:15703211}. |
| Q8TEQ0 | SNX29 | S642 | ochoa | Sorting nexin-29 (RUN domain-containing protein 2A) | None |
| Q8TF72 | SHROOM3 | S1656 | ochoa | Protein Shroom3 (Shroom-related protein) (hShrmL) | Controls cell shape changes in the neuroepithelium during neural tube closure. Induces apical constriction in epithelial cells by promoting the apical accumulation of F-actin and myosin II, and probably by bundling stress fibers (By similarity). Induces apicobasal cell elongation by redistributing gamma-tubulin and directing the assembly of robust apicobasal microtubule arrays (By similarity). {ECO:0000250|UniProtKB:Q27IV2, ECO:0000250|UniProtKB:Q9QXN0}. |
| Q8WWI1 | LMO7 | S704 | ochoa | LIM domain only protein 7 (LMO-7) (F-box only protein 20) (LOMP) | None |
| Q8WXX5 | DNAJC9 | S88 | ochoa | DnaJ homolog subfamily C member 9 (HDJC9) (DnaJ protein SB73) | Acts as a dual histone chaperone and heat shock co-chaperone (PubMed:33857403). As a histone chaperone, forms a co-chaperone complex with MCM2 and histone H3-H4 heterodimers; and may thereby assist MCM2 in histone H3-H4 heterodimer recognition and facilitate the assembly of histones into nucleosomes (PubMed:33857403). May also act as a histone co-chaperone together with TONSL (PubMed:33857403). May recruit histone chaperones ASF1A, NASP and SPT2 to histone H3-H4 heterodimers (PubMed:33857403). Also plays a role as co-chaperone of the HSP70 family of molecular chaperone proteins, such as HSPA1A, HSPA1B and HSPA8 (PubMed:17182002, PubMed:33857403). As a co-chaperone, may play a role in the recruitment of HSP70-type molecular chaperone machinery to histone H3-H4 substrates, thereby maintaining the histone structural integrity (PubMed:33857403). Exhibits activity to assemble histones onto DNA in vitro (PubMed:33857403). {ECO:0000269|PubMed:17182002, ECO:0000269|PubMed:33857403}. |
| Q92541 | RTF1 | S53 | ochoa | RNA polymerase-associated protein RTF1 homolog | Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Binds single-stranded DNA. Required for maximal induction of heat-shock genes. Required for the trimethylation of histone H3 'Lys-4' (H3K4me3) on genes involved in stem cell pluripotency; this function is synergistic with CXXC1 indicative for an involvement of a SET1 complex (By similarity). {ECO:0000250, ECO:0000269|PubMed:19345177, ECO:0000269|PubMed:20178742}. |
| Q92585 | MAML1 | S168 | ochoa | Mastermind-like protein 1 (Mam-1) | Acts as a transcriptional coactivator for NOTCH proteins. Has been shown to amplify NOTCH-induced transcription of HES1. Enhances phosphorylation and proteolytic turnover of the NOTCH intracellular domain in the nucleus through interaction with CDK8. Binds to CREBBP/CBP which promotes nucleosome acetylation at NOTCH enhancers and activates transcription. Induces phosphorylation and localization of CREBBP to nuclear foci. Plays a role in hematopoietic development by regulating NOTCH-mediated lymphoid cell fate decisions. {ECO:0000269|PubMed:11101851, ECO:0000269|PubMed:11390662, ECO:0000269|PubMed:12050117, ECO:0000269|PubMed:15546612, ECO:0000269|PubMed:17317671}. |
| Q92616 | GCN1 | S2490 | ochoa | Stalled ribosome sensor GCN1 (GCN1 eIF-2-alpha kinase activator homolog) (GCN1-like protein 1) (General control of amino-acid synthesis 1-like protein 1) (Translational activator GCN1) (HsGCN1) | Ribosome collision sensor that plays a key role in the RNF14-RNF25 translation quality control pathway, a pathway that takes place when a ribosome has stalled during translation, and which promotes ubiquitination and degradation of translation factors on stalled ribosomes (PubMed:32610081, PubMed:36638793, PubMed:37651229, PubMed:37951215, PubMed:37951216). Directly binds to the ribosome and acts as a sentinel for colliding ribosomes: activated following ribosome stalling and promotes recruitment of RNF14, which directly ubiquitinates EEF1A1/eEF1A, leading to its degradation (PubMed:36638793, PubMed:37951215, PubMed:37951216). In addition to EEF1A1/eEF1A, the RNF14-RNF25 translation quality control pathway mediates degradation of ETF1/eRF1 and ubiquitination of ribosomal protein (PubMed:36638793, PubMed:37651229). GCN1 also acts as a positive activator of the integrated stress response (ISR) by mediating activation of EIF2AK4/GCN2 in response to amino acid starvation (By similarity). Interaction with EIF2AK4/GCN2 on translating ribosomes stimulates EIF2AK4/GCN2 kinase activity, leading to phosphorylation of eukaryotic translation initiation factor 2 (eIF-2-alpha/EIF2S1) (By similarity). EIF2S1/eIF-2-alpha phosphorylation converts EIF2S1/eIF-2-alpha into a global protein synthesis inhibitor, leading to a global attenuation of cap-dependent translation, and thus to a reduced overall utilization of amino acids, while concomitantly initiating the preferential translation of ISR-specific mRNAs, such as the transcriptional activator ATF4, and hence allowing ATF4-mediated reprogramming of amino acid biosynthetic gene expression to alleviate nutrient depletion (By similarity). {ECO:0000250|UniProtKB:E9PVA8, ECO:0000269|PubMed:32610081, ECO:0000269|PubMed:36638793, ECO:0000269|PubMed:37651229, ECO:0000269|PubMed:37951215, ECO:0000269|PubMed:37951216}. |
| Q92622 | RUBCN | S443 | ochoa | Run domain Beclin-1-interacting and cysteine-rich domain-containing protein (Rubicon) (Beclin-1 associated RUN domain containing protein) (Baron) | Inhibits PIK3C3 activity; under basal conditions negatively regulates PI3K complex II (PI3KC3-C2) function in autophagy. Negatively regulates endosome maturation and degradative endocytic trafficking and impairs autophagosome maturation process. Can sequester UVRAG from association with a class C Vps complex (possibly the HOPS complex) and negatively regulates Rab7 activation (PubMed:20974968, PubMed:21062745). {ECO:0000269|PubMed:20974968, ECO:0000269|PubMed:21062745}.; FUNCTION: Involved in regulation of pathogen-specific host defense of activated macrophages. Following bacterial infection promotes NADH oxidase activity by association with CYBA thereby affecting TLR2 signaling and probably other TLR-NOX pathways. Stabilizes the CYBA:CYBB NADPH oxidase heterodimer, increases its association with TLR2 and its phagosome trafficking to induce antimicrobial burst of ROS and production of inflammatory cytokines (PubMed:22423966). Following fungal or viral infection (implicating CLEC7A (dectin-1)-mediated myeloid cell activation or RIGI-dependent sensing of RNA viruses) negatively regulates pro-inflammatory cytokine production by association with CARD9 and sequestering it from signaling complexes (PubMed:22423967). {ECO:0000269|PubMed:22423966, ECO:0000269|PubMed:22423967}. |
| Q92729 | PTPRU | Y865 | ochoa | Receptor-type tyrosine-protein phosphatase U (R-PTP-U) (EC 3.1.3.48) (Pancreatic carcinoma phosphatase 2) (PCP-2) (Protein-tyrosine phosphatase J) (PTP-J) (hPTP-J) (Protein-tyrosine phosphatase pi) (PTP pi) (Protein-tyrosine phosphatase receptor omicron) (PTP-RO) (Receptor-type protein-tyrosine phosphatase psi) (R-PTP-psi) | Tyrosine-protein phosphatase which dephosphorylates CTNNB1. Regulates CTNNB1 function both in cell adhesion and signaling. May function in cell proliferation and migration and play a role in the maintenance of epithelial integrity. May play a role in megakaryocytopoiesis. {ECO:0000269|PubMed:10397721, ECO:0000269|PubMed:12501215, ECO:0000269|PubMed:16574648}. |
| Q92903 | CDS1 | S35 | ochoa | Phosphatidate cytidylyltransferase 1 (EC 2.7.7.41) (CDP-DAG synthase 1) (CDP-DG synthase 1) (CDP-diacylglycerol synthase 1) (CDS 1) (CDP-diglyceride pyrophosphorylase 1) (CDP-diglyceride synthase 1) (CTP:phosphatidate cytidylyltransferase 1) | Catalyzes the conversion of phosphatidic acid (PA) to CDP-diacylglycerol (CDP-DAG), an essential intermediate in the synthesis of phosphatidylglycerol, cardiolipin and phosphatidylinositol (PubMed:25375833, PubMed:9407135). Exhibits almost no acyl chain preference for PA, showing no discrimination for the sn-1/sn-2 acyl chain composition of PAs (PubMed:25375833). Plays an important role in regulating the growth of lipid droplets which are storage organelles at the center of lipid and energy homeostasis (PubMed:26946540, PubMed:31548309). Positively regulates the differentiation and development of adipocytes (By similarity). {ECO:0000250|UniProtKB:P98191, ECO:0000269|PubMed:25375833, ECO:0000269|PubMed:26946540, ECO:0000269|PubMed:31548309, ECO:0000269|PubMed:9407135}. |
| Q92917 | GPKOW | S42 | ochoa | G-patch domain and KOW motifs-containing protein (G-patch domain-containing protein 5) (Protein MOS2 homolog) (Protein T54) | RNA-binding protein involved in pre-mRNA splicing. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). {ECO:0000269|PubMed:25296192, ECO:0000305|PubMed:33509932}. |
| Q92966 | SNAPC3 | S79 | ochoa | snRNA-activating protein complex subunit 3 (SNAPc subunit 3) (Proximal sequence element-binding transcription factor subunit beta) (PSE-binding factor subunit beta) (PTF subunit beta) (Small nuclear RNA-activating complex polypeptide 3) (snRNA-activating protein complex 50 kDa subunit) (SNAPc 50 kDa subunit) | Part of the SNAPc complex required for the transcription of both RNA polymerase II and III small-nuclear RNA genes. Binds to the proximal sequence element (PSE), a non-TATA-box basal promoter element common to these 2 types of genes. Recruits TBP and BRF2 to the U6 snRNA TATA box. {ECO:0000269|PubMed:12621023}. |
| Q96AE4 | FUBP1 | S52 | ochoa | Far upstream element-binding protein 1 (FBP) (FUSE-binding protein 1) (DNA helicase V) (hDH V) | Regulates MYC expression by binding to a single-stranded far-upstream element (FUSE) upstream of the MYC promoter. May act both as activator and repressor of transcription. {ECO:0000269|PubMed:8125259}. |
| Q96E39 | RBMXL1 | S184 | ochoa | RNA binding motif protein, X-linked-like-1 (Heterogeneous nuclear ribonucleoprotein G-like 1) | RNA-binding protein which may be involved in pre-mRNA splicing. {ECO:0000250}. |
| Q96HU1 | SGSM3 | S60 | ochoa | Small G protein signaling modulator 3 (Merlin-associated protein) (RUN and TBC1 domain-containing protein 3) (Rab-GTPase-activating protein-like protein) (RabGAPLP) | May play a cooperative role in NF2-mediated growth suppression of cells. {ECO:0000269|PubMed:15541357}. |
| Q96JN0 | LCOR | S148 | ochoa | Ligand-dependent corepressor (LCoR) (Mblk1-related protein 2) | May act as transcription activator that binds DNA elements with the sequence 5'-CCCTATCGATCGATCTCTACCT-3' (By similarity). Repressor of ligand-dependent transcription activation by target nuclear receptors. Repressor of ligand-dependent transcription activation by ESR1, ESR2, NR3C1, PGR, RARA, RARB, RARG, RXRA and VDR. {ECO:0000250, ECO:0000269|PubMed:12535528}. |
| Q96KM6 | ZNF512B | S679 | ochoa | Zinc finger protein 512B | Involved in transcriptional regulation by repressing gene expression (PubMed:39460621). Associates with the nucleosome remodeling and histone deacetylase (NuRD) complex, which promotes transcriptional repression by histone deacetylation and nucleosome remodeling (PubMed:39460621). {ECO:0000269|PubMed:39460621}. |
| Q96LD4 | TRIM47 | S399 | ochoa | E3 ubiquitin-protein ligase TRIM47 (EC 2.3.2.27) (Gene overexpressed in astrocytoma protein) (RING finger protein 100) (Tripartite motif-containing protein 47) | E3 ubiquitin-protein ligase that mediates the ubiquitination and proteasomal degradation of CYLD. {ECO:0000269|PubMed:29291351}. |
| Q96PE3 | INPP4A | S517 | ochoa | Inositol polyphosphate-4-phosphatase type I A (Inositol polyphosphate 4-phosphatase type I) (Type I inositol 3,4-bisphosphate 4-phosphatase) (EC 3.1.3.66) | Catalyzes the hydrolysis of the 4-position phosphate of phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) (PubMed:15716355, PubMed:20463662). Also catalyzes inositol 1,3,4-trisphosphate and inositol 1,4-bisphosphate (By similarity). Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival (By similarity) (PubMed:30071275). May protect neurons from excitotoxic cell death by regulating the synaptic localization of cell surface N-methyl-D-aspartate-type glutamate receptors (NMDARs) and NMDAR-mediated excitatory postsynaptic current (By similarity). {ECO:0000250|UniProtKB:Q62784, ECO:0000250|UniProtKB:Q9EPW0, ECO:0000269|PubMed:15716355, ECO:0000269|PubMed:20463662, ECO:0000269|PubMed:30071275}.; FUNCTION: [Isoform 4]: Displays no 4-phosphatase activity for PtdIns(3,4)P2, Ins(3,4)P2, or Ins(1,3,4)P3. {ECO:0000269|PubMed:9295334}. |
| Q96RL1 | UIMC1 | S410 | ochoa | BRCA1-A complex subunit RAP80 (Receptor-associated protein 80) (Retinoid X receptor-interacting protein 110) (Ubiquitin interaction motif-containing protein 1) | Ubiquitin-binding protein (PubMed:24627472). Specifically recognizes and binds 'Lys-63'-linked ubiquitin (PubMed:19328070, Ref.38). Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. Also weakly binds monoubiquitin but with much less affinity than 'Lys-63'-linked ubiquitin. May interact with monoubiquitinated histones H2A and H2B; the relevance of such results is however unclear in vivo. Does not bind Lys-48'-linked ubiquitin. May indirectly act as a transcriptional repressor by inhibiting the interaction of NR6A1 with the corepressor NCOR1. {ECO:0000269|PubMed:12080054, ECO:0000269|PubMed:17525340, ECO:0000269|PubMed:17525341, ECO:0000269|PubMed:17525342, ECO:0000269|PubMed:17621610, ECO:0000269|PubMed:17643121, ECO:0000269|PubMed:19015238, ECO:0000269|PubMed:19202061, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19328070, ECO:0000269|PubMed:24627472, ECO:0000269|Ref.38}. |
| Q96RL1 | UIMC1 | S554 | ochoa | BRCA1-A complex subunit RAP80 (Receptor-associated protein 80) (Retinoid X receptor-interacting protein 110) (Ubiquitin interaction motif-containing protein 1) | Ubiquitin-binding protein (PubMed:24627472). Specifically recognizes and binds 'Lys-63'-linked ubiquitin (PubMed:19328070, Ref.38). Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. Also weakly binds monoubiquitin but with much less affinity than 'Lys-63'-linked ubiquitin. May interact with monoubiquitinated histones H2A and H2B; the relevance of such results is however unclear in vivo. Does not bind Lys-48'-linked ubiquitin. May indirectly act as a transcriptional repressor by inhibiting the interaction of NR6A1 with the corepressor NCOR1. {ECO:0000269|PubMed:12080054, ECO:0000269|PubMed:17525340, ECO:0000269|PubMed:17525341, ECO:0000269|PubMed:17525342, ECO:0000269|PubMed:17621610, ECO:0000269|PubMed:17643121, ECO:0000269|PubMed:19015238, ECO:0000269|PubMed:19202061, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19328070, ECO:0000269|PubMed:24627472, ECO:0000269|Ref.38}. |
| Q96RL1 | UIMC1 | S597 | ochoa | BRCA1-A complex subunit RAP80 (Receptor-associated protein 80) (Retinoid X receptor-interacting protein 110) (Ubiquitin interaction motif-containing protein 1) | Ubiquitin-binding protein (PubMed:24627472). Specifically recognizes and binds 'Lys-63'-linked ubiquitin (PubMed:19328070, Ref.38). Plays a central role in the BRCA1-A complex by specifically binding 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites of DNA damage at double-strand breaks (DSBs). The BRCA1-A complex also possesses deubiquitinase activity that specifically removes 'Lys-63'-linked ubiquitin on histones H2A and H2AX. Also weakly binds monoubiquitin but with much less affinity than 'Lys-63'-linked ubiquitin. May interact with monoubiquitinated histones H2A and H2B; the relevance of such results is however unclear in vivo. Does not bind Lys-48'-linked ubiquitin. May indirectly act as a transcriptional repressor by inhibiting the interaction of NR6A1 with the corepressor NCOR1. {ECO:0000269|PubMed:12080054, ECO:0000269|PubMed:17525340, ECO:0000269|PubMed:17525341, ECO:0000269|PubMed:17525342, ECO:0000269|PubMed:17621610, ECO:0000269|PubMed:17643121, ECO:0000269|PubMed:19015238, ECO:0000269|PubMed:19202061, ECO:0000269|PubMed:19261748, ECO:0000269|PubMed:19328070, ECO:0000269|PubMed:24627472, ECO:0000269|Ref.38}. |
| Q96S38 | RPS6KC1 | S282 | ochoa | Ribosomal protein S6 kinase delta-1 (S6K-delta-1) (EC 2.7.11.1) (52 kDa ribosomal protein S6 kinase) (Ribosomal S6 kinase-like protein with two PSK domains 118 kDa protein) (SPHK1-binding protein) | May be involved in transmitting sphingosine-1 phosphate (SPP)-mediated signaling into the cell (PubMed:12077123). Plays a role in the recruitment of PRDX3 to early endosomes (PubMed:15750338). {ECO:0000269|PubMed:12077123, ECO:0000269|PubMed:15750338}. |
| Q96T58 | SPEN | S1392 | ochoa | Msx2-interacting protein (SMART/HDAC1-associated repressor protein) (SPEN homolog) | May serve as a nuclear matrix platform that organizes and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergizes with RUNX2 to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway. Negative regulator of the Notch pathway via its interaction with RBPSUH, which prevents the association between NOTCH1 and RBPSUH, and therefore suppresses the transactivation activity of Notch signaling. Blocks the differentiation of precursor B-cells into marginal zone B-cells. Probably represses transcription via the recruitment of large complexes containing histone deacetylase proteins. May bind both to DNA and RNA. {ECO:0000250|UniProtKB:Q62504, ECO:0000269|PubMed:11331609, ECO:0000269|PubMed:12374742}. |
| Q96T88 | UHRF1 | S661 | psp | E3 ubiquitin-protein ligase UHRF1 (EC 2.3.2.27) (Inverted CCAAT box-binding protein of 90 kDa) (Nuclear protein 95) (Nuclear zinc finger protein Np95) (HuNp95) (hNp95) (RING finger protein 106) (RING-type E3 ubiquitin transferase UHRF1) (Transcription factor ICBP90) (Ubiquitin-like PHD and RING finger domain-containing protein 1) (hUHRF1) (Ubiquitin-like-containing PHD and RING finger domains protein 1) | Multidomain protein that acts as a key epigenetic regulator by bridging DNA methylation and chromatin modification. Specifically recognizes and binds hemimethylated DNA at replication forks via its YDG domain and recruits DNMT1 methyltransferase to ensure faithful propagation of the DNA methylation patterns through DNA replication. In addition to its role in maintenance of DNA methylation, also plays a key role in chromatin modification: through its tudor-like regions and PHD-type zinc fingers, specifically recognizes and binds histone H3 trimethylated at 'Lys-9' (H3K9me3) and unmethylated at 'Arg-2' (H3R2me0), respectively, and recruits chromatin proteins. Enriched in pericentric heterochromatin where it recruits different chromatin modifiers required for this chromatin replication. Also localizes to euchromatic regions where it negatively regulates transcription possibly by impacting DNA methylation and histone modifications. Has E3 ubiquitin-protein ligase activity by mediating the ubiquitination of target proteins such as histone H3 and PML. It is still unclear how E3 ubiquitin-protein ligase activity is related to its role in chromatin in vivo. Plays a role in DNA repair by cooperating with UHRF2 to ensure recruitment of FANCD2 to interstrand cross-links (ICLs) leading to FANCD2 activation. Acts as a critical player of proper spindle architecture by catalyzing the 'Lys-63'-linked ubiquitination of KIF11, thereby controlling KIF11 localization on the spindle (PubMed:37728657). {ECO:0000269|PubMed:10646863, ECO:0000269|PubMed:15009091, ECO:0000269|PubMed:15361834, ECO:0000269|PubMed:17673620, ECO:0000269|PubMed:17967883, ECO:0000269|PubMed:19056828, ECO:0000269|PubMed:21745816, ECO:0000269|PubMed:21777816, ECO:0000269|PubMed:22945642, ECO:0000269|PubMed:30335751, ECO:0000269|PubMed:37728657}. |
| Q99569 | PKP4 | S457 | ochoa | Plakophilin-4 (p0071) | Plays a role as a regulator of Rho activity during cytokinesis. May play a role in junctional plaques. {ECO:0000269|PubMed:17115030}. |
| Q99607 | ELF4 | S545 | ochoa | ETS-related transcription factor Elf-4 (E74-like factor 4) (Myeloid Elf-1-like factor) | Transcriptional activator that binds to DNA sequences containing the consensus 5'-WGGA-3'. Transactivates promoters of the hematopoietic growth factor genes CSF2, IL3, IL8, and of the bovine lysozyme gene. Acts synergistically with RUNX1 to transactivate the IL3 promoter (By similarity). Transactivates the PRF1 promoter in natural killer (NK) cells and CD8+ T cells (PubMed:34326534). Plays a role in the development and function of NK and NK T-cells and in innate immunity. Controls the proliferation and homing of CD8+ T-cells via the Kruppel-like factors KLF4 and KLF2 (By similarity). Controls cell senescence in a p53-dependent manner. Can also promote cellular transformation through inhibition of the p16 pathway. Is a transcriptional regulator of inflammation, controlling T-helper 17 (Th17) cells and macrophage inflammatory responses. Required for sustained transcription of anti-inflammatory genes, including IL1RN (PubMed:34326534, PubMed:35266071). Is a negative regulator of pro-inflammatory cytokines expression including IL17A, IL1B, IL6, TNFA and CXCL1 (PubMed:34326534, PubMed:35266071). Down-regulates expression of TREM1, a cell surface receptor involved in the amplification of inflammatory responses (By similarity) (PubMed:34326534, PubMed:35266071). {ECO:0000250, ECO:0000269|PubMed:10207087, ECO:0000269|PubMed:14625302, ECO:0000269|PubMed:14976184, ECO:0000269|PubMed:19380490, ECO:0000269|PubMed:34326534, ECO:0000269|PubMed:35266071, ECO:0000269|PubMed:8895518, ECO:0000269|PubMed:9524226}. |
| Q99801 | NKX3-1 | S195 | psp | Homeobox protein Nkx-3.1 (Homeobox protein NK-3 homolog A) | Transcription factor, which binds preferentially the consensus sequence 5'-TAAGT[AG]-3' and can behave as a transcriptional repressor. Plays an important role in normal prostate development, regulating proliferation of glandular epithelium and in the formation of ducts in prostate. Acts as a tumor suppressor controlling prostate carcinogenesis, as shown by the ability to inhibit proliferation and invasion activities of PC-3 prostate cancer cells. {ECO:0000269|PubMed:19462257}. |
| Q9BTC0 | DIDO1 | S1746 | ochoa | Death-inducer obliterator 1 (DIO-1) (hDido1) (Death-associated transcription factor 1) (DATF-1) | Putative transcription factor, weakly pro-apoptotic when overexpressed (By similarity). Tumor suppressor. Required for early embryonic stem cell development. {ECO:0000250, ECO:0000269|PubMed:16127461}.; FUNCTION: [Isoform 2]: Displaces isoform 4 at the onset of differentiation, required for repression of stemness genes. {ECO:0000269|PubMed:16127461}. |
| Q9BV36 | MLPH | S339 | ochoa | Melanophilin (Exophilin-3) (Slp homolog lacking C2 domains a) (SlaC2-a) (Synaptotagmin-like protein 2a) | Rab effector protein involved in melanosome transport. Serves as link between melanosome-bound RAB27A and the motor protein MYO5A. {ECO:0000269|PubMed:12062444}. |
| Q9BV38 | WDR18 | S368 | ochoa | WD repeat-containing protein 18 | Functions as a component of the Five Friends of Methylated CHTOP (5FMC) complex; the 5FMC complex is recruited to ZNF148 by methylated CHTOP, leading to desumoylation of ZNF148 and subsequent transactivation of ZNF148 target genes (PubMed:22872859). Component of the PELP1 complex involved in the nucleolar steps of 28S rRNA maturation and the subsequent nucleoplasmic transit of the pre-60S ribosomal subunit (PubMed:21326211). May play a role during development (By similarity). {ECO:0000250|UniProtKB:Q68EI0, ECO:0000269|PubMed:21326211, ECO:0000269|PubMed:22872859}. |
| Q9BW04 | SARG | S469 | ochoa | Specifically androgen-regulated gene protein | Putative androgen-specific receptor. {ECO:0000269|PubMed:15525603}. |
| Q9BWH6 | RPAP1 | S200 | ochoa | RNA polymerase II-associated protein 1 | Forms an interface between the RNA polymerase II enzyme and chaperone/scaffolding protein, suggesting that it is required to connect RNA polymerase II to regulators of protein complex formation. Required for interaction of the RNA polymerase II complex with acetylated histone H3. {ECO:0000269|PubMed:17643375}. |
| Q9BYW2 | SETD2 | S939 | ochoa | Histone-lysine N-methyltransferase SETD2 (EC 2.1.1.359) (HIF-1) (Huntingtin yeast partner B) (Huntingtin-interacting protein 1) (HIP-1) (Huntingtin-interacting protein B) (Lysine N-methyltransferase 3A) (Protein-lysine N-methyltransferase SETD2) (EC 2.1.1.-) (SET domain-containing protein 2) (hSET2) (p231HBP) | Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate (PubMed:16118227, PubMed:19141475, PubMed:21526191, PubMed:21792193, PubMed:23043551, PubMed:27474439). It is capable of trimethylating unmethylated H3K36 (H3K36me0) in vitro (PubMed:19332550). Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation (By similarity). Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A (PubMed:23325844). Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction (PubMed:23622243). Required for DNA double-strand break repair in response to DNA damage: acts by mediating formation of H3K36me3, promoting recruitment of RAD51 and DNA repair via homologous recombination (HR) (PubMed:24843002). Acts as a tumor suppressor (PubMed:24509477). H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A (PubMed:27317772). H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase (PubMed:21792193). Required during angiogenesis (By similarity). Required for endoderm development by promoting embryonic stem cell differentiation toward endoderm: acts by mediating formation of H3K36me3 in distal promoter regions of FGFR3, leading to regulate transcription initiation of FGFR3 (By similarity). In addition to histones, also mediates methylation of other proteins, such as tubulins and STAT1 (PubMed:27518565, PubMed:28753426). Trimethylates 'Lys-40' of alpha-tubulins such as TUBA1B (alpha-TubK40me3); alpha-TubK40me3 is required for normal mitosis and cytokinesis and may be a specific tag in cytoskeletal remodeling (PubMed:27518565). Involved in interferon-alpha-induced antiviral defense by mediating both monomethylation of STAT1 at 'Lys-525' and catalyzing H3K36me3 on promoters of some interferon-stimulated genes (ISGs) to activate gene transcription (PubMed:28753426). {ECO:0000250|UniProtKB:E9Q5F9, ECO:0000269|PubMed:16118227, ECO:0000269|PubMed:19141475, ECO:0000269|PubMed:21526191, ECO:0000269|PubMed:21792193, ECO:0000269|PubMed:23043551, ECO:0000269|PubMed:23325844, ECO:0000269|PubMed:23622243, ECO:0000269|PubMed:24509477, ECO:0000269|PubMed:24843002, ECO:0000269|PubMed:27317772, ECO:0000269|PubMed:27474439, ECO:0000269|PubMed:27518565, ECO:0000269|PubMed:28753426}.; FUNCTION: (Microbial infection) Recruited to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression. {ECO:0000269|PubMed:11461154}. |
| Q9C0D6 | FHDC1 | S1123 | ochoa | FH2 domain-containing protein 1 (Inverted formin-1) | Microtubule-associated formin which regulates both actin and microtubule dynamics. Induces microtubule acetylation and stabilization and actin stress fiber formation (PubMed:18815276). Regulates Golgi ribbon formation (PubMed:26564798). Required for normal cilia assembly. Early in cilia assembly, may assist in the maturation and positioning of the centrosome/basal body, and once cilia assembly has initiated, may also promote cilia elongation by inhibiting disassembly (PubMed:29742020). {ECO:0000269|PubMed:18815276, ECO:0000269|PubMed:26564798, ECO:0000269|PubMed:29742020}. |
| Q9C0G0 | ZNF407 | S1262 | ochoa | Zinc finger protein 407 | May be involved in transcriptional regulation. |
| Q9H2F5 | EPC1 | S427 | ochoa | Enhancer of polycomb homolog 1 | Component of the NuA4 histone acetyltransferase (HAT) complex, a multiprotein complex involved in transcriptional activation of select genes principally by acetylation of nucleosomal histones H4 and H2A (PubMed:14966270). The NuA4 complex plays a direct role in repair of DNA double-strand breaks (DSBs) by promoting homologous recombination (HR) (PubMed:27153538). The NuA4 complex is also required for spermatid development by promoting acetylation of histones: histone acetylation is required for histone replacement during the transition from round to elongating spermatids (By similarity). In the NuA4 complex, EPC1 is required to recruit MBTD1 into the complex (PubMed:32209463). {ECO:0000250|UniProtKB:Q8C9X6, ECO:0000269|PubMed:14966270, ECO:0000269|PubMed:27153538, ECO:0000269|PubMed:32209463}. |
| Q9H3Q1 | CDC42EP4 | S64 | ochoa | Cdc42 effector protein 4 (Binder of Rho GTPases 4) | Probably involved in the organization of the actin cytoskeleton. May act downstream of CDC42 to induce actin filament assembly leading to cell shape changes. Induces pseudopodia formation, when overexpressed in fibroblasts. |
| Q9H8M2 | BRD9 | S571 | ochoa | Bromodomain-containing protein 9 (Rhabdomyosarcoma antigen MU-RMS-40.8) | Plays a role in chromatin remodeling and regulation of transcription (PubMed:22464331, PubMed:26365797). Acts as a chromatin reader that recognizes and binds acylated histones: binds histones that are acetylated and/or butyrylated (PubMed:26365797). Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058). Also orchestrates the RAD51-RAD54 complex formation and thereby plays a role in homologous recombination (HR) (PubMed:32457312). {ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:26365797, ECO:0000269|PubMed:29374058, ECO:0000269|PubMed:32457312}. |
| Q9H9C1 | VIPAS39 | S126 | ochoa | Spermatogenesis-defective protein 39 homolog (hSPE-39) (VPS33B-interacting protein in apical-basolateral polarity regulator) (VPS33B-interacting protein in polarity and apical restriction) | Proposed to be involved in endosomal maturation implicating in part VPS33B. In epithelial cells, the VPS33B:VIPAS39 complex may play a role in the apical RAB11A-dependent recycling pathway and in the maintenance of the apical-basolateral polarity (PubMed:20190753). May play a role in lysosomal trafficking, probably via association with the core HOPS complex in a discrete population of endosomes; the functions seems to be independent of VPS33B (PubMed:19109425). May play a role in vesicular trafficking during spermatogenesis (By similarity). May be involved in direct or indirect transcriptional regulation of E-cadherin (By similarity). {ECO:0000250|UniProtKB:Q23288, ECO:0000269|PubMed:19109425, ECO:0000269|PubMed:20190753}. |
| Q9H9R9 | DBNDD1 | S121 | ochoa | Dysbindin domain-containing protein 1 | None |
| Q9HBA9 | FOLH1B | S82 | ochoa | Putative N-acetylated-alpha-linked acidic dipeptidase (NAALADase) (EC 3.4.-.-) (Cell growth-inhibiting gene 26 protein) (Prostate-specific membrane antigen-like protein) (Putative folate hydrolase 1B) | Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. {ECO:0000250}.; FUNCTION: Exhibits a dipeptidyl-peptidase IV type activity. {ECO:0000250}. |
| Q9HBE5 | IL21R | S299 | ochoa | Interleukin-21 receptor (IL-21 receptor) (IL-21R) (Novel interleukin receptor) (CD antigen CD360) | This is a receptor for interleukin-21. |
| Q9NPG3 | UBN1 | S978 | ochoa | Ubinuclein-1 (HIRA-binding protein) (Protein VT4) (Ubiquitously expressed nuclear protein) | Acts as a novel regulator of senescence. Involved in the formation of senescence-associated heterochromatin foci (SAHF), which represses expression of proliferation-promoting genes. Binds to proliferation-promoting genes. May be required for replication-independent chromatin assembly. {ECO:0000269|PubMed:14718166, ECO:0000269|PubMed:19029251}. |
| Q9NQ86 | TRIM36 | S620 | ochoa | E3 ubiquitin-protein ligase TRIM36 (EC 2.3.2.27) (RING finger protein 98) (RING-type E3 ubiquitin transferase TRIM36) (Tripartite motif-containing protein 36) (Zinc-binding protein Rbcc728) | E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Involved in chromosome segregation and cell cycle regulation (PubMed:28087737). May play a role in the acrosome reaction and fertilization. {ECO:0000250|UniProtKB:Q80WG7, ECO:0000269|PubMed:28087737}. |
| Q9NRF2 | SH2B1 | S279 | ochoa | SH2B adapter protein 1 (Pro-rich, PH and SH2 domain-containing signaling mediator) (PSM) (SH2 domain-containing protein 1B) | Adapter protein for several members of the tyrosine kinase receptor family. Involved in multiple signaling pathways mediated by Janus kinase (JAK) and receptor tyrosine kinases, including the receptors of insulin (INS), insulin-like growth factor 1 (IGF1), nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), platelet-derived growth factor (PDGF) and fibroblast growth factors (FGFs). In growth hormone (GH) signaling, autophosphorylated ('Tyr-813') JAK2 recruits SH2B1, which in turn is phosphorylated by JAK2 on tyrosine residues. These phosphotyrosines form potential binding sites for other signaling proteins. GH also promotes serine/threonine phosphorylation of SH2B1 and these phosphorylated residues may serve to recruit other proteins to the GHR-JAK2-SH2B1 complexes, such as RAC1. In leptin (LEP) signaling, binds to and potentiates the activation of JAK2 by globally enhancing downstream pathways. In response to leptin, binds simultaneously to both, JAK2 and IRS1 or IRS2, thus mediating formation of a complex of JAK2, SH2B1 and IRS1 or IRS2. Mediates tyrosine phosphorylation of IRS1 and IRS2, resulting in activation of the PI 3-kinase pathway. Acts as a positive regulator of NGF-mediated activation of the Akt/Forkhead pathway; prolongs NGF-induced phosphorylation of AKT1 on 'Ser-473' and AKT1 enzymatic activity. Enhances the kinase activity of the cytokine receptor-associated tyrosine kinase JAK2 and of other receptor tyrosine kinases, such as FGFR3 and NTRK1. For JAK2, the mechanism seems to involve dimerization of both, SH2B1 and JAK2. Enhances RET phosphorylation and kinase activity. Isoforms seem to be differentially involved in IGF1 and PDGF-induced mitogenesis (By similarity). {ECO:0000250|UniProtKB:Q91ZM2, ECO:0000269|PubMed:11827956, ECO:0000269|PubMed:14565960, ECO:0000269|PubMed:15767667, ECO:0000269|PubMed:16569669, ECO:0000269|PubMed:17471236, ECO:0000269|PubMed:9694882, ECO:0000269|PubMed:9742218}. |
| Q9NRY4 | ARHGAP35 | S980 | ochoa | Rho GTPase-activating protein 35 (Glucocorticoid receptor DNA-binding factor 1) (Glucocorticoid receptor repression factor 1) (GRF-1) (Rho GAP p190A) (p190-A) | Rho GTPase-activating protein (GAP) (PubMed:19673492, PubMed:28894085). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity (PubMed:19673492). This binding is inhibited by phosphorylation by PRKCA (PubMed:19673492). Involved in cell differentiation as well as cell adhesion and migration, plays an important role in retinal tissue morphogenesis, neural tube fusion, midline fusion of the cerebral hemispheres and mammary gland branching morphogenesis (By similarity). Transduces signals from p21-ras to the nucleus, acting via the ras GTPase-activating protein (GAP) (By similarity). Transduces SRC-dependent signals from cell-surface adhesion molecules, such as laminin, to promote neurite outgrowth. Regulates axon outgrowth, guidance and fasciculation (By similarity). Modulates Rho GTPase-dependent F-actin polymerization, organization and assembly, is involved in polarized cell migration and in the positive regulation of ciliogenesis and cilia elongation (By similarity). During mammary gland development, is required in both the epithelial and stromal compartments for ductal outgrowth (By similarity). Represses transcription of the glucocorticoid receptor by binding to the cis-acting regulatory sequence 5'-GAGAAAAGAAACTGGAGAAACTC-3'; this function is however unclear and would need additional experimental evidences (PubMed:1894621). {ECO:0000250|UniProtKB:P81128, ECO:0000250|UniProtKB:Q91YM2, ECO:0000269|PubMed:1894621, ECO:0000269|PubMed:19673492, ECO:0000269|PubMed:28894085}. |
| Q9NTM9 | CUTC | S238 | ochoa | Copper homeostasis protein cutC homolog | May play a role in copper homeostasis. Can bind one Cu(1+) per subunit. {ECO:0000269|PubMed:16182249, ECO:0000269|PubMed:19878721}. |
| Q9NYT6 | ZNF226 | S292 | ochoa | Zinc finger protein 226 | May be involved in transcriptional regulation. |
| Q9NZ56 | FMN2 | S93 | ochoa | Formin-2 | Actin-binding protein that is involved in actin cytoskeleton assembly and reorganization (PubMed:21730168, PubMed:22330775). Acts as an actin nucleation factor and promotes assembly of actin filaments together with SPIRE1 and SPIRE2 (PubMed:21730168, PubMed:22330775). Involved in intracellular vesicle transport along actin fibers, providing a novel link between actin cytoskeleton dynamics and intracellular transport (By similarity). Required for asymmetric spindle positioning, asymmetric oocyte division and polar body extrusion during female germ cell meiosis (By similarity). Plays a role in responses to DNA damage, cellular stress and hypoxia by protecting CDKN1A against degradation, and thereby plays a role in stress-induced cell cycle arrest (PubMed:23375502). Also acts in the nucleus: together with SPIRE1 and SPIRE2, promotes assembly of nuclear actin filaments in response to DNA damage in order to facilitate movement of chromatin and repair factors after DNA damage (PubMed:26287480). Protects cells against apoptosis by protecting CDKN1A against degradation (PubMed:23375502). {ECO:0000250|UniProtKB:Q9JL04, ECO:0000269|PubMed:21730168, ECO:0000269|PubMed:22330775, ECO:0000269|PubMed:23375502, ECO:0000269|PubMed:26287480}. |
| Q9P225 | DNAH2 | S334 | ochoa | Dynein axonemal heavy chain 2 (Axonemal beta dynein heavy chain 2) (Ciliary dynein heavy chain 2) (Dynein heavy chain domain-containing protein 3) | As part of the axonemal inner dynein arm complex plays a central role in ciliary beat (PubMed:30811583). Expressed in sperm flagellum, it is required for sperm motility (PubMed:30811583). Dyneins are microtubule-based molecular motors possessing ATPase activities that can convert the chemical energy of ATP into relative sliding between adjacent microtubule doublets to generate ciliary bending (PubMed:30811583). {ECO:0000269|PubMed:30811583}. |
| Q9P244 | LRFN1 | S674 | ochoa | Leucine-rich repeat and fibronectin type III domain-containing protein 1 (Synaptic adhesion-like molecule 2) | Promotes neurite outgrowth in hippocampal neurons. Involved in the regulation and maintenance of excitatory synapses. Induces the clustering of excitatory postsynaptic proteins, including DLG4, DLGAP1, GRIA1 and GRIN1 (By similarity). {ECO:0000250}. |
| Q9UBC2 | EPS15L1 | S371 | ochoa | Epidermal growth factor receptor substrate 15-like 1 (Eps15-related protein) (Eps15R) | Seems to be a constitutive component of clathrin-coated pits that is required for receptor-mediated endocytosis. Involved in endocytosis of integrin beta-1 (ITGB1) and transferrin receptor (TFR); internalization of ITGB1 as DAB2-dependent cargo but not TFR seems to require association with DAB2. {ECO:0000269|PubMed:22648170, ECO:0000269|PubMed:9407958}. |
| Q9UBS3 | DNAJB9 | S103 | ochoa | DnaJ homolog subfamily B member 9 (Endoplasmic reticulum DNA J domain-containing protein 4) (ER-resident protein ERdj4) (ERdj4) (Microvascular endothelial differentiation gene 1 protein) (Mdg-1) | Co-chaperone for Hsp70 protein HSPA5/BiP that acts as a key repressor of the ERN1/IRE1-mediated unfolded protein response (UPR) (By similarity). J domain-containing co-chaperones stimulate the ATPase activity of Hsp70 proteins and are required for efficient substrate recognition by Hsp70 proteins (PubMed:18400946). In the unstressed endoplasmic reticulum, interacts with the luminal region of ERN1/IRE1 and selectively recruits HSPA5/BiP: HSPA5/BiP disrupts the dimerization of the active ERN1/IRE1 luminal region, thereby inactivating ERN1/IRE1 (By similarity). Also involved in endoplasmic reticulum-associated degradation (ERAD) of misfolded proteins. Required for survival of B-cell progenitors and normal antibody production (By similarity). {ECO:0000250|UniProtKB:G3H0N9, ECO:0000250|UniProtKB:Q9QYI6, ECO:0000269|PubMed:18400946}. |
| Q9UDT6 | CLIP2 | S931 | ochoa | CAP-Gly domain-containing linker protein 2 (Cytoplasmic linker protein 115) (CLIP-115) (Cytoplasmic linker protein 2) (Williams-Beuren syndrome chromosomal region 3 protein) (Williams-Beuren syndrome chromosomal region 4 protein) | Seems to link microtubules to dendritic lamellar body (DLB), a membranous organelle predominantly present in bulbous dendritic appendages of neurons linked by dendrodendritic gap junctions. May operate in the control of brain-specific organelle translocations (By similarity). {ECO:0000250}. |
| Q9UFC0 | LRWD1 | S264 | ochoa | Leucine-rich repeat and WD repeat-containing protein 1 (Centromere protein 33) (CENP-33) (Origin recognition complex-associated protein) (ORC-associated protein) (ORCA) | Required for G1/S transition. Recruits and stabilizes the origin recognition complex (ORC) onto chromatin during G1 to establish pre-replication complex (preRC) and to heterochromatic sites in post-replicated cells. Binds a combination of DNA and histone methylation repressive marks on heterochromatin. Binds histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3 in a cooperative manner with DNA methylation. Required for silencing of major satellite repeats. May be important ORC2, ORC3 and ORC4 stability. {ECO:0000269|PubMed:20850016, ECO:0000269|PubMed:20932478, ECO:0000269|PubMed:21029866, ECO:0000269|PubMed:22427655, ECO:0000269|PubMed:22645314}. |
| Q9UHL9 | GTF2IRD1 | S113 | ochoa | General transcription factor II-I repeat domain-containing protein 1 (GTF2I repeat domain-containing protein 1) (General transcription factor III) (MusTRD1/BEN) (Muscle TFII-I repeat domain-containing protein 1) (Slow-muscle-fiber enhancer-binding protein) (USE B1-binding protein) (Williams-Beuren syndrome chromosomal region 11 protein) (Williams-Beuren syndrome chromosomal region 12 protein) | May be a transcription regulator involved in cell-cycle progression and skeletal muscle differentiation. May repress GTF2I transcriptional functions, by preventing its nuclear residency, or by inhibiting its transcriptional activation. May contribute to slow-twitch fiber type specificity during myogenesis and in regenerating muscles. Binds troponin I slow-muscle fiber enhancer (USE B1). Binds specifically and with high affinity to the EFG sequences derived from the early enhancer of HOXC8 (By similarity). {ECO:0000250, ECO:0000269|PubMed:11438732}. |
| Q9UK97 | FBXO9 | S145 | ochoa | F-box only protein 9 (Cross-immune reaction antigen 1) (Renal carcinoma antigen NY-REN-57) | Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins and plays a role in several biological processes such as cell cycle, cell proliferation, or maintenance of chromosome stability (PubMed:23263282, PubMed:34480022). Ubiquitinates mTORC1-bound TTI1 and TELO2 when they are phosphorylated by CK2 following growth factor deprivation, leading to their degradation. In contrast, does not mediate ubiquitination of TTI1 and TELO2 when they are part of the mTORC2 complex. As a consequence, mTORC1 is inactivated to restrain cell growth and protein translation, while mTORC2 is the activated due to the relief of feedback inhibition by mTORC1 (PubMed:23263282). Plays a role in maintaining epithelial cell survival by regulating the turn-over of chromatin modulator PRMT4 through ubiquitination and degradation by the proteasomal pathway (PubMed:34480022). Regulates also PPARgamma stability by facilitating PPARgamma/PPARG ubiquitination and thereby plays a role in adipocyte differentiation (By similarity). {ECO:0000250|UniProtKB:Q8BK06, ECO:0000269|PubMed:23263282, ECO:0000269|PubMed:34480022}. |
| Q9ULJ3 | ZBTB21 | S320 | ochoa | Zinc finger and BTB domain-containing protein 21 (Zinc finger protein 295) | Acts as a transcription repressor. {ECO:0000269|PubMed:15629158}. |
| Q9ULT0 | TTC7A | S647 | ochoa | Tetratricopeptide repeat protein 7A (TPR repeat protein 7A) | Component of a complex required to localize phosphatidylinositol 4-kinase (PI4K) to the plasma membrane (PubMed:23229899, PubMed:24417819). The complex acts as a regulator of phosphatidylinositol 4-phosphate (PtdIns(4)P) synthesis (Probable). In the complex, plays a central role in bridging PI4KA to EFR3B and HYCC1, via direct interactions (By similarity). {ECO:0000250|UniProtKB:Q86TV6, ECO:0000269|PubMed:23229899, ECO:0000269|PubMed:24417819}. |
| Q9ULU8 | CADPS | S93 | ochoa | Calcium-dependent secretion activator 1 (Calcium-dependent activator protein for secretion 1) (CAPS-1) | Calcium-binding protein involved in exocytosis of vesicles filled with neurotransmitters and neuropeptides. Probably acts upstream of fusion in the biogenesis or maintenance of mature secretory vesicles. Regulates catecholamine loading of DCVs. May specifically mediate the Ca(2+)-dependent exocytosis of large dense-core vesicles (DCVs) and other dense-core vesicles by acting as a PtdIns(4,5)P2-binding protein that acts at prefusion step following ATP-dependent priming and participates in DCVs-membrane fusion. However, it may also participate in small clear synaptic vesicles (SVs) exocytosis and it is unclear whether its function is related to Ca(2+) triggering (By similarity). {ECO:0000250}. |
| Q9UPY3 | DICER1 | S1142 | ochoa | Endoribonuclease Dicer (EC 3.1.26.3) (Helicase with RNase motif) (Helicase MOI) | Double-stranded RNA (dsRNA) endoribonuclease playing a central role in short dsRNA-mediated post-transcriptional gene silencing. Cleaves naturally occurring long dsRNAs and short hairpin pre-microRNAs (miRNA) into fragments of twenty-one to twenty-three nucleotides with 3' overhang of two nucleotides, producing respectively short interfering RNAs (siRNA) and mature microRNAs. SiRNAs and miRNAs serve as guide to direct the RNA-induced silencing complex (RISC) to complementary RNAs to degrade them or prevent their translation. Gene silencing mediated by siRNAs, also called RNA interference, controls the elimination of transcripts from mobile and repetitive DNA elements of the genome but also the degradation of exogenous RNA of viral origin for instance. The miRNA pathway on the other side is a mean to specifically regulate the expression of target genes. {ECO:0000269|PubMed:15242644, ECO:0000269|PubMed:15973356, ECO:0000269|PubMed:16142218, ECO:0000269|PubMed:16271387, ECO:0000269|PubMed:16289642, ECO:0000269|PubMed:16357216, ECO:0000269|PubMed:16424907, ECO:0000269|PubMed:17452327, ECO:0000269|PubMed:18178619}. |
| Q9UQ88 | CDK11A | Y582 | ochoa | Cyclin-dependent kinase 11A (EC 2.7.11.22) (Cell division cycle 2-like protein kinase 2) (Cell division protein kinase 11A) (Galactosyltransferase-associated protein kinase p58/GTA) (PITSLRE serine/threonine-protein kinase CDC2L2) | Appears to play multiple roles in cell cycle progression, cytokinesis and apoptosis. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression. {ECO:0000269|PubMed:12501247, ECO:0000269|PubMed:12624090}. |
| Q9Y2F5 | ICE1 | S589 | ochoa | Little elongation complex subunit 1 (Interactor of little elongator complex ELL subunit 1) | Component of the little elongation complex (LEC), a complex required to regulate small nuclear RNA (snRNA) gene transcription by RNA polymerase II and III (PubMed:22195968, PubMed:23932780). Specifically acts as a scaffold protein that promotes the LEC complex formation and recruitment and RNA polymerase II occupancy at snRNA genes in subnuclear bodies (PubMed:23932780). {ECO:0000269|PubMed:22195968, ECO:0000269|PubMed:23932780}. |
| Q9Y2K7 | KDM2A | S750 | ochoa | Lysine-specific demethylase 2A (EC 1.14.11.27) (CXXC-type zinc finger protein 8) (F-box and leucine-rich repeat protein 11) (F-box protein FBL7) (F-box protein Lilina) (F-box/LRR-repeat protein 11) (JmjC domain-containing histone demethylation protein 1A) ([Histone-H3]-lysine-36 demethylase 1A) | Histone demethylase that specifically demethylates 'Lys-36' of histone H3, thereby playing a central role in histone code. Preferentially demethylates dimethylated H3 'Lys-36' residue while it has weak or no activity for mono- and tri-methylated H3 'Lys-36'. May also recognize and bind to some phosphorylated proteins and promote their ubiquitination and degradation. Required to maintain the heterochromatic state. Associates with centromeres and represses transcription of small non-coding RNAs that are encoded by the clusters of satellite repeats at the centromere. Required to sustain centromeric integrity and genomic stability, particularly during mitosis. Regulates circadian gene expression by repressing the transcriptional activator activity of CLOCK-BMAL1 heterodimer and RORA in a catalytically-independent manner (PubMed:26037310). {ECO:0000269|PubMed:16362057, ECO:0000269|PubMed:19001877, ECO:0000269|PubMed:26037310, ECO:0000269|PubMed:28262558}. |
| Q9Y478 | PRKAB1 | S101 | ochoa | 5'-AMP-activated protein kinase subunit beta-1 (AMPK subunit beta-1) (AMPKb) | Non-catalytic subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. AMPK acts via direct phosphorylation of metabolic enzymes, and by longer-term effects via phosphorylation of transcription regulators. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton; probably by indirectly activating myosin. Beta non-catalytic subunit acts as a scaffold on which the AMPK complex assembles, via its C-terminus that bridges alpha (PRKAA1 or PRKAA2) and gamma subunits (PRKAG1, PRKAG2 or PRKAG3). |
| Q9Y4B4 | RAD54L2 | S1234 | ochoa | Helicase ARIP4 (EC 3.6.4.12) (Androgen receptor-interacting protein 4) (RAD54-like protein 2) | DNA helicase that modulates androgen receptor (AR)-dependent transactivation in a promoter-dependent manner. Not able to remodel mononucleosomes in vitro (By similarity). {ECO:0000250}. |
| Q9Y4F5 | CEP170B | S1040 | ochoa | Centrosomal protein of 170 kDa protein B (Centrosomal protein 170B) (Cep170B) | Plays a role in microtubule organization. {ECO:0000250|UniProtKB:Q5SW79}. |
| Q9Y6D6 | ARFGEF1 | S410 | ochoa | Brefeldin A-inhibited guanine nucleotide-exchange protein 1 (Brefeldin A-inhibited GEP 1) (ADP-ribosylation factor guanine nucleotide-exchange factor 1) (p200 ARF guanine nucleotide exchange factor) (p200 ARF-GEP1) | Promotes guanine-nucleotide exchange on ARF1 and ARF3. Promotes the activation of ARF1/ARF3 through replacement of GDP with GTP. Involved in vesicular trafficking. Required for the maintenance of Golgi structure; the function may be independent of its GEF activity. Required for the maturation of integrin beta-1 in the Golgi. Involved in the establishment and persistence of cell polarity during directed cell movement in wound healing. Proposed to act as A kinase-anchoring protein (AKAP) and may mediate crosstalk between Arf and PKA pathways. Inhibits GAP activity of MYO9B probably through competitive RhoA binding. The function in the nucleus remains to be determined. {ECO:0000269|PubMed:12571360, ECO:0000269|PubMed:15644318, ECO:0000269|PubMed:17227842, ECO:0000269|PubMed:20360857, ECO:0000269|PubMed:22084092}. |
| P32929 | CTH | S56 | Sugiyama | Cystathionine gamma-lyase (CGL) (CSE) (EC 4.4.1.1) (Cysteine desulfhydrase) (Cysteine-protein sulfhydrase) (Gamma-cystathionase) (Homocysteine desulfhydrase) (EC 4.4.1.2) | Catalyzes the last step in the trans-sulfuration pathway from L-methionine to L-cysteine in a pyridoxal-5'-phosphate (PLP)-dependent manner, which consists on cleaving the L,L-cystathionine molecule into L-cysteine, ammonia and 2-oxobutanoate (PubMed:10212249, PubMed:18476726, PubMed:19261609, PubMed:19961860). Part of the L-cysteine derived from the trans-sulfuration pathway is utilized for biosynthesis of the ubiquitous antioxidant glutathione (PubMed:18476726). Besides its role in the conversion of L-cystathionine into L-cysteine, it utilizes L-cysteine and L-homocysteine as substrates (at much lower rates than L,L-cystathionine) to produce the endogenous gaseous signaling molecule hydrogen sulfide (H2S) (PubMed:10212249, PubMed:19019829, PubMed:19261609, PubMed:19961860). In vitro, it converts two L-cysteine molecules into lanthionine and H2S, also two L-homocysteine molecules to homolanthionine and H2S, which can be particularly relevant under conditions of severe hyperhomocysteinemia (which is a risk factor for cardiovascular disease, diabetes, and Alzheimer's disease) (PubMed:19261609). Lanthionine and homolanthionine are structural homologs of L,L-cystathionine that differ by the absence or presence of an extra methylene group, respectively (PubMed:19261609). Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function (PubMed:22169477). By generating the gasotransmitter H2S, it participates in a number of physiological processes such as vasodilation, bone protection, and inflammation (Probable) (PubMed:29254196). Plays an essential role in myogenesis by contributing to the biogenesis of H2S in skeletal muscle tissue (By similarity). Can also accept homoserine as substrate (By similarity). Catalyzes the elimination of selenocystathionine (which can be derived from the diet) to yield selenocysteine, ammonia and 2-oxobutanoate (By similarity). {ECO:0000250|UniProtKB:P18757, ECO:0000250|UniProtKB:Q8VCN5, ECO:0000269|PubMed:10212249, ECO:0000269|PubMed:18476726, ECO:0000269|PubMed:19019829, ECO:0000269|PubMed:19261609, ECO:0000269|PubMed:19961860, ECO:0000269|PubMed:22169477, ECO:0000269|PubMed:29254196, ECO:0000303|PubMed:18476726, ECO:0000305|PubMed:18476726, ECO:0000305|PubMed:19019829}. |
| P49588 | AARS1 | S188 | Sugiyama | Alanine--tRNA ligase, cytoplasmic (EC 6.1.1.7) (Alanyl-tRNA synthetase) (AlaRS) (Protein lactyltransferase AARS1) (EC 6.-.-.-) (Renal carcinoma antigen NY-REN-42) | Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine residues in target proteins, such as TEAD1, TP53/p53 and YAP1 (PubMed:38512451, PubMed:38653238). Protein lactylation takes place in a two-step reaction: lactate is first activated by ATP to form lactate-AMP and then transferred to lysine residues of target proteins (PubMed:38512451, PubMed:38653238, PubMed:39322678). Acts as an inhibitor of TP53/p53 activity by catalyzing lactylation of TP53/p53 (PubMed:38653238). Acts as a positive regulator of the Hippo pathway by mediating lactylation of TEAD1 and YAP1 (PubMed:38512451). {ECO:0000269|PubMed:27622773, ECO:0000269|PubMed:27911835, ECO:0000269|PubMed:28493438, ECO:0000269|PubMed:29273753, ECO:0000269|PubMed:33909043, ECO:0000269|PubMed:38512451, ECO:0000269|PubMed:38653238, ECO:0000269|PubMed:39322678}. |
| P63151 | PPP2R2A | S75 | Sugiyama | Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PP2A subunit B isoform B55-alpha) (B55) (PP2A subunit B isoform PR55-alpha) (PP2A subunit B isoform R2-alpha) (PP2A subunit B isoform alpha) | Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit (PubMed:1849734, PubMed:33108758). Involved in chromosome clustering during late mitosis by mediating dephosphorylation of MKI67 (By similarity). Essential for serine/threonine-protein phosphatase 2A-mediated dephosphorylation of WEE1, preventing its ubiquitin-mediated proteolysis, increasing WEE1 protein levels, and promoting the G2/M checkpoint (PubMed:33108758). {ECO:0000250|UniProtKB:Q6P1F6, ECO:0000269|PubMed:1849734, ECO:0000269|PubMed:33108758}. |
| Q00005 | PPP2R2B | S71 | Sugiyama | Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B beta isoform (PP2A subunit B isoform B55-beta) (PP2A subunit B isoform PR55-beta) (PP2A subunit B isoform R2-beta) (PP2A subunit B isoform beta) | The B regulatory subunit might modulate substrate selectivity and catalytic activity, and might also direct the localization of the catalytic enzyme to a particular subcellular compartment. Within the PP2A holoenzyme complex, isoform 2 is required to promote proapoptotic activity (By similarity). Isoform 2 regulates neuronal survival through the mitochondrial fission and fusion balance (By similarity). {ECO:0000250}. |
| Q66LE6 | PPP2R2D | S81 | Sugiyama | Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B delta isoform (PP2A subunit B isoform B55-delta) (PP2A subunit B isoform PR55-delta) (PP2A subunit B isoform R2-delta) (PP2A subunit B isoform delta) | Substrate-recognition subunit of protein phosphatase 2A (PP2A) that plays a key role in cell cycle by controlling mitosis entry and exit. Involved in chromosome clustering during late mitosis by mediating dephosphorylation of MKI67 (By similarity). The activity of PP2A complexes containing PPP2R2D (PR55-delta) fluctuate during the cell cycle: the activity is high in interphase and low in mitosis (By similarity). {ECO:0000250|UniProtKB:Q7ZX64, ECO:0000250|UniProtKB:Q925E7}. |
| P52209 | PGD | S126 | Sugiyama | 6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44) | Catalyzes the oxidative decarboxylation of 6-phosphogluconate to ribulose 5-phosphate and CO(2), with concomitant reduction of NADP to NADPH. {ECO:0000250}. |
| Q99584 | S100A13 | S34 | Sugiyama | Protein S100-A13 (S100 calcium-binding protein A13) | Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion does not interfere with calcium binding. Required for the copper-dependent stress-induced export of IL1A and FGF1. The calcium-free protein binds to lipid vesicles containing phosphatidylserine, but not to vesicles containing phosphatidylcholine (By similarity). {ECO:0000250|UniProtKB:P97352, ECO:0000269|PubMed:12746488, ECO:0000269|PubMed:20863990}. |
| Q13155 | AIMP2 | S48 | Sugiyama | Aminoacyl tRNA synthase complex-interacting multifunctional protein 2 (Multisynthase complex auxiliary component p38) (Protein JTV-1) | Required for assembly and stability of the aminoacyl-tRNA synthase complex (PubMed:19131329). Mediates ubiquitination and degradation of FUBP1, a transcriptional activator of MYC, leading to MYC down-regulation which is required for aveolar type II cell differentiation. Blocks MDM2-mediated ubiquitination and degradation of p53/TP53. Functions as a proapoptotic factor. {ECO:0000269|PubMed:16135753, ECO:0000269|PubMed:19131329}. |
| Q6IBS0 | TWF2 | S139 | Sugiyama | Twinfilin-2 (A6-related protein) (hA6RP) (Protein tyrosine kinase 9-like) (Twinfilin-1-like protein) | Actin-binding protein involved in motile and morphological processes. Inhibits actin polymerization, likely by sequestering G-actin. By capping the barbed ends of filaments, it also regulates motility. Seems to play an important role in clathrin-mediated endocytosis and distribution of endocytic organelles. May play a role in regulating the mature length of the middle and short rows of stereocilia (By similarity). {ECO:0000250}. |
| P60228 | EIF3E | Y116 | Sugiyama | Eukaryotic translation initiation factor 3 subunit E (eIF3e) (Eukaryotic translation initiation factor 3 subunit 6) (Viral integration site protein INT-6 homolog) (eIF-3 p48) | Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis (PubMed:17581632, PubMed:25849773, PubMed:27462815). The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi and eIF-5 to form the 43S pre-initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes and subsequently prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation (PubMed:17581632). The eIF-3 complex specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression (PubMed:25849773). Required for nonsense-mediated mRNA decay (NMD); may act in conjunction with UPF2 to divert mRNAs from translation to the NMD pathway (PubMed:17468741). May interact with MCM7 and EPAS1 and regulate the proteasome-mediated degradation of these proteins (PubMed:17310990, PubMed:17324924). {ECO:0000255|HAMAP-Rule:MF_03004, ECO:0000269|PubMed:17310990, ECO:0000269|PubMed:17324924, ECO:0000269|PubMed:17468741, ECO:0000269|PubMed:17581632, ECO:0000269|PubMed:25849773, ECO:0000269|PubMed:27462815}. |
| P22087 | FBL | Y134 | Sugiyama | rRNA 2'-O-methyltransferase fibrillarin (EC 2.1.1.-) (34 kDa nucleolar scleroderma antigen) (Histone-glutamine methyltransferase) (U6 snRNA 2'-O-methyltransferase fibrillarin) | S-adenosyl-L-methionine-dependent methyltransferase that has the ability to methylate both RNAs and proteins (PubMed:24352239, PubMed:30540930, PubMed:32017898). Involved in pre-rRNA processing by catalyzing the site-specific 2'-hydroxyl methylation of ribose moieties in pre-ribosomal RNA (PubMed:30540930). Site specificity is provided by a guide RNA that base pairs with the substrate (By similarity). Methylation occurs at a characteristic distance from the sequence involved in base pairing with the guide RNA (By similarity). Probably catalyzes 2'-O-methylation of U6 snRNAs in box C/D RNP complexes (PubMed:32017898). U6 snRNA 2'-O-methylation is required for mRNA splicing fidelity (PubMed:32017898). Also acts as a protein methyltransferase by mediating methylation of 'Gln-105' of histone H2A (H2AQ104me), a modification that impairs binding of the FACT complex and is specifically present at 35S ribosomal DNA locus (PubMed:24352239, PubMed:30540930). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797). {ECO:0000250|UniProtKB:P15646, ECO:0000269|PubMed:24352239, ECO:0000269|PubMed:30540930, ECO:0000269|PubMed:32017898, ECO:0000269|PubMed:34516797}. |
| P35244 | RPA3 | S44 | Sugiyama | Replication protein A 14 kDa subunit (RP-A p14) (Replication factor A protein 3) (RF-A protein 3) | As part of the heterotrimeric replication protein A complex (RPA/RP-A), binds and stabilizes single-stranded DNA intermediates that form during DNA replication or upon DNA stress. It prevents their reannealing and in parallel, recruits and activates different proteins and complexes involved in DNA metabolism. Thereby, it plays an essential role both in DNA replication and the cellular response to DNA damage (PubMed:17596542, PubMed:9430682). In the cellular response to DNA damage, the RPA complex controls DNA repair and DNA damage checkpoint activation. Through recruitment of ATRIP activates the ATR kinase a master regulator of the DNA damage response (PubMed:24332808). It is required for the recruitment of the DNA double-strand break repair factors RAD51 and RAD52 to chromatin, in response to DNA damage. Also recruits to sites of DNA damage proteins like XPA and XPG that are involved in nucleotide excision repair and is required for this mechanism of DNA repair (PubMed:7697716). Also plays a role in base excision repair (BER), probably through interaction with UNG (PubMed:9765279). RPA stimulates 5'-3' helicase activity of BRIP1/FANCJ (PubMed:17596542). Also recruits SMARCAL1/HARP, which is involved in replication fork restart, to sites of DNA damage. May also play a role in telomere maintenance. RPA3 has its own single-stranded DNA-binding activity and may be responsible for polarity of the binding of the complex to DNA (PubMed:19010961). As part of the alternative replication protein A complex, aRPA, binds single-stranded DNA and probably plays a role in DNA repair. Compared to the RPA2-containing, canonical RPA complex, may not support chromosomal DNA replication and cell cycle progression through S-phase. The aRPA may not promote efficient priming by DNA polymerase alpha but could support DNA synthesis by polymerase delta in presence of PCNA and replication factor C (RFC), the dual incision/excision reaction of nucleotide excision repair and RAD51-dependent strand exchange (PubMed:19996105). {ECO:0000269|PubMed:17596542, ECO:0000269|PubMed:19010961, ECO:0000269|PubMed:19116208, ECO:0000269|PubMed:19996105, ECO:0000269|PubMed:7697716, ECO:0000269|PubMed:9430682, ECO:0000269|PubMed:9765279, ECO:0000303|PubMed:24332808}. |
| P32929 | CTH | S63 | Sugiyama | Cystathionine gamma-lyase (CGL) (CSE) (EC 4.4.1.1) (Cysteine desulfhydrase) (Cysteine-protein sulfhydrase) (Gamma-cystathionase) (Homocysteine desulfhydrase) (EC 4.4.1.2) | Catalyzes the last step in the trans-sulfuration pathway from L-methionine to L-cysteine in a pyridoxal-5'-phosphate (PLP)-dependent manner, which consists on cleaving the L,L-cystathionine molecule into L-cysteine, ammonia and 2-oxobutanoate (PubMed:10212249, PubMed:18476726, PubMed:19261609, PubMed:19961860). Part of the L-cysteine derived from the trans-sulfuration pathway is utilized for biosynthesis of the ubiquitous antioxidant glutathione (PubMed:18476726). Besides its role in the conversion of L-cystathionine into L-cysteine, it utilizes L-cysteine and L-homocysteine as substrates (at much lower rates than L,L-cystathionine) to produce the endogenous gaseous signaling molecule hydrogen sulfide (H2S) (PubMed:10212249, PubMed:19019829, PubMed:19261609, PubMed:19961860). In vitro, it converts two L-cysteine molecules into lanthionine and H2S, also two L-homocysteine molecules to homolanthionine and H2S, which can be particularly relevant under conditions of severe hyperhomocysteinemia (which is a risk factor for cardiovascular disease, diabetes, and Alzheimer's disease) (PubMed:19261609). Lanthionine and homolanthionine are structural homologs of L,L-cystathionine that differ by the absence or presence of an extra methylene group, respectively (PubMed:19261609). Acts as a cysteine-protein sulfhydrase by mediating sulfhydration of target proteins: sulfhydration consists of converting -SH groups into -SSH on specific cysteine residues of target proteins such as GAPDH, PTPN1 and NF-kappa-B subunit RELA, thereby regulating their function (PubMed:22169477). By generating the gasotransmitter H2S, it participates in a number of physiological processes such as vasodilation, bone protection, and inflammation (Probable) (PubMed:29254196). Plays an essential role in myogenesis by contributing to the biogenesis of H2S in skeletal muscle tissue (By similarity). Can also accept homoserine as substrate (By similarity). Catalyzes the elimination of selenocystathionine (which can be derived from the diet) to yield selenocysteine, ammonia and 2-oxobutanoate (By similarity). {ECO:0000250|UniProtKB:P18757, ECO:0000250|UniProtKB:Q8VCN5, ECO:0000269|PubMed:10212249, ECO:0000269|PubMed:18476726, ECO:0000269|PubMed:19019829, ECO:0000269|PubMed:19261609, ECO:0000269|PubMed:19961860, ECO:0000269|PubMed:22169477, ECO:0000269|PubMed:29254196, ECO:0000303|PubMed:18476726, ECO:0000305|PubMed:18476726, ECO:0000305|PubMed:19019829}. |
| Q13526 | PIN1 | S126 | Sugiyama | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (EC 5.2.1.8) (Peptidyl-prolyl cis-trans isomerase Pin1) (PPIase Pin1) (Rotamase Pin1) | Peptidyl-prolyl cis/trans isomerase (PPIase) that binds to and isomerizes specific phosphorylated Ser/Thr-Pro (pSer/Thr-Pro) motifs (PubMed:21497122, PubMed:23623683, PubMed:29686383). By inducing conformational changes in a subset of phosphorylated proteins, acts as a molecular switch in multiple cellular processes (PubMed:21497122, PubMed:22033920, PubMed:23623683). Displays a preference for acidic residues located N-terminally to the proline bond to be isomerized. Regulates mitosis presumably by interacting with NIMA and attenuating its mitosis-promoting activity. Down-regulates kinase activity of BTK (PubMed:16644721). Can transactivate multiple oncogenes and induce centrosome amplification, chromosome instability and cell transformation. Required for the efficient dephosphorylation and recycling of RAF1 after mitogen activation (PubMed:15664191). Binds and targets PML and BCL6 for degradation in a phosphorylation-dependent manner (PubMed:17828269). Acts as a regulator of JNK cascade by binding to phosphorylated FBXW7, disrupting FBXW7 dimerization and promoting FBXW7 autoubiquitination and degradation: degradation of FBXW7 leads to subsequent stabilization of JUN (PubMed:22608923). May facilitate the ubiquitination and proteasomal degradation of RBBP8/CtIP through CUL3/KLHL15 E3 ubiquitin-protein ligase complex, hence favors DNA double-strand repair through error-prone non-homologous end joining (NHEJ) over error-free, RBBP8-mediated homologous recombination (HR) (PubMed:23623683, PubMed:27561354). Upon IL33-induced lung inflammation, catalyzes cis-trans isomerization of phosphorylated IRAK3/IRAK-M, inducing IRAK3 stabilization, nuclear translocation and expression of pro-inflammatory genes in dendritic cells (PubMed:29686383). Catalyzes cis-trans isomerization of phosphorylated phosphoglycerate kinase PGK1 under hypoxic conditions to promote its binding to the TOM complex and targeting to the mitochondrion (PubMed:26942675). {ECO:0000269|PubMed:15664191, ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:17828269, ECO:0000269|PubMed:21497122, ECO:0000269|PubMed:22033920, ECO:0000269|PubMed:22608923, ECO:0000269|PubMed:23623683, ECO:0000269|PubMed:26942675, ECO:0000269|PubMed:27561354, ECO:0000269|PubMed:29686383}. |
| P11413 | G6PD | S180 | SIGNOR | Glucose-6-phosphate 1-dehydrogenase (G6PD) (EC 1.1.1.49) | Catalyzes the rate-limiting step of the oxidative pentose-phosphate pathway, which represents a route for the dissimilation of carbohydrates besides glycolysis. The main function of this enzyme is to provide reducing power (NADPH) and pentose phosphates for fatty acid and nucleic acid synthesis. {ECO:0000269|PubMed:15858258, ECO:0000269|PubMed:24769394, ECO:0000269|PubMed:26479991, ECO:0000269|PubMed:35122041, ECO:0000269|PubMed:38066190, ECO:0000269|PubMed:743300}. |
| Q9UHF1 | EGFL7 | S43 | Sugiyama | Epidermal growth factor-like protein 7 (EGF-like protein 7) (Multiple epidermal growth factor-like domains protein 7) (Multiple EGF-like domains protein 7) (NOTCH4-like protein) (Vascular endothelial statin) (VE-statin) (Zneu1) | Regulates vascular tubulogenesis in vivo. Inhibits platelet-derived growth factor (PDGF)-BB-induced smooth muscle cell migration and promotes endothelial cell adhesion to the extracellular matrix and angiogenesis. {ECO:0000269|PubMed:23386126, ECO:0000269|PubMed:23639441}. |
| Q01844 | EWSR1 | S443 | Sugiyama | RNA-binding protein EWS (EWS oncogene) (Ewing sarcoma breakpoint region 1 protein) | Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3' (PubMed:21256132). Might normally function as a transcriptional repressor (PubMed:10767297). EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. {ECO:0000269|PubMed:10767297, ECO:0000269|PubMed:21256132}. |
| Q8N568 | DCLK2 | Y276 | Sugiyama | Serine/threonine-protein kinase DCLK2 (EC 2.7.11.1) (CaMK-like CREB regulatory kinase 2) (CL2) (CLICK-II) (CLICK2) (Doublecortin domain-containing protein 3B) (Doublecortin-like and CAM kinase-like 2) (Doublecortin-like kinase 2) | Protein kinase with a significantly reduced C(a2+)/CAM affinity and dependence compared to other members of the CaMK family. May play a role in the down-regulation of CRE-dependent gene activation probably by phosphorylation of the CREB coactivator CRTC2/TORC2 and the resulting retention of TORC2 in the cytoplasm (By similarity). {ECO:0000250}. |
| Q8TD08 | MAPK15 | S353 | Sugiyama | Mitogen-activated protein kinase 15 (MAP kinase 15) (MAPK 15) (EC 2.7.11.24) (Extracellular signal-regulated kinase 7) (ERK-7) (Extracellular signal-regulated kinase 8) (ERK-8) | Atypical MAPK protein that regulates several process such as autophagy, ciliogenesis, protein trafficking/secretion and genome integrity, in a kinase activity-dependent manner (PubMed:20733054, PubMed:21847093, PubMed:22948227, PubMed:24618899, PubMed:29021280). Controls both, basal and starvation-induced autophagy throught its interaction with GABARAP, MAP1LC3B and GABARAPL1 leading to autophagosome formation, SQSTM1 degradation and reduced MAP1LC3B inhibitory phosphorylation (PubMed:22948227). Regulates primary cilium formation and the localization of ciliary proteins involved in cilium structure, transport, and signaling (PubMed:29021280). Prevents the relocation of the sugar-adding enzymes from the Golgi to the endoplasmic reticulum, thereby restricting the production of sugar-coated proteins (PubMed:24618899). Upon amino-acid starvation, mediates transitional endoplasmic reticulum site disassembly and inhibition of secretion (PubMed:21847093). Binds to chromatin leading to MAPK15 activation and interaction with PCNA, that which protects genomic integrity by inhibiting MDM2-mediated degradation of PCNA (PubMed:20733054). Regulates DA transporter (DAT) activity and protein expression via activation of RhoA (PubMed:28842414). In response to H(2)O(2) treatment phosphorylates ELAVL1, thus preventing it from binding to the PDCD4 3'UTR and rendering the PDCD4 mRNA accessible to miR-21 and leading to its degradation and loss of protein expression (PubMed:26595526). Also functions in a kinase activity-independent manner as a negative regulator of growth (By similarity). Phosphorylates in vitro FOS and MBP (PubMed:11875070, PubMed:16484222, PubMed:19166846, PubMed:20638370). During oocyte maturation, plays a key role in the microtubule organization and meiotic cell cycle progression in oocytes, fertilized eggs, and early embryos (By similarity). Interacts with ESRRA promoting its re-localization from the nucleus to the cytoplasm and then prevents its transcriptional activity (PubMed:21190936). {ECO:0000250|UniProtKB:Q80Y86, ECO:0000250|UniProtKB:Q9Z2A6, ECO:0000269|PubMed:11875070, ECO:0000269|PubMed:16484222, ECO:0000269|PubMed:19166846, ECO:0000269|PubMed:20638370, ECO:0000269|PubMed:20733054, ECO:0000269|PubMed:21190936, ECO:0000269|PubMed:21847093, ECO:0000269|PubMed:22948227, ECO:0000269|PubMed:24618899, ECO:0000269|PubMed:26595526, ECO:0000269|PubMed:28842414, ECO:0000269|PubMed:29021280}. |
| Q9Y6D5 | ARFGEF2 | S700 | Sugiyama | Brefeldin A-inhibited guanine nucleotide-exchange protein 2 (Brefeldin A-inhibited GEP 2) (ADP-ribosylation factor guanine nucleotide-exchange factor 2) | Promotes guanine-nucleotide exchange on ARF1 and ARF3 and to a lower extent on ARF5 and ARF6. Promotes the activation of ARF1/ARF5/ARF6 through replacement of GDP with GTP. Involved in the regulation of Golgi vesicular transport. Required for the integrity of the endosomal compartment. Involved in trafficking from the trans-Golgi network (TGN) to endosomes and is required for membrane association of the AP-1 complex and GGA1. Seems to be involved in recycling of the transferrin receptor from recycling endosomes to the plasma membrane. Probably is involved in the exit of GABA(A) receptors from the endoplasmic reticulum. Involved in constitutive release of tumor necrosis factor receptor 1 via exosome-like vesicles; the function seems to involve PKA and specifically PRKAR2B. Proposed to act as A kinase-anchoring protein (AKAP) and may mediate crosstalk between Arf and PKA pathways. {ECO:0000269|PubMed:12051703, ECO:0000269|PubMed:12571360, ECO:0000269|PubMed:15385626, ECO:0000269|PubMed:16477018, ECO:0000269|PubMed:17276987, ECO:0000269|PubMed:18625701, ECO:0000269|PubMed:20360857}. |
| Q9H093 | NUAK2 | S585 | Sugiyama | NUAK family SNF1-like kinase 2 (EC 2.7.11.1) (Omphalocele kinase 2) (SNF1/AMP kinase-related kinase) (SNARK) | Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Phosphorylates LATS1 and LATS2. Plays a key role in neural tube closure during embryonic development through LATS2 phosphorylation and regulation of the nuclear localization of YAP1 a critical downstream regulatory target in the Hippo signaling pathway (PubMed:32845958). {ECO:0000269|PubMed:14575707, ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:15345718, ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:32845958}. |
| O15198 | SMAD9 | Y92 | Sugiyama | Mothers against decapentaplegic homolog 9 (MAD homolog 9) (Mothers against DPP homolog 9) (Madh6) (SMAD family member 9) (SMAD 9) (Smad9) | Transcriptional modulator activated by BMP (bone morphogenetic proteins) type 1 receptor kinase. SMAD9 is a receptor-regulated SMAD (R-SMAD). |
| P84022 | SMAD3 | Y88 | Sugiyama | Mothers against decapentaplegic homolog 3 (MAD homolog 3) (Mad3) (Mothers against DPP homolog 3) (hMAD-3) (JV15-2) (SMAD family member 3) (SMAD 3) (Smad3) (hSMAD3) | Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD3/SMAD4 complex, activates transcription. Also can form a SMAD3/SMAD4/JUN/FOS complex at the AP-1/SMAD site to regulate TGF-beta-mediated transcription. Has an inhibitory effect on wound healing probably by modulating both growth and migration of primary keratinocytes and by altering the TGF-mediated chemotaxis of monocytes. This effect on wound healing appears to be hormone-sensitive. Regulator of chondrogenesis and osteogenesis and inhibits early healing of bone fractures. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. {ECO:0000269|PubMed:10995748, ECO:0000269|PubMed:15241418, ECO:0000269|PubMed:15588252, ECO:0000269|PubMed:16156666, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19218245, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:9732876, ECO:0000269|PubMed:9892009}. |
| Q15796 | SMAD2 | Y128 | Sugiyama | Mothers against decapentaplegic homolog 2 (MAD homolog 2) (Mothers against DPP homolog 2) (JV18-1) (Mad-related protein 2) (hMAD-2) (SMAD family member 2) (SMAD 2) (Smad2) (hSMAD2) | Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. Promotes TGFB1-mediated transcription of odontoblastic differentiation genes in dental papilla cells (By similarity). Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator. May act as a tumor suppressor in colorectal carcinoma (PubMed:8752209). {ECO:0000250|UniProtKB:Q62432, ECO:0000269|PubMed:16751101, ECO:0000269|PubMed:16862174, ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:19289081, ECO:0000269|PubMed:8752209, ECO:0000269|PubMed:9892009}. |
| Q15797 | SMAD1 | Y88 | Sugiyama | Mothers against decapentaplegic homolog 1 (MAD homolog 1) (Mothers against DPP homolog 1) (JV4-1) (Mad-related protein 1) (SMAD family member 1) (SMAD 1) (Smad1) (hSMAD1) (Transforming growth factor-beta-signaling protein 1) (BSP-1) | Transcriptional modulator that plays a role in various cellular processes, including embryonic development, cell differentiation, and tissue homeostasis (PubMed:9335504). Upon BMP ligand binding to their receptors at the cell surface, is phosphorylated by activated type I BMP receptors (BMPRIs) and associates with SMAD4 to form a heteromeric complex which translocates into the nucleus acting as transcription factor (PubMed:33667543). In turn, the hetero-trimeric complex recognizes cis-regulatory elements containing Smad Binding Elements (SBEs) to modulate the outcome of the signaling network (PubMed:33667543). SMAD1/OAZ1/PSMB4 complex mediates the degradation of the CREBBP/EP300 repressor SNIP1. Positively regulates BMP4-induced expression of odontogenic development regulator MSX1 following IPO7-mediated nuclear import (By similarity). {ECO:0000250|UniProtKB:P70340, ECO:0000269|PubMed:12097147, ECO:0000269|PubMed:33667543, ECO:0000269|PubMed:9335504}. |
| Q99717 | SMAD5 | Y89 | Sugiyama | Mothers against decapentaplegic homolog 5 (MAD homolog 5) (Mothers against DPP homolog 5) (JV5-1) (SMAD family member 5) (SMAD 5) (Smad5) (hSmad5) | Transcriptional regulator that plays a role in various cellular processes including embryonic development, cell differentiation, angiogenesis and tissue homeostasis (PubMed:12064918, PubMed:16516194). Upon BMP ligand binding to their receptors at the cell surface, is phosphorylated by activated type I BMP receptors (BMPRIs) and associates with SMAD4 to form a heteromeric complex which translocates into the nucleus acting as transcription factor (PubMed:9442019). In turn, the hetero-trimeric complex recognizes cis-regulatory elements containing Smad Binding Elements (SBEs) to modulate the outcome of the signaling network (PubMed:33510867). Non-phosphorylated SMAD5 has a cytoplasmic role in energy metabolism regulation by promoting mitochondrial respiration and glycolysis in response to cytoplasmic pH changes (PubMed:28675158). Mechanistically, interacts with hexokinase 1/HK1 and thereby accelerates glycolysis (PubMed:28675158). {ECO:0000269|PubMed:12064918, ECO:0000269|PubMed:16516194, ECO:0000269|PubMed:28675158, ECO:0000269|PubMed:33510867, ECO:0000269|PubMed:9442019}. |
| P12277 | CKB | S147 | Sugiyama | Creatine kinase B-type (EC 2.7.3.2) (Brain creatine kinase) (B-CK) (Creatine kinase B chain) (Creatine phosphokinase B-type) (CPK-B) | Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate) (PubMed:8186255). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle, heart, brain and spermatozoa (Probable). Acts as a key regulator of adaptive thermogenesis as part of the futile creatine cycle: localizes to the mitochondria of thermogenic fat cells and acts by mediating phosphorylation of creatine to initiate a futile cycle of creatine phosphorylation and dephosphorylation (By similarity). During the futile creatine cycle, creatine and N-phosphocreatine are in a futile cycle, which dissipates the high energy charge of N-phosphocreatine as heat without performing any mechanical or chemical work (By similarity). {ECO:0000250|UniProtKB:Q04447, ECO:0000269|PubMed:8186255, ECO:0000305}. |
Download
| reactome_id | name | p | -log10_p |
|---|---|---|---|
| R-HSA-9818028 | NFE2L2 regulates pentose phosphate pathway genes | 1.079233e-07 | 6.967 |
| R-HSA-9764561 | Regulation of CDH1 Function | 5.608810e-07 | 6.251 |
| R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 2.687915e-05 | 4.571 |
| R-HSA-9764265 | Regulation of CDH1 Expression and Function | 2.687915e-05 | 4.571 |
| R-HSA-9913351 | Formation of the dystrophin-glycoprotein complex (DGC) | 1.870491e-05 | 4.728 |
| R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 7.843377e-05 | 4.105 |
| R-HSA-418990 | Adherens junctions interactions | 1.994162e-04 | 3.700 |
| R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 3.089219e-04 | 3.510 |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 3.692855e-04 | 3.433 |
| R-HSA-9700206 | Signaling by ALK in cancer | 3.692855e-04 | 3.433 |
| R-HSA-6804757 | Regulation of TP53 Degradation | 4.322469e-04 | 3.364 |
| R-HSA-9013695 | NOTCH4 Intracellular Domain Regulates Transcription | 5.868607e-04 | 3.231 |
| R-HSA-421270 | Cell-cell junction organization | 6.284551e-04 | 3.202 |
| R-HSA-6806003 | Regulation of TP53 Expression and Degradation | 5.849852e-04 | 3.233 |
| R-HSA-3315487 | SMAD2/3 MH2 Domain Mutants in Cancer | 8.962057e-04 | 3.048 |
| R-HSA-3311021 | SMAD4 MH2 Domain Mutants in Cancer | 8.962057e-04 | 3.048 |
| R-HSA-3304347 | Loss of Function of SMAD4 in Cancer | 8.962057e-04 | 3.048 |
| R-HSA-9759194 | Nuclear events mediated by NFE2L2 | 8.345407e-04 | 3.079 |
| R-HSA-446728 | Cell junction organization | 1.405185e-03 | 2.852 |
| R-HSA-1500931 | Cell-Cell communication | 1.282577e-03 | 2.892 |
| R-HSA-3000171 | Non-integrin membrane-ECM interactions | 1.383726e-03 | 2.859 |
| R-HSA-8941333 | RUNX2 regulates genes involved in differentiation of myeloid cells | 3.484810e-03 | 2.458 |
| R-HSA-3656532 | TGFBR1 KD Mutants in Cancer | 3.484810e-03 | 2.458 |
| R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 2.571216e-03 | 2.590 |
| R-HSA-5693565 | Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at... | 3.012405e-03 | 2.521 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 3.581417e-03 | 2.446 |
| R-HSA-5660489 | MTF1 activates gene expression | 3.484810e-03 | 2.458 |
| R-HSA-453279 | Mitotic G1 phase and G1/S transition | 2.788935e-03 | 2.555 |
| R-HSA-9755511 | KEAP1-NFE2L2 pathway | 3.339125e-03 | 2.476 |
| R-HSA-74713 | IRS activation | 4.698790e-03 | 2.328 |
| R-HSA-3304356 | SMAD2/3 Phosphorylation Motif Mutants in Cancer | 4.698790e-03 | 2.328 |
| R-HSA-5693606 | DNA Double Strand Break Response | 4.831874e-03 | 2.316 |
| R-HSA-69481 | G2/M Checkpoints | 4.771460e-03 | 2.321 |
| R-HSA-3656534 | Loss of Function of TGFBR1 in Cancer | 4.698790e-03 | 2.328 |
| R-HSA-1640170 | Cell Cycle | 4.528508e-03 | 2.344 |
| R-HSA-5633007 | Regulation of TP53 Activity | 4.538257e-03 | 2.343 |
| R-HSA-69278 | Cell Cycle, Mitotic | 5.159065e-03 | 2.287 |
| R-HSA-1181150 | Signaling by NODAL | 5.831748e-03 | 2.234 |
| R-HSA-3304349 | Loss of Function of SMAD2/3 in Cancer | 6.079782e-03 | 2.216 |
| R-HSA-9617828 | FOXO-mediated transcription of cell cycle genes | 7.194655e-03 | 2.143 |
| R-HSA-69473 | G2/M DNA damage checkpoint | 6.969608e-03 | 2.157 |
| R-HSA-2995383 | Initiation of Nuclear Envelope (NE) Reformation | 7.194655e-03 | 2.143 |
| R-HSA-9013694 | Signaling by NOTCH4 | 6.969608e-03 | 2.157 |
| R-HSA-69236 | G1 Phase | 7.039148e-03 | 2.152 |
| R-HSA-69231 | Cyclin D associated events in G1 | 7.039148e-03 | 2.152 |
| R-HSA-3304351 | Signaling by TGF-beta Receptor Complex in Cancer | 7.622823e-03 | 2.118 |
| R-HSA-982772 | Growth hormone receptor signaling | 8.731034e-03 | 2.059 |
| R-HSA-5674400 | Constitutive Signaling by AKT1 E17K in Cancer | 8.731034e-03 | 2.059 |
| R-HSA-8949275 | RUNX3 Regulates Immune Response and Cell Migration | 9.323059e-03 | 2.030 |
| R-HSA-69275 | G2/M Transition | 1.016225e-02 | 1.993 |
| R-HSA-196025 | Formation of annular gap junctions | 1.117574e-02 | 1.952 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 1.072352e-02 | 1.970 |
| R-HSA-525793 | Myogenesis | 1.137040e-02 | 1.944 |
| R-HSA-8939246 | RUNX1 regulates transcription of genes involved in differentiation of myeloid ce... | 1.117574e-02 | 1.952 |
| R-HSA-4420097 | VEGFA-VEGFR2 Pathway | 1.139547e-02 | 1.943 |
| R-HSA-201451 | Signaling by BMP | 1.234125e-02 | 1.909 |
| R-HSA-190873 | Gap junction degradation | 1.317621e-02 | 1.880 |
| R-HSA-2465910 | MASTL Facilitates Mitotic Progression | 1.317621e-02 | 1.880 |
| R-HSA-6804756 | Regulation of TP53 Activity through Phosphorylation | 1.254896e-02 | 1.901 |
| R-HSA-8878166 | Transcriptional regulation by RUNX2 | 1.306631e-02 | 1.884 |
| R-HSA-74749 | Signal attenuation | 1.531993e-02 | 1.815 |
| R-HSA-9006936 | Signaling by TGFB family members | 1.516162e-02 | 1.819 |
| R-HSA-69206 | G1/S Transition | 1.639103e-02 | 1.785 |
| R-HSA-9008059 | Interleukin-37 signaling | 1.553169e-02 | 1.809 |
| R-HSA-2586552 | Signaling by Leptin | 1.531993e-02 | 1.815 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 1.637090e-02 | 1.786 |
| R-HSA-194138 | Signaling by VEGF | 1.639103e-02 | 1.785 |
| R-HSA-1257604 | PIP3 activates AKT signaling | 1.650048e-02 | 1.783 |
| R-HSA-9635465 | Suppression of apoptosis | 1.760244e-02 | 1.754 |
| R-HSA-210990 | PECAM1 interactions | 1.760244e-02 | 1.754 |
| R-HSA-8953897 | Cellular responses to stimuli | 1.732240e-02 | 1.761 |
| R-HSA-1538133 | G0 and Early G1 | 1.789265e-02 | 1.747 |
| R-HSA-5688426 | Deubiquitination | 1.879575e-02 | 1.726 |
| R-HSA-2559586 | DNA Damage/Telomere Stress Induced Senescence | 1.897594e-02 | 1.722 |
| R-HSA-8878159 | Transcriptional regulation by RUNX3 | 2.057210e-02 | 1.687 |
| R-HSA-2559584 | Formation of Senescence-Associated Heterochromatin Foci (SAHF) | 2.523970e-02 | 1.598 |
| R-HSA-9933947 | Formation of the non-canonical BAF (ncBAF) complex | 2.523970e-02 | 1.598 |
| R-HSA-9796292 | Formation of axial mesoderm | 2.523970e-02 | 1.598 |
| R-HSA-75035 | Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 2.523970e-02 | 1.598 |
| R-HSA-9860927 | Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZ... | 2.318128e-02 | 1.635 |
| R-HSA-5654227 | Phospholipase C-mediated cascade; FGFR3 | 2.803481e-02 | 1.552 |
| R-HSA-5654228 | Phospholipase C-mediated cascade; FGFR4 | 3.094787e-02 | 1.509 |
| R-HSA-380270 | Recruitment of mitotic centrosome proteins and complexes | 3.018409e-02 | 1.520 |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 2.610964e-02 | 1.583 |
| R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants | 2.610964e-02 | 1.583 |
| R-HSA-169131 | Inhibition of PKR | 2.828438e-02 | 1.548 |
| R-HSA-8856828 | Clathrin-mediated endocytosis | 2.976038e-02 | 1.526 |
| R-HSA-1502540 | Signaling by Activin | 3.094787e-02 | 1.509 |
| R-HSA-9735871 | SARS-CoV-1 targets host intracellular signalling and regulatory pathways | 3.094787e-02 | 1.509 |
| R-HSA-1433559 | Regulation of KIT signaling | 2.803481e-02 | 1.552 |
| R-HSA-71336 | Pentose phosphate pathway | 2.922693e-02 | 1.534 |
| R-HSA-1445148 | Translocation of SLC2A4 (GLUT4) to the plasma membrane | 3.018409e-02 | 1.520 |
| R-HSA-9860931 | Response of endothelial cells to shear stress | 2.602649e-02 | 1.585 |
| R-HSA-451927 | Interleukin-2 family signaling | 3.085616e-02 | 1.511 |
| R-HSA-201556 | Signaling by ALK | 2.922693e-02 | 1.534 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 3.094787e-02 | 1.509 |
| R-HSA-380287 | Centrosome maturation | 3.256372e-02 | 1.487 |
| R-HSA-9615017 | FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 3.425500e-02 | 1.465 |
| R-HSA-5674135 | MAP2K and MAPK activation | 3.425500e-02 | 1.465 |
| R-HSA-9656223 | Signaling by RAF1 mutants | 3.425500e-02 | 1.465 |
| R-HSA-1362300 | Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL... | 3.397501e-02 | 1.469 |
| R-HSA-1169408 | ISG15 antiviral mechanism | 3.256372e-02 | 1.487 |
| R-HSA-5218920 | VEGFR2 mediated vascular permeability | 3.253224e-02 | 1.488 |
| R-HSA-9856651 | MITF-M-dependent gene expression | 3.545241e-02 | 1.450 |
| R-HSA-6791462 | TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | 4.212642e-02 | 1.375 |
| R-HSA-6791055 | TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | 4.212642e-02 | 1.375 |
| R-HSA-5654219 | Phospholipase C-mediated cascade: FGFR1 | 4.035631e-02 | 1.394 |
| R-HSA-5693571 | Nonhomologous End-Joining (NHEJ) | 4.760090e-02 | 1.322 |
| R-HSA-5654741 | Signaling by FGFR3 | 4.160828e-02 | 1.381 |
| R-HSA-5654743 | Signaling by FGFR4 | 3.783968e-02 | 1.422 |
| R-HSA-5693607 | Processing of DNA double-strand break ends | 4.034548e-02 | 1.394 |
| R-HSA-8849932 | Synaptic adhesion-like molecules | 4.370312e-02 | 1.359 |
| R-HSA-1500620 | Meiosis | 4.607104e-02 | 1.337 |
| R-HSA-9649948 | Signaling downstream of RAS mutants | 4.356084e-02 | 1.361 |
| R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants | 4.356084e-02 | 1.361 |
| R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF | 4.356084e-02 | 1.361 |
| R-HSA-68875 | Mitotic Prophase | 4.518868e-02 | 1.345 |
| R-HSA-9754189 | Germ layer formation at gastrulation | 4.714925e-02 | 1.327 |
| R-HSA-165159 | MTOR signalling | 3.602422e-02 | 1.443 |
| R-HSA-4419969 | Depolymerization of the Nuclear Lamina | 4.370312e-02 | 1.359 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 4.459932e-02 | 1.351 |
| R-HSA-6802949 | Signaling by RAS mutants | 4.356084e-02 | 1.361 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 3.632303e-02 | 1.440 |
| R-HSA-2173789 | TGF-beta receptor signaling activates SMADs | 3.783968e-02 | 1.422 |
| R-HSA-430039 | mRNA decay by 5' to 3' exoribonuclease | 3.711240e-02 | 1.430 |
| R-HSA-4839726 | Chromatin organization | 4.176501e-02 | 1.379 |
| R-HSA-5693538 | Homology Directed Repair | 4.286164e-02 | 1.368 |
| R-HSA-2995410 | Nuclear Envelope (NE) Reassembly | 3.898135e-02 | 1.409 |
| R-HSA-5637810 | Constitutive Signaling by EGFRvIII | 4.035631e-02 | 1.394 |
| R-HSA-5637812 | Signaling by EGFRvIII in Cancer | 4.035631e-02 | 1.394 |
| R-HSA-9855142 | Cellular responses to mechanical stimuli | 3.632303e-02 | 1.440 |
| R-HSA-2219528 | PI3K/AKT Signaling in Cancer | 4.286164e-02 | 1.368 |
| R-HSA-1592230 | Mitochondrial biogenesis | 4.172587e-02 | 1.380 |
| R-HSA-9725371 | Nuclear events stimulated by ALK signaling in cancer | 4.760090e-02 | 1.322 |
| R-HSA-1433557 | Signaling by SCF-KIT | 3.783968e-02 | 1.422 |
| R-HSA-5660526 | Response to metal ions | 3.711240e-02 | 1.430 |
| R-HSA-167021 | PLC-gamma1 signalling | 6.922425e-02 | 1.160 |
| R-HSA-9034793 | Activated NTRK3 signals through PLCG1 | 6.922425e-02 | 1.160 |
| R-HSA-9026527 | Activated NTRK2 signals through PLCG1 | 8.248556e-02 | 1.084 |
| R-HSA-8952158 | RUNX3 regulates BCL2L11 (BIM) transcription | 8.248556e-02 | 1.084 |
| R-HSA-211163 | AKT-mediated inactivation of FOXO1A | 8.248556e-02 | 1.084 |
| R-HSA-1251932 | PLCG1 events in ERBB2 signaling | 8.248556e-02 | 1.084 |
| R-HSA-69200 | Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 ... | 8.248556e-02 | 1.084 |
| R-HSA-68911 | G2 Phase | 9.555873e-02 | 1.020 |
| R-HSA-9706377 | FLT3 signaling by CBL mutants | 9.555873e-02 | 1.020 |
| R-HSA-9833576 | CDH11 homotypic and heterotypic interactions | 1.084464e-01 | 0.965 |
| R-HSA-8849470 | PTK6 Regulates Cell Cycle | 1.084464e-01 | 0.965 |
| R-HSA-69478 | G2/M DNA replication checkpoint | 1.211513e-01 | 0.917 |
| R-HSA-113507 | E2F-enabled inhibition of pre-replication complex formation | 1.211513e-01 | 0.917 |
| R-HSA-428890 | Role of ABL in ROBO-SLIT signaling | 1.336758e-01 | 0.874 |
| R-HSA-112412 | SOS-mediated signalling | 1.336758e-01 | 0.874 |
| R-HSA-2470946 | Cohesin Loading onto Chromatin | 1.336758e-01 | 0.874 |
| R-HSA-190371 | FGFR3b ligand binding and activation | 1.336758e-01 | 0.874 |
| R-HSA-212718 | EGFR interacts with phospholipase C-gamma | 1.460226e-01 | 0.836 |
| R-HSA-190370 | FGFR1b ligand binding and activation | 1.460226e-01 | 0.836 |
| R-HSA-9020958 | Interleukin-21 signaling | 1.581943e-01 | 0.801 |
| R-HSA-5654221 | Phospholipase C-mediated cascade; FGFR2 | 5.069123e-02 | 1.295 |
| R-HSA-2468052 | Establishment of Sister Chromatid Cohesion | 1.701931e-01 | 0.769 |
| R-HSA-9027277 | Erythropoietin activates Phospholipase C gamma (PLCG) | 1.701931e-01 | 0.769 |
| R-HSA-164843 | 2-LTR circle formation | 1.701931e-01 | 0.769 |
| R-HSA-390450 | Folding of actin by CCT/TriC | 1.701931e-01 | 0.769 |
| R-HSA-2197563 | NOTCH2 intracellular domain regulates transcription | 2.051776e-01 | 0.688 |
| R-HSA-8949613 | Cristae formation | 8.208484e-02 | 1.086 |
| R-HSA-190375 | FGFR2c ligand binding and activation | 2.165096e-01 | 0.665 |
| R-HSA-9661069 | Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 2.165096e-01 | 0.665 |
| R-HSA-5334118 | DNA methylation | 9.067063e-02 | 1.043 |
| R-HSA-9927432 | Developmental Lineage of Mammary Gland Myoepithelial Cells | 9.067063e-02 | 1.043 |
| R-HSA-390522 | Striated Muscle Contraction | 1.131820e-01 | 0.946 |
| R-HSA-5656121 | Translesion synthesis by POLI | 2.495493e-01 | 0.603 |
| R-HSA-3301854 | Nuclear Pore Complex (NPC) Disassembly | 1.225525e-01 | 0.912 |
| R-HSA-5655862 | Translesion synthesis by POLK | 2.602514e-01 | 0.585 |
| R-HSA-9845323 | Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | 7.545572e-02 | 1.122 |
| R-HSA-5651801 | PCNA-Dependent Long Patch Base Excision Repair | 2.812016e-01 | 0.551 |
| R-HSA-6807505 | RNA polymerase II transcribes snRNA genes | 4.909500e-02 | 1.309 |
| R-HSA-912631 | Regulation of signaling by CBL | 2.914541e-01 | 0.535 |
| R-HSA-174048 | APC/C:Cdc20 mediated degradation of Cyclin B | 2.914541e-01 | 0.535 |
| R-HSA-174184 | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 2.130814e-01 | 0.671 |
| R-HSA-73772 | RNA Polymerase I Promoter Escape | 2.130814e-01 | 0.671 |
| R-HSA-72649 | Translation initiation complex formation | 2.235626e-01 | 0.651 |
| R-HSA-3214815 | HDACs deacetylate histones | 2.288185e-01 | 0.641 |
| R-HSA-6782210 | Gap-filling DNA repair synthesis and ligation in TC-NER | 2.340828e-01 | 0.631 |
| R-HSA-72702 | Ribosomal scanning and start codon recognition | 2.340828e-01 | 0.631 |
| R-HSA-6782135 | Dual incision in TC-NER | 2.446314e-01 | 0.611 |
| R-HSA-380284 | Loss of proteins required for interphase microtubule organization from the centr... | 2.710631e-01 | 0.567 |
| R-HSA-380259 | Loss of Nlp from mitotic centrosomes | 2.710631e-01 | 0.567 |
| R-HSA-8854518 | AURKA Activation by TPX2 | 2.869185e-01 | 0.542 |
| R-HSA-6791226 | Major pathway of rRNA processing in the nucleolus and cytosol | 2.880058e-01 | 0.541 |
| R-HSA-5654687 | Downstream signaling of activated FGFR1 | 1.225525e-01 | 0.912 |
| R-HSA-5654708 | Downstream signaling of activated FGFR3 | 9.067063e-02 | 1.043 |
| R-HSA-5654716 | Downstream signaling of activated FGFR4 | 9.505847e-02 | 1.022 |
| R-HSA-5654696 | Downstream signaling of activated FGFR2 | 1.225525e-01 | 0.912 |
| R-HSA-182971 | EGFR downregulation | 9.950607e-02 | 1.002 |
| R-HSA-9823730 | Formation of definitive endoderm | 5.069123e-02 | 1.295 |
| R-HSA-380972 | Energy dependent regulation of mTOR by LKB1-AMPK | 9.505847e-02 | 1.022 |
| R-HSA-5654710 | PI-3K cascade:FGFR3 | 2.914541e-01 | 0.535 |
| R-HSA-187577 | SCF(Skp2)-mediated degradation of p27/p21 | 1.717781e-01 | 0.765 |
| R-HSA-5685938 | HDR through Single Strand Annealing (SSA) | 1.085703e-01 | 0.964 |
| R-HSA-1221632 | Meiotic synapsis | 2.183165e-01 | 0.661 |
| R-HSA-190236 | Signaling by FGFR | 2.069034e-01 | 0.684 |
| R-HSA-9842860 | Regulation of endogenous retroelements | 2.217345e-01 | 0.654 |
| R-HSA-198203 | PI3K/AKT activation | 1.701931e-01 | 0.769 |
| R-HSA-110312 | Translesion synthesis by REV1 | 2.386932e-01 | 0.622 |
| R-HSA-9614657 | FOXO-mediated transcription of cell death genes | 2.812016e-01 | 0.551 |
| R-HSA-6802952 | Signaling by BRAF and RAF1 fusions | 8.876692e-02 | 1.052 |
| R-HSA-2299718 | Condensation of Prophase Chromosomes | 1.819860e-01 | 0.740 |
| R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 6.550535e-02 | 1.184 |
| R-HSA-9614085 | FOXO-mediated transcription | 2.105900e-01 | 0.677 |
| R-HSA-9931530 | Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | 2.051776e-01 | 0.688 |
| R-HSA-69166 | Removal of the Flap Intermediate | 2.276807e-01 | 0.643 |
| R-HSA-9931521 | The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CL... | 2.602514e-01 | 0.585 |
| R-HSA-174437 | Removal of the Flap Intermediate from the C-strand | 2.708014e-01 | 0.567 |
| R-HSA-427389 | ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 1.467317e-01 | 0.833 |
| R-HSA-110320 | Translesion Synthesis by POLH | 2.914541e-01 | 0.535 |
| R-HSA-2173795 | Downregulation of SMAD2/3:SMAD4 transcriptional activity | 1.040109e-01 | 0.983 |
| R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | 1.089107e-01 | 0.963 |
| R-HSA-5696398 | Nucleotide Excision Repair | 2.367713e-01 | 0.626 |
| R-HSA-8941856 | RUNX3 regulates NOTCH signaling | 2.051776e-01 | 0.688 |
| R-HSA-5250913 | Positive epigenetic regulation of rRNA expression | 1.059315e-01 | 0.975 |
| R-HSA-69202 | Cyclin E associated events during G1/S transition | 1.029852e-01 | 0.987 |
| R-HSA-5654738 | Signaling by FGFR2 | 1.338551e-01 | 0.873 |
| R-HSA-5654736 | Signaling by FGFR1 | 6.550535e-02 | 1.184 |
| R-HSA-190377 | FGFR2b ligand binding and activation | 1.820217e-01 | 0.740 |
| R-HSA-190373 | FGFR1c ligand binding and activation | 2.165096e-01 | 0.665 |
| R-HSA-190239 | FGFR3 ligand binding and activation | 2.386932e-01 | 0.622 |
| R-HSA-176187 | Activation of ATR in response to replication stress | 1.085703e-01 | 0.964 |
| R-HSA-9821002 | Chromatin modifications during the maternal to zygotic transition (MZT) | 1.516795e-01 | 0.819 |
| R-HSA-3214847 | HATs acetylate histones | 7.514634e-02 | 1.124 |
| R-HSA-5250924 | B-WICH complex positively regulates rRNA expression | 2.183165e-01 | 0.661 |
| R-HSA-8875360 | InlB-mediated entry of Listeria monocytogenes into host cell | 2.386932e-01 | 0.622 |
| R-HSA-75955 | RNA Polymerase II Transcription Elongation | 2.183165e-01 | 0.661 |
| R-HSA-5655332 | Signaling by FGFR3 in disease | 8.208484e-02 | 1.086 |
| R-HSA-5655253 | Signaling by FGFR2 in disease | 2.026503e-01 | 0.693 |
| R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 1.034244e-01 | 0.985 |
| R-HSA-426486 | Small interfering RNA (siRNA) biogenesis | 1.211513e-01 | 0.917 |
| R-HSA-9614399 | Regulation of localization of FOXO transcription factors | 1.820217e-01 | 0.740 |
| R-HSA-77595 | Processing of Intronless Pre-mRNAs | 2.602514e-01 | 0.585 |
| R-HSA-2033519 | Activated point mutants of FGFR2 | 2.812016e-01 | 0.551 |
| R-HSA-9664422 | FCGR3A-mediated phagocytosis | 1.902678e-01 | 0.721 |
| R-HSA-9664417 | Leishmania phagocytosis | 1.902678e-01 | 0.721 |
| R-HSA-9664407 | Parasite infection | 1.902678e-01 | 0.721 |
| R-HSA-74752 | Signaling by Insulin receptor | 1.815509e-01 | 0.741 |
| R-HSA-140342 | Apoptosis induced DNA fragmentation | 1.701931e-01 | 0.769 |
| R-HSA-190242 | FGFR1 ligand binding and activation | 2.812016e-01 | 0.551 |
| R-HSA-73864 | RNA Polymerase I Transcription | 1.274421e-01 | 0.895 |
| R-HSA-74751 | Insulin receptor signalling cascade | 8.602988e-02 | 1.065 |
| R-HSA-68962 | Activation of the pre-replicative complex | 9.505847e-02 | 1.022 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 1.461607e-01 | 0.835 |
| R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 7.133521e-02 | 1.147 |
| R-HSA-2980766 | Nuclear Envelope Breakdown | 6.793267e-02 | 1.168 |
| R-HSA-176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 2.288185e-01 | 0.641 |
| R-HSA-176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 2.340828e-01 | 0.631 |
| R-HSA-202433 | Generation of second messenger molecules | 1.467317e-01 | 0.833 |
| R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis | 1.463240e-01 | 0.835 |
| R-HSA-6802957 | Oncogenic MAPK signaling | 1.503574e-01 | 0.823 |
| R-HSA-9708296 | tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | 5.577212e-02 | 1.254 |
| R-HSA-8941855 | RUNX3 regulates CDKN1A transcription | 1.084464e-01 | 0.965 |
| R-HSA-6791465 | Pentose phosphate pathway disease | 1.084464e-01 | 0.965 |
| R-HSA-176417 | Phosphorylation of Emi1 | 1.084464e-01 | 0.965 |
| R-HSA-1614603 | Cysteine formation from homocysteine | 1.336758e-01 | 0.874 |
| R-HSA-9762292 | Regulation of CDH11 function | 1.701931e-01 | 0.769 |
| R-HSA-2151209 | Activation of PPARGC1A (PGC-1alpha) by phosphorylation | 1.701931e-01 | 0.769 |
| R-HSA-9821993 | Replacement of protamines by nucleosomes in the male pronucleus | 6.972233e-02 | 1.157 |
| R-HSA-1839122 | Signaling by activated point mutants of FGFR1 | 1.936824e-01 | 0.713 |
| R-HSA-68884 | Mitotic Telophase/Cytokinesis | 1.936824e-01 | 0.713 |
| R-HSA-418890 | Role of second messengers in netrin-1 signaling | 2.051776e-01 | 0.688 |
| R-HSA-445095 | Interaction between L1 and Ankyrins | 8.208484e-02 | 1.086 |
| R-HSA-190322 | FGFR4 ligand binding and activation | 2.165096e-01 | 0.665 |
| R-HSA-9659787 | Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 2.165096e-01 | 0.665 |
| R-HSA-190372 | FGFR3c ligand binding and activation | 2.276807e-01 | 0.643 |
| R-HSA-912446 | Meiotic recombination | 5.399303e-02 | 1.268 |
| R-HSA-176412 | Phosphorylation of the APC/C | 2.495493e-01 | 0.603 |
| R-HSA-9912633 | Antigen processing: Ub, ATP-independent proteasomal degradation | 2.602514e-01 | 0.585 |
| R-HSA-9843743 | Transcriptional regulation of brown and beige adipocyte differentiation | 1.467317e-01 | 0.833 |
| R-HSA-9844594 | Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | 1.467317e-01 | 0.833 |
| R-HSA-8851708 | Signaling by FGFR2 IIIa TM | 2.914541e-01 | 0.535 |
| R-HSA-73854 | RNA Polymerase I Promoter Clearance | 1.211439e-01 | 0.917 |
| R-HSA-68949 | Orc1 removal from chromatin | 2.130814e-01 | 0.671 |
| R-HSA-112382 | Formation of RNA Pol II elongation complex | 2.130814e-01 | 0.671 |
| R-HSA-179419 | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of th... | 2.183165e-01 | 0.661 |
| R-HSA-5696399 | Global Genome Nucleotide Excision Repair (GG-NER) | 1.470056e-01 | 0.833 |
| R-HSA-69017 | CDK-mediated phosphorylation and removal of Cdc6 | 2.235626e-01 | 0.651 |
| R-HSA-2428928 | IRS-related events triggered by IGF1R | 2.604859e-01 | 0.584 |
| R-HSA-2029482 | Regulation of actin dynamics for phagocytic cup formation | 1.931531e-01 | 0.714 |
| R-HSA-177929 | Signaling by EGFR | 6.550535e-02 | 1.184 |
| R-HSA-379716 | Cytosolic tRNA aminoacylation | 1.616711e-01 | 0.791 |
| R-HSA-69242 | S Phase | 9.249675e-02 | 1.034 |
| R-HSA-68886 | M Phase | 6.718194e-02 | 1.173 |
| R-HSA-112399 | IRS-mediated signalling | 2.393542e-01 | 0.621 |
| R-HSA-5654732 | Negative regulation of FGFR3 signaling | 8.634519e-02 | 1.064 |
| R-HSA-5654733 | Negative regulation of FGFR4 signaling | 9.067063e-02 | 1.043 |
| R-HSA-69183 | Processive synthesis on the lagging strand | 2.386932e-01 | 0.622 |
| R-HSA-9768727 | Regulation of CDH1 posttranslational processing and trafficking to plasma membra... | 1.131820e-01 | 0.946 |
| R-HSA-5654727 | Negative regulation of FGFR2 signaling | 1.178435e-01 | 0.929 |
| R-HSA-6811558 | PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 1.358812e-01 | 0.867 |
| R-HSA-69620 | Cell Cycle Checkpoints | 4.887648e-02 | 1.311 |
| R-HSA-9603381 | Activated NTRK3 signals through PI3K | 1.336758e-01 | 0.874 |
| R-HSA-5654726 | Negative regulation of FGFR1 signaling | 1.085703e-01 | 0.964 |
| R-HSA-5696395 | Formation of Incision Complex in GG-NER | 1.467317e-01 | 0.833 |
| R-HSA-453276 | Regulation of mitotic cell cycle | 1.059315e-01 | 0.975 |
| R-HSA-174143 | APC/C-mediated degradation of cell cycle proteins | 1.059315e-01 | 0.975 |
| R-HSA-9931269 | AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | 2.130814e-01 | 0.671 |
| R-HSA-73894 | DNA Repair | 4.916396e-02 | 1.308 |
| R-HSA-202403 | TCR signaling | 2.558044e-01 | 0.592 |
| R-HSA-166208 | mTORC1-mediated signalling | 6.185858e-02 | 1.209 |
| R-HSA-2173788 | Downregulation of TGF-beta receptor signaling | 6.185858e-02 | 1.209 |
| R-HSA-176408 | Regulation of APC/C activators between G1/S and early anaphase | 8.066692e-02 | 1.093 |
| R-HSA-2428924 | IGF1R signaling cascade | 2.763507e-01 | 0.559 |
| R-HSA-9932451 | SWI/SNF chromatin remodelers | 7.377055e-02 | 1.132 |
| R-HSA-9932444 | ATP-dependent chromatin remodelers | 7.377055e-02 | 1.132 |
| R-HSA-5655302 | Signaling by FGFR1 in disease | 1.566600e-01 | 0.805 |
| R-HSA-157118 | Signaling by NOTCH | 1.726819e-01 | 0.763 |
| R-HSA-163754 | Insulin effects increased synthesis of Xylulose-5-Phosphate | 1.336758e-01 | 0.874 |
| R-HSA-1433617 | Regulation of signaling by NODAL | 1.581943e-01 | 0.801 |
| R-HSA-428359 | Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RN... | 1.701931e-01 | 0.769 |
| R-HSA-1483226 | Synthesis of PI | 1.820217e-01 | 0.740 |
| R-HSA-416550 | Sema4D mediated inhibition of cell attachment and migration | 1.936824e-01 | 0.713 |
| R-HSA-217271 | FMO oxidises nucleophiles | 1.936824e-01 | 0.713 |
| R-HSA-9617629 | Regulation of FOXO transcriptional activity by acetylation | 2.051776e-01 | 0.688 |
| R-HSA-1839130 | Signaling by activated point mutants of FGFR3 | 2.165096e-01 | 0.665 |
| R-HSA-168276 | NS1 Mediated Effects on Host Pathways | 1.418184e-01 | 0.848 |
| R-HSA-73762 | RNA Polymerase I Transcription Initiation | 1.616711e-01 | 0.791 |
| R-HSA-72695 | Formation of the ternary complex, and subsequently, the 43S complex | 1.819860e-01 | 0.740 |
| R-HSA-72662 | Activation of the mRNA upon binding of the cap-binding complex and eIFs, and sub... | 2.446314e-01 | 0.611 |
| R-HSA-3247509 | Chromatin modifying enzymes | 7.533996e-02 | 1.123 |
| R-HSA-2404192 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 2.816362e-01 | 0.550 |
| R-HSA-68882 | Mitotic Anaphase | 5.545258e-02 | 1.256 |
| R-HSA-8985947 | Interleukin-9 signaling | 1.460226e-01 | 0.836 |
| R-HSA-2555396 | Mitotic Metaphase and Anaphase | 5.646041e-02 | 1.248 |
| R-HSA-9842663 | Signaling by LTK | 2.051776e-01 | 0.688 |
| R-HSA-9766229 | Degradation of CDH1 | 1.974572e-01 | 0.705 |
| R-HSA-199418 | Negative regulation of the PI3K/AKT network | 1.568193e-01 | 0.805 |
| R-HSA-3214842 | HDMs demethylate histones | 7.377055e-02 | 1.132 |
| R-HSA-157579 | Telomere Maintenance | 2.032319e-01 | 0.692 |
| R-HSA-9759475 | Regulation of CDH11 Expression and Function | 9.067063e-02 | 1.043 |
| R-HSA-74160 | Gene expression (Transcription) | 8.532334e-02 | 1.069 |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 7.462370e-02 | 1.127 |
| R-HSA-211000 | Gene Silencing by RNA | 9.352763e-02 | 1.029 |
| R-HSA-1295596 | Spry regulation of FGF signaling | 2.386932e-01 | 0.622 |
| R-HSA-9764260 | Regulation of Expression and Function of Type II Classical Cadherins | 1.085703e-01 | 0.964 |
| R-HSA-8943724 | Regulation of PTEN gene transcription | 2.551984e-01 | 0.593 |
| R-HSA-9034015 | Signaling by NTRK3 (TRKC) | 5.804918e-02 | 1.236 |
| R-HSA-512988 | Interleukin-3, Interleukin-5 and GM-CSF signaling | 1.616711e-01 | 0.791 |
| R-HSA-5637815 | Signaling by Ligand-Responsive EGFR Variants in Cancer | 5.432565e-02 | 1.265 |
| R-HSA-1236382 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 5.432565e-02 | 1.265 |
| R-HSA-9816359 | Maternal to zygotic transition (MZT) | 1.358812e-01 | 0.867 |
| R-HSA-69239 | Synthesis of DNA | 2.443560e-01 | 0.612 |
| R-HSA-9927353 | Co-inhibition by BTLA | 9.555873e-02 | 1.020 |
| R-HSA-2980767 | Activation of NIMA Kinases NEK9, NEK6, NEK7 | 1.211513e-01 | 0.917 |
| R-HSA-390696 | Adrenoceptors | 1.460226e-01 | 0.836 |
| R-HSA-8849469 | PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 1.460226e-01 | 0.836 |
| R-HSA-198693 | AKT phosphorylates targets in the nucleus | 1.581943e-01 | 0.801 |
| R-HSA-110056 | MAPK3 (ERK1) activation | 1.701931e-01 | 0.769 |
| R-HSA-2514853 | Condensation of Prometaphase Chromosomes | 1.936824e-01 | 0.713 |
| R-HSA-9839394 | TGFBR3 expression | 7.377055e-02 | 1.132 |
| R-HSA-877312 | Regulation of IFNG signaling | 2.051776e-01 | 0.688 |
| R-HSA-879415 | Advanced glycosylation endproduct receptor signaling | 2.051776e-01 | 0.688 |
| R-HSA-9706369 | Negative regulation of FLT3 | 2.495493e-01 | 0.603 |
| R-HSA-210744 | Regulation of gene expression in late stage (branching morphogenesis) pancreatic... | 2.495493e-01 | 0.603 |
| R-HSA-445355 | Smooth Muscle Contraction | 5.847127e-02 | 1.233 |
| R-HSA-113510 | E2F mediated regulation of DNA replication | 2.914541e-01 | 0.535 |
| R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 2.130814e-01 | 0.671 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 9.787764e-02 | 1.009 |
| R-HSA-6790901 | rRNA modification in the nucleus and cytosol | 2.710631e-01 | 0.567 |
| R-HSA-73857 | RNA Polymerase II Transcription | 1.483496e-01 | 0.829 |
| R-HSA-1643713 | Signaling by EGFR in Cancer | 7.789235e-02 | 1.109 |
| R-HSA-379724 | tRNA Aminoacylation | 2.551984e-01 | 0.593 |
| R-HSA-400685 | Sema4D in semaphorin signaling | 7.377055e-02 | 1.132 |
| R-HSA-1660516 | Synthesis of PIPs at the early endosome membrane | 7.377055e-02 | 1.132 |
| R-HSA-8948751 | Regulation of PTEN stability and activity | 2.183165e-01 | 0.661 |
| R-HSA-69580 | p53-Dependent G1/S DNA damage checkpoint | 4.968771e-02 | 1.304 |
| R-HSA-69563 | p53-Dependent G1 DNA Damage Response | 4.968771e-02 | 1.304 |
| R-HSA-1614558 | Degradation of cysteine and homocysteine | 1.768703e-01 | 0.752 |
| R-HSA-1474165 | Reproduction | 1.595177e-01 | 0.797 |
| R-HSA-5358606 | Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 2.708014e-01 | 0.567 |
| R-HSA-9758941 | Gastrulation | 2.197047e-01 | 0.658 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 1.447089e-01 | 0.840 |
| R-HSA-162906 | HIV Infection | 2.820689e-01 | 0.550 |
| R-HSA-9824585 | Regulation of MITF-M-dependent genes involved in pigmentation | 1.768703e-01 | 0.752 |
| R-HSA-9762293 | Regulation of CDH11 gene transcription | 1.581943e-01 | 0.801 |
| R-HSA-162592 | Integration of provirus | 1.936824e-01 | 0.713 |
| R-HSA-437239 | Recycling pathway of L1 | 1.871234e-01 | 0.728 |
| R-HSA-389948 | Co-inhibition by PD-1 | 2.080254e-01 | 0.682 |
| R-HSA-69615 | G1/S DNA Damage Checkpoints | 8.332970e-02 | 1.079 |
| R-HSA-212436 | Generic Transcription Pathway | 2.521807e-01 | 0.598 |
| R-HSA-69306 | DNA Replication | 2.318083e-01 | 0.635 |
| R-HSA-9764302 | Regulation of CDH19 Expression and Function | 1.084464e-01 | 0.965 |
| R-HSA-164944 | Nef and signal transduction | 1.211513e-01 | 0.917 |
| R-HSA-9613354 | Lipophagy | 1.581943e-01 | 0.801 |
| R-HSA-2033514 | FGFR3 mutant receptor activation | 2.165096e-01 | 0.665 |
| R-HSA-5655291 | Signaling by FGFR4 in disease | 2.276807e-01 | 0.643 |
| R-HSA-9933937 | Formation of the canonical BAF (cBAF) complex | 2.276807e-01 | 0.643 |
| R-HSA-173599 | Formation of the active cofactor, UDP-glucuronate | 2.276807e-01 | 0.643 |
| R-HSA-3270619 | IRF3-mediated induction of type I IFN | 2.386932e-01 | 0.622 |
| R-HSA-9933946 | Formation of the embryonic stem cell BAF (esBAF) complex | 2.386932e-01 | 0.622 |
| R-HSA-1483148 | Synthesis of PG | 2.602514e-01 | 0.585 |
| R-HSA-5358565 | Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 2.708014e-01 | 0.567 |
| R-HSA-69541 | Stabilization of p53 | 1.418184e-01 | 0.848 |
| R-HSA-190828 | Gap junction trafficking | 1.717781e-01 | 0.765 |
| R-HSA-8852276 | The role of GTSE1 in G2/M progression after G2 checkpoint | 2.657745e-01 | 0.575 |
| R-HSA-162582 | Signal Transduction | 5.332443e-02 | 1.273 |
| R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | 8.332970e-02 | 1.079 |
| R-HSA-8848021 | Signaling by PTK6 | 8.332970e-02 | 1.079 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 1.516795e-01 | 0.819 |
| R-HSA-69601 | Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | 1.768703e-01 | 0.752 |
| R-HSA-69613 | p53-Independent G1/S DNA Damage Checkpoint | 1.768703e-01 | 0.752 |
| R-HSA-180786 | Extension of Telomeres | 2.499132e-01 | 0.602 |
| R-HSA-2559583 | Cellular Senescence | 1.597993e-01 | 0.796 |
| R-HSA-5358508 | Mismatch Repair | 2.812016e-01 | 0.551 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 1.186242e-01 | 0.926 |
| R-HSA-397014 | Muscle contraction | 1.190394e-01 | 0.924 |
| R-HSA-1483249 | Inositol phosphate metabolism | 2.634782e-01 | 0.579 |
| R-HSA-9818030 | NFE2L2 regulating tumorigenic genes | 2.165096e-01 | 0.665 |
| R-HSA-162658 | Golgi Cisternae Pericentriolar Stack Reorganization | 2.165096e-01 | 0.665 |
| R-HSA-9933939 | Formation of the polybromo-BAF (pBAF) complex | 2.276807e-01 | 0.643 |
| R-HSA-157858 | Gap junction trafficking and regulation | 1.974572e-01 | 0.705 |
| R-HSA-109704 | PI3K Cascade | 2.026503e-01 | 0.693 |
| R-HSA-388841 | Regulation of T cell activation by CD28 family | 1.046675e-01 | 0.980 |
| R-HSA-909733 | Interferon alpha/beta signaling | 2.827795e-01 | 0.549 |
| R-HSA-9659379 | Sensory processing of sound | 1.306346e-01 | 0.884 |
| R-HSA-186712 | Regulation of beta-cell development | 2.499132e-01 | 0.602 |
| R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | 8.066692e-02 | 1.093 |
| R-HSA-9764790 | Positive Regulation of CDH1 Gene Transcription | 1.701931e-01 | 0.769 |
| R-HSA-1170546 | Prolactin receptor signaling | 2.276807e-01 | 0.643 |
| R-HSA-196783 | Coenzyme A biosynthesis | 2.602514e-01 | 0.585 |
| R-HSA-1660517 | Synthesis of PIPs at the late endosome membrane | 2.708014e-01 | 0.567 |
| R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 9.719355e-02 | 1.012 |
| R-HSA-1268020 | Mitochondrial protein import | 2.657745e-01 | 0.575 |
| R-HSA-5684996 | MAPK1/MAPK3 signaling | 1.713151e-01 | 0.766 |
| R-HSA-9824594 | Regulation of MITF-M-dependent genes involved in apoptosis | 5.432565e-02 | 1.265 |
| R-HSA-9665348 | Signaling by ERBB2 ECD mutants | 2.812016e-01 | 0.551 |
| R-HSA-5673001 | RAF/MAP kinase cascade | 2.846681e-01 | 0.546 |
| R-HSA-5683057 | MAPK family signaling cascades | 1.601219e-01 | 0.796 |
| R-HSA-6811555 | PI5P Regulates TP53 Acetylation | 2.165096e-01 | 0.665 |
| R-HSA-399955 | SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | 2.495493e-01 | 0.603 |
| R-HSA-9662361 | Sensory processing of sound by outer hair cells of the cochlea | 6.550535e-02 | 1.184 |
| R-HSA-8941326 | RUNX2 regulates bone development | 1.273067e-01 | 0.895 |
| R-HSA-5687128 | MAPK6/MAPK4 signaling | 1.503574e-01 | 0.823 |
| R-HSA-6807070 | PTEN Regulation | 1.873966e-01 | 0.727 |
| R-HSA-1483255 | PI Metabolism | 2.217345e-01 | 0.654 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 2.273117e-01 | 0.643 |
| R-HSA-6804116 | TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 2.495493e-01 | 0.603 |
| R-HSA-5628897 | TP53 Regulates Metabolic Genes | 2.789078e-01 | 0.555 |
| R-HSA-389357 | CD28 dependent PI3K/Akt signaling | 8.208484e-02 | 1.086 |
| R-HSA-432142 | Platelet sensitization by LDL | 2.812016e-01 | 0.551 |
| R-HSA-3928665 | EPH-ephrin mediated repulsion of cells | 1.871234e-01 | 0.728 |
| R-HSA-9793380 | Formation of paraxial mesoderm | 2.604859e-01 | 0.584 |
| R-HSA-9825892 | Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 5.804918e-02 | 1.236 |
| R-HSA-8949215 | Mitochondrial calcium ion transport | 5.804918e-02 | 1.236 |
| R-HSA-391160 | Signal regulatory protein family interactions | 2.276807e-01 | 0.643 |
| R-HSA-429914 | Deadenylation-dependent mRNA decay | 2.499132e-01 | 0.602 |
| R-HSA-373755 | Semaphorin interactions | 8.332970e-02 | 1.079 |
| R-HSA-8963693 | Aspartate and asparagine metabolism | 9.950607e-02 | 1.002 |
| R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 2.602514e-01 | 0.585 |
| R-HSA-9839373 | Signaling by TGFBR3 | 1.819860e-01 | 0.740 |
| R-HSA-6804760 | Regulation of TP53 Activity through Methylation | 2.812016e-01 | 0.551 |
| R-HSA-3700989 | Transcriptional Regulation by TP53 | 1.635023e-01 | 0.786 |
| R-HSA-2262752 | Cellular responses to stress | 1.120942e-01 | 0.950 |
| R-HSA-5689880 | Ub-specific processing proteases | 6.006133e-02 | 1.221 |
| R-HSA-9616222 | Transcriptional regulation of granulopoiesis | 2.657745e-01 | 0.575 |
| R-HSA-69205 | G1/S-Specific Transcription | 1.273067e-01 | 0.895 |
| R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes | 2.393542e-01 | 0.621 |
| R-HSA-9637690 | Response of Mtb to phagocytosis | 1.667111e-01 | 0.778 |
| R-HSA-9730414 | MITF-M-regulated melanocyte development | 5.249700e-02 | 1.280 |
| R-HSA-9856530 | High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR... | 1.338551e-01 | 0.873 |
| R-HSA-9711123 | Cellular response to chemical stress | 5.765397e-02 | 1.239 |
| R-HSA-9692914 | SARS-CoV-1-host interactions | 2.405586e-01 | 0.619 |
| R-HSA-449147 | Signaling by Interleukins | 2.199541e-01 | 0.658 |
| R-HSA-446652 | Interleukin-1 family signaling | 2.287667e-01 | 0.641 |
| R-HSA-2682334 | EPH-Ephrin signaling | 1.815509e-01 | 0.741 |
| R-HSA-1834941 | STING mediated induction of host immune responses | 2.914541e-01 | 0.535 |
| R-HSA-389356 | Co-stimulation by CD28 | 1.922811e-01 | 0.716 |
| R-HSA-1059683 | Interleukin-6 signaling | 2.165096e-01 | 0.665 |
| R-HSA-3928662 | EPHB-mediated forward signaling | 1.717781e-01 | 0.765 |
| R-HSA-8950505 | Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulati... | 2.816362e-01 | 0.550 |
| R-HSA-1474244 | Extracellular matrix organization | 2.413939e-01 | 0.617 |
| R-HSA-163210 | Formation of ATP by chemiosmotic coupling | 3.015610e-01 | 0.521 |
| R-HSA-9934037 | Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | 3.015610e-01 | 0.521 |
| R-HSA-5654720 | PI-3K cascade:FGFR4 | 3.015610e-01 | 0.521 |
| R-HSA-6807004 | Negative regulation of MET activity | 3.015610e-01 | 0.521 |
| R-HSA-5620916 | VxPx cargo-targeting to cilium | 3.015610e-01 | 0.521 |
| R-HSA-71288 | Creatine metabolism | 3.015610e-01 | 0.521 |
| R-HSA-416572 | Sema4D induced cell migration and growth-cone collapse | 3.015610e-01 | 0.521 |
| R-HSA-9629569 | Protein hydroxylation | 3.015610e-01 | 0.521 |
| R-HSA-983231 | Factors involved in megakaryocyte development and platelet production | 3.039777e-01 | 0.517 |
| R-HSA-2500257 | Resolution of Sister Chromatid Cohesion | 3.060938e-01 | 0.514 |
| R-HSA-73886 | Chromosome Maintenance | 3.060938e-01 | 0.514 |
| R-HSA-3371556 | Cellular response to heat stress | 3.060938e-01 | 0.514 |
| R-HSA-9843940 | Regulation of endogenous retroelements by KRAB-ZFP proteins | 3.079979e-01 | 0.511 |
| R-HSA-9764560 | Regulation of CDH1 Gene Transcription | 3.079979e-01 | 0.511 |
| R-HSA-5654704 | SHC-mediated cascade:FGFR3 | 3.115244e-01 | 0.507 |
| R-HSA-190241 | FGFR2 ligand binding and activation | 3.115244e-01 | 0.507 |
| R-HSA-69186 | Lagging Strand Synthesis | 3.115244e-01 | 0.507 |
| R-HSA-162594 | Early Phase of HIV Life Cycle | 3.115244e-01 | 0.507 |
| R-HSA-427413 | NoRC negatively regulates rRNA expression | 3.132506e-01 | 0.504 |
| R-HSA-1266738 | Developmental Biology | 3.171682e-01 | 0.499 |
| R-HSA-162909 | Host Interactions of HIV factors | 3.177851e-01 | 0.498 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 3.184947e-01 | 0.497 |
| R-HSA-9924644 | Developmental Lineages of the Mammary Gland | 3.184947e-01 | 0.497 |
| R-HSA-499943 | Interconversion of nucleotide di- and triphosphates | 3.184947e-01 | 0.497 |
| R-HSA-5654706 | FRS-mediated FGFR3 signaling | 3.213462e-01 | 0.493 |
| R-HSA-5654719 | SHC-mediated cascade:FGFR4 | 3.213462e-01 | 0.493 |
| R-HSA-5696397 | Gap-filling DNA repair synthesis and ligation in GG-NER | 3.213462e-01 | 0.493 |
| R-HSA-8876384 | Listeria monocytogenes entry into host cells | 3.213462e-01 | 0.493 |
| R-HSA-69052 | Switching of origins to a post-replicative state | 3.237295e-01 | 0.490 |
| R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 3.289541e-01 | 0.483 |
| R-HSA-1226099 | Signaling by FGFR in disease | 3.289541e-01 | 0.483 |
| R-HSA-5654712 | FRS-mediated FGFR4 signaling | 3.310286e-01 | 0.480 |
| R-HSA-76071 | RNA Polymerase III Transcription Initiation From Type 3 Promoter | 3.310286e-01 | 0.480 |
| R-HSA-5654689 | PI-3K cascade:FGFR1 | 3.310286e-01 | 0.480 |
| R-HSA-350054 | Notch-HLH transcription pathway | 3.310286e-01 | 0.480 |
| R-HSA-912694 | Regulation of IFNA/IFNB signaling | 3.310286e-01 | 0.480 |
| R-HSA-112409 | RAF-independent MAPK1/3 activation | 3.310286e-01 | 0.480 |
| R-HSA-6781827 | Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 3.341678e-01 | 0.476 |
| R-HSA-8852135 | Protein ubiquitination | 3.341678e-01 | 0.476 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 3.372817e-01 | 0.472 |
| R-HSA-5689603 | UCH proteinases | 3.393697e-01 | 0.469 |
| R-HSA-9020591 | Interleukin-12 signaling | 3.393697e-01 | 0.469 |
| R-HSA-167160 | RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 3.405733e-01 | 0.468 |
| R-HSA-77075 | RNA Pol II CTD phosphorylation and interaction with CE | 3.405733e-01 | 0.468 |
| R-HSA-389957 | Prefoldin mediated transfer of substrate to CCT/TriC | 3.405733e-01 | 0.468 |
| R-HSA-912526 | Interleukin receptor SHC signaling | 3.405733e-01 | 0.468 |
| R-HSA-164952 | The role of Nef in HIV-1 replication and disease pathogenesis | 3.405733e-01 | 0.468 |
| R-HSA-8868773 | rRNA processing in the nucleus and cytosol | 3.458757e-01 | 0.461 |
| R-HSA-8953854 | Metabolism of RNA | 3.461015e-01 | 0.461 |
| R-HSA-5654688 | SHC-mediated cascade:FGFR1 | 3.499825e-01 | 0.456 |
| R-HSA-202430 | Translocation of ZAP-70 to Immunological synapse | 3.499825e-01 | 0.456 |
| R-HSA-110314 | Recognition of DNA damage by PCNA-containing replication complex | 3.499825e-01 | 0.456 |
| R-HSA-75067 | Processing of Capped Intronless Pre-mRNA | 3.499825e-01 | 0.456 |
| R-HSA-9665686 | Signaling by ERBB2 TMD/JMD mutants | 3.499825e-01 | 0.456 |
| R-HSA-6783589 | Interleukin-6 family signaling | 3.499825e-01 | 0.456 |
| R-HSA-9909396 | Circadian clock | 3.567495e-01 | 0.448 |
| R-HSA-5654693 | FRS-mediated FGFR1 signaling | 3.592580e-01 | 0.445 |
| R-HSA-5654695 | PI-3K cascade:FGFR2 | 3.592580e-01 | 0.445 |
| R-HSA-203927 | MicroRNA (miRNA) biogenesis | 3.592580e-01 | 0.445 |
| R-HSA-5218921 | VEGFR2 mediated cell proliferation | 3.592580e-01 | 0.445 |
| R-HSA-5601884 | PIWI-interacting RNA (piRNA) biogenesis | 3.592580e-01 | 0.445 |
| R-HSA-1266695 | Interleukin-7 signaling | 3.592580e-01 | 0.445 |
| R-HSA-9833482 | PKR-mediated signaling | 3.600464e-01 | 0.444 |
| R-HSA-5250941 | Negative epigenetic regulation of rRNA expression | 3.600464e-01 | 0.444 |
| R-HSA-913531 | Interferon Signaling | 3.604517e-01 | 0.443 |
| R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 3.604517e-01 | 0.443 |
| R-HSA-68877 | Mitotic Prometaphase | 3.620497e-01 | 0.441 |
| R-HSA-2151201 | Transcriptional activation of mitochondrial biogenesis | 3.651794e-01 | 0.437 |
| R-HSA-199991 | Membrane Trafficking | 3.655766e-01 | 0.437 |
| R-HSA-110373 | Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 3.684017e-01 | 0.434 |
| R-HSA-9615933 | Postmitotic nuclear pore complex (NPC) reformation | 3.684017e-01 | 0.434 |
| R-HSA-1660514 | Synthesis of PIPs at the Golgi membrane | 3.684017e-01 | 0.434 |
| R-HSA-5689901 | Metalloprotease DUBs | 3.684017e-01 | 0.434 |
| R-HSA-1855183 | Synthesis of IP2, IP, and Ins in the cytosol | 3.684017e-01 | 0.434 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 3.699149e-01 | 0.432 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 3.702968e-01 | 0.431 |
| R-HSA-5654699 | SHC-mediated cascade:FGFR2 | 3.774154e-01 | 0.423 |
| R-HSA-171306 | Packaging Of Telomere Ends | 3.774154e-01 | 0.423 |
| R-HSA-73863 | RNA Polymerase I Transcription Termination | 3.774154e-01 | 0.423 |
| R-HSA-202427 | Phosphorylation of CD3 and TCR zeta chains | 3.774154e-01 | 0.423 |
| R-HSA-73728 | RNA Polymerase I Promoter Opening | 3.774154e-01 | 0.423 |
| R-HSA-174414 | Processive synthesis on the C-strand of the telomere | 3.774154e-01 | 0.423 |
| R-HSA-3928663 | EPHA-mediated growth cone collapse | 3.774154e-01 | 0.423 |
| R-HSA-9006115 | Signaling by NTRK2 (TRKB) | 3.774154e-01 | 0.423 |
| R-HSA-264876 | Insulin processing | 3.774154e-01 | 0.423 |
| R-HSA-6798695 | Neutrophil degranulation | 3.796522e-01 | 0.421 |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 3.804821e-01 | 0.420 |
| R-HSA-6794362 | Protein-protein interactions at synapses | 3.855488e-01 | 0.414 |
| R-HSA-5654700 | FRS-mediated FGFR2 signaling | 3.863011e-01 | 0.413 |
| R-HSA-9619483 | Activation of AMPK downstream of NMDARs | 3.863011e-01 | 0.413 |
| R-HSA-5205685 | PINK1-PRKN Mediated Mitophagy | 3.863011e-01 | 0.413 |
| R-HSA-77387 | Insulin receptor recycling | 3.863011e-01 | 0.413 |
| R-HSA-113418 | Formation of the Early Elongation Complex | 3.863011e-01 | 0.413 |
| R-HSA-171319 | Telomere Extension By Telomerase | 3.863011e-01 | 0.413 |
| R-HSA-167158 | Formation of the HIV-1 Early Elongation Complex | 3.863011e-01 | 0.413 |
| R-HSA-8940973 | RUNX2 regulates osteoblast differentiation | 3.863011e-01 | 0.413 |
| R-HSA-9909615 | Regulation of PD-L1(CD274) Post-translational modification | 3.905977e-01 | 0.408 |
| R-HSA-9709570 | Impaired BRCA2 binding to RAD51 | 3.950605e-01 | 0.403 |
| R-HSA-5656169 | Termination of translesion DNA synthesis | 3.950605e-01 | 0.403 |
| R-HSA-72086 | mRNA Capping | 3.950605e-01 | 0.403 |
| R-HSA-210745 | Regulation of gene expression in beta cells | 3.950605e-01 | 0.403 |
| R-HSA-9006335 | Signaling by Erythropoietin | 3.950605e-01 | 0.403 |
| R-HSA-9664565 | Signaling by ERBB2 KD Mutants | 3.950605e-01 | 0.403 |
| R-HSA-1632852 | Macroautophagy | 3.954166e-01 | 0.403 |
| R-HSA-1614635 | Sulfur amino acid metabolism | 3.956280e-01 | 0.403 |
| R-HSA-381038 | XBP1(S) activates chaperone genes | 3.956280e-01 | 0.403 |
| R-HSA-390466 | Chaperonin-mediated protein folding | 4.006394e-01 | 0.397 |
| R-HSA-447115 | Interleukin-12 family signaling | 4.006394e-01 | 0.397 |
| R-HSA-5619107 | Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC... | 4.036954e-01 | 0.394 |
| R-HSA-9013508 | NOTCH3 Intracellular Domain Regulates Transcription | 4.036954e-01 | 0.394 |
| R-HSA-2424491 | DAP12 signaling | 4.036954e-01 | 0.394 |
| R-HSA-9687139 | Aberrant regulation of mitotic cell cycle due to RB1 defects | 4.036954e-01 | 0.394 |
| R-HSA-76046 | RNA Polymerase III Transcription Initiation | 4.036954e-01 | 0.394 |
| R-HSA-1227990 | Signaling by ERBB2 in Cancer | 4.036954e-01 | 0.394 |
| R-HSA-380320 | Recruitment of NuMA to mitotic centrosomes | 4.056313e-01 | 0.392 |
| R-HSA-9663891 | Selective autophagy | 4.056313e-01 | 0.392 |
| R-HSA-1855196 | IP3 and IP4 transport between cytosol and nucleus | 4.122076e-01 | 0.385 |
| R-HSA-1855229 | IP6 and IP7 transport between cytosol and nucleus | 4.122076e-01 | 0.385 |
| R-HSA-389958 | Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 4.122076e-01 | 0.385 |
| R-HSA-211733 | Regulation of activated PAK-2p34 by proteasome mediated degradation | 4.122076e-01 | 0.385 |
| R-HSA-186763 | Downstream signal transduction | 4.122076e-01 | 0.385 |
| R-HSA-936440 | Negative regulators of DDX58/IFIH1 signaling | 4.122076e-01 | 0.385 |
| R-HSA-9833109 | Evasion by RSV of host interferon responses | 4.122076e-01 | 0.385 |
| R-HSA-5620912 | Anchoring of the basal body to the plasma membrane | 4.155549e-01 | 0.381 |
| R-HSA-73884 | Base Excision Repair | 4.155549e-01 | 0.381 |
| R-HSA-202424 | Downstream TCR signaling | 4.155549e-01 | 0.381 |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 4.204858e-01 | 0.376 |
| R-HSA-350562 | Regulation of ornithine decarboxylase (ODC) | 4.205987e-01 | 0.376 |
| R-HSA-69190 | DNA strand elongation | 4.205987e-01 | 0.376 |
| R-HSA-110330 | Recognition and association of DNA glycosylase with site containing an affected ... | 4.205987e-01 | 0.376 |
| R-HSA-9675126 | Diseases of mitotic cell cycle | 4.205987e-01 | 0.376 |
| R-HSA-422475 | Axon guidance | 4.243941e-01 | 0.372 |
| R-HSA-381070 | IRE1alpha activates chaperones | 4.253954e-01 | 0.371 |
| R-HSA-166520 | Signaling by NTRKs | 4.259138e-01 | 0.371 |
| R-HSA-1855170 | IPs transport between nucleus and cytosol | 4.288706e-01 | 0.368 |
| R-HSA-159227 | Transport of the SLBP independent Mature mRNA | 4.288706e-01 | 0.368 |
| R-HSA-68616 | Assembly of the ORC complex at the origin of replication | 4.288706e-01 | 0.368 |
| R-HSA-1855204 | Synthesis of IP3 and IP4 in the cytosol | 4.288706e-01 | 0.368 |
| R-HSA-1839124 | FGFR1 mutant receptor activation | 4.288706e-01 | 0.368 |
| R-HSA-9733709 | Cardiogenesis | 4.288706e-01 | 0.368 |
| R-HSA-6804758 | Regulation of TP53 Activity through Acetylation | 4.288706e-01 | 0.368 |
| R-HSA-5675482 | Regulation of necroptotic cell death | 4.288706e-01 | 0.368 |
| R-HSA-391251 | Protein folding | 4.302834e-01 | 0.366 |
| R-HSA-9658195 | Leishmania infection | 4.335940e-01 | 0.363 |
| R-HSA-9824443 | Parasitic Infection Pathways | 4.335940e-01 | 0.363 |
| R-HSA-68867 | Assembly of the pre-replicative complex | 4.351495e-01 | 0.361 |
| R-HSA-159230 | Transport of the SLBP Dependant Mature mRNA | 4.370250e-01 | 0.359 |
| R-HSA-390471 | Association of TriC/CCT with target proteins during biosynthesis | 4.370250e-01 | 0.359 |
| R-HSA-170822 | Regulation of Glucokinase by Glucokinase Regulatory Protein | 4.370250e-01 | 0.359 |
| R-HSA-5696394 | DNA Damage Recognition in GG-NER | 4.370250e-01 | 0.359 |
| R-HSA-180534 | Vpu mediated degradation of CD4 | 4.370250e-01 | 0.359 |
| R-HSA-114508 | Effects of PIP2 hydrolysis | 4.370250e-01 | 0.359 |
| R-HSA-199220 | Vitamin B5 (pantothenate) metabolism | 4.370250e-01 | 0.359 |
| R-HSA-2219530 | Constitutive Signaling by Aberrant PI3K in Cancer | 4.399932e-01 | 0.357 |
| R-HSA-9837999 | Mitochondrial protein degradation | 4.399932e-01 | 0.357 |
| R-HSA-5696400 | Dual Incision in GG-NER | 4.450633e-01 | 0.352 |
| R-HSA-9843970 | Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | 4.450633e-01 | 0.352 |
| R-HSA-5205647 | Mitophagy | 4.450633e-01 | 0.352 |
| R-HSA-9680350 | Signaling by CSF1 (M-CSF) in myeloid cells | 4.450633e-01 | 0.352 |
| R-HSA-1980145 | Signaling by NOTCH2 | 4.450633e-01 | 0.352 |
| R-HSA-9735869 | SARS-CoV-1 modulates host translation machinery | 4.450633e-01 | 0.352 |
| R-HSA-180746 | Nuclear import of Rev protein | 4.450633e-01 | 0.352 |
| R-HSA-9701190 | Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 4.450633e-01 | 0.352 |
| R-HSA-349425 | Autodegradation of the E3 ubiquitin ligase COP1 | 4.450633e-01 | 0.352 |
| R-HSA-75815 | Ubiquitin-dependent degradation of Cyclin D | 4.450633e-01 | 0.352 |
| R-HSA-9675136 | Diseases of DNA Double-Strand Break Repair | 4.450633e-01 | 0.352 |
| R-HSA-110328 | Recognition and association of DNA glycosylase with site containing an affected ... | 4.450633e-01 | 0.352 |
| R-HSA-72689 | Formation of a pool of free 40S subunits | 4.496122e-01 | 0.347 |
| R-HSA-8854050 | FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 4.529874e-01 | 0.344 |
| R-HSA-174113 | SCF-beta-TrCP mediated degradation of Emi1 | 4.529874e-01 | 0.344 |
| R-HSA-2408508 | Metabolism of ingested SeMet, Sec, MeSec into H2Se | 4.529874e-01 | 0.344 |
| R-HSA-169911 | Regulation of Apoptosis | 4.529874e-01 | 0.344 |
| R-HSA-5693616 | Presynaptic phase of homologous DNA pairing and strand exchange | 4.529874e-01 | 0.344 |
| R-HSA-2559585 | Oncogene Induced Senescence | 4.529874e-01 | 0.344 |
| R-HSA-9612973 | Autophagy | 4.558663e-01 | 0.341 |
| R-HSA-9610379 | HCMV Late Events | 4.595657e-01 | 0.338 |
| R-HSA-162587 | HIV Life Cycle | 4.595657e-01 | 0.338 |
| R-HSA-212300 | PRC2 methylates histones and DNA | 4.607989e-01 | 0.336 |
| R-HSA-1839126 | FGFR2 mutant receptor activation | 4.607989e-01 | 0.336 |
| R-HSA-180585 | Vif-mediated degradation of APOBEC3G | 4.607989e-01 | 0.336 |
| R-HSA-450408 | AUF1 (hnRNP D0) binds and destabilizes mRNA | 4.607989e-01 | 0.336 |
| R-HSA-74158 | RNA Polymerase III Transcription | 4.607989e-01 | 0.336 |
| R-HSA-749476 | RNA Polymerase III Abortive And Retractive Initiation | 4.607989e-01 | 0.336 |
| R-HSA-3371511 | HSF1 activation | 4.607989e-01 | 0.336 |
| R-HSA-114604 | GPVI-mediated activation cascade | 4.607989e-01 | 0.336 |
| R-HSA-8853659 | RET signaling | 4.607989e-01 | 0.336 |
| R-HSA-9682385 | FLT3 signaling in disease | 4.607989e-01 | 0.336 |
| R-HSA-9711097 | Cellular response to starvation | 4.632545e-01 | 0.334 |
| R-HSA-427359 | SIRT1 negatively regulates rRNA expression | 4.684992e-01 | 0.329 |
| R-HSA-180910 | Vpr-mediated nuclear import of PICs | 4.684992e-01 | 0.329 |
| R-HSA-4641258 | Degradation of DVL | 4.684992e-01 | 0.329 |
| R-HSA-4641257 | Degradation of AXIN | 4.684992e-01 | 0.329 |
| R-HSA-9762114 | GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 4.684992e-01 | 0.329 |
| R-HSA-110331 | Cleavage of the damaged purine | 4.684992e-01 | 0.329 |
| R-HSA-5689896 | Ovarian tumor domain proteases | 4.684992e-01 | 0.329 |
| R-HSA-196757 | Metabolism of folate and pterines | 4.684992e-01 | 0.329 |
| R-HSA-1483257 | Phospholipid metabolism | 4.724159e-01 | 0.326 |
| R-HSA-73927 | Depurination | 4.760901e-01 | 0.322 |
| R-HSA-165054 | Rev-mediated nuclear export of HIV RNA | 4.760901e-01 | 0.322 |
| R-HSA-452723 | Transcriptional regulation of pluripotent stem cells | 4.760901e-01 | 0.322 |
| R-HSA-5693579 | Homologous DNA Pairing and Strand Exchange | 4.760901e-01 | 0.322 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 4.760901e-01 | 0.322 |
| R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | 4.825274e-01 | 0.316 |
| R-HSA-159231 | Transport of Mature mRNA Derived from an Intronless Transcript | 4.835730e-01 | 0.316 |
| R-HSA-167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | 4.835730e-01 | 0.316 |
| R-HSA-1236978 | Cross-presentation of soluble exogenous antigens (endosomes) | 4.835730e-01 | 0.316 |
| R-HSA-9929356 | GSK3B-mediated proteasomal degradation of PD-L1(CD274) | 4.835730e-01 | 0.316 |
| R-HSA-9931509 | Expression of BMAL (ARNTL), CLOCK, and NPAS2 | 4.835730e-01 | 0.316 |
| R-HSA-8953750 | Transcriptional Regulation by E2F6 | 4.835730e-01 | 0.316 |
| R-HSA-2467813 | Separation of Sister Chromatids | 4.851520e-01 | 0.314 |
| R-HSA-2408522 | Selenoamino acid metabolism | 4.851520e-01 | 0.314 |
| R-HSA-72312 | rRNA processing | 4.889900e-01 | 0.311 |
| R-HSA-159234 | Transport of Mature mRNAs Derived from Intronless Transcripts | 4.909495e-01 | 0.309 |
| R-HSA-9670095 | Inhibition of DNA recombination at telomere | 4.909495e-01 | 0.309 |
| R-HSA-167152 | Formation of HIV elongation complex in the absence of HIV Tat | 4.909495e-01 | 0.309 |
| R-HSA-177243 | Interactions of Rev with host cellular proteins | 4.909495e-01 | 0.309 |
| R-HSA-167246 | Tat-mediated elongation of the HIV-1 transcript | 4.909495e-01 | 0.309 |
| R-HSA-176033 | Interactions of Vpr with host cellular proteins | 4.909495e-01 | 0.309 |
| R-HSA-167169 | HIV Transcription Elongation | 4.909495e-01 | 0.309 |
| R-HSA-9854311 | Maturation of TCA enzymes and regulation of TCA cycle | 4.909495e-01 | 0.309 |
| R-HSA-73779 | RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 4.909495e-01 | 0.309 |
| R-HSA-9604323 | Negative regulation of NOTCH4 signaling | 4.909495e-01 | 0.309 |
| R-HSA-8941858 | Regulation of RUNX3 expression and activity | 4.909495e-01 | 0.309 |
| R-HSA-9633012 | Response of EIF2AK4 (GCN2) to amino acid deficiency | 4.917082e-01 | 0.308 |
| R-HSA-8856825 | Cargo recognition for clathrin-mediated endocytosis | 4.917082e-01 | 0.308 |
| R-HSA-110313 | Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA templa... | 4.982211e-01 | 0.303 |
| R-HSA-5625886 | Activated PKN1 stimulates transcription of AR (androgen receptor) regulated gene... | 4.982211e-01 | 0.303 |
| R-HSA-168271 | Transport of Ribonucleoproteins into the Host Nucleus | 4.982211e-01 | 0.303 |
| R-HSA-5362768 | Hh mutants are degraded by ERAD | 4.982211e-01 | 0.303 |
| R-HSA-9929491 | SPOP-mediated proteasomal degradation of PD-L1(CD274) | 4.982211e-01 | 0.303 |
| R-HSA-9820841 | M-decay: degradation of maternal mRNAs by maternally stored factors | 4.982211e-01 | 0.303 |
| R-HSA-73933 | Resolution of Abasic Sites (AP sites) | 4.982211e-01 | 0.303 |
| R-HSA-5676590 | NIK-->noncanonical NF-kB signaling | 4.982211e-01 | 0.303 |
| R-HSA-9607240 | FLT3 Signaling | 4.982211e-01 | 0.303 |
| R-HSA-9675108 | Nervous system development | 4.991279e-01 | 0.302 |
| R-HSA-167162 | RNA Polymerase II HIV Promoter Escape | 5.053892e-01 | 0.296 |
| R-HSA-167161 | HIV Transcription Initiation | 5.053892e-01 | 0.296 |
| R-HSA-75953 | RNA Polymerase II Transcription Initiation | 5.053892e-01 | 0.296 |
| R-HSA-9932298 | Degradation of CRY and PER proteins | 5.053892e-01 | 0.296 |
| R-HSA-5610780 | Degradation of GLI1 by the proteasome | 5.053892e-01 | 0.296 |
| R-HSA-5610783 | Degradation of GLI2 by the proteasome | 5.053892e-01 | 0.296 |
| R-HSA-5610785 | GLI3 is processed to GLI3R by the proteasome | 5.053892e-01 | 0.296 |
| R-HSA-174417 | Telomere C-strand (Lagging Strand) Synthesis | 5.053892e-01 | 0.296 |
| R-HSA-110329 | Cleavage of the damaged pyrimidine | 5.124554e-01 | 0.290 |
| R-HSA-73928 | Depyrimidination | 5.124554e-01 | 0.290 |
| R-HSA-72706 | GTP hydrolysis and joining of the 60S ribosomal subunit | 5.142073e-01 | 0.289 |
| R-HSA-156827 | L13a-mediated translational silencing of Ceruloplasmin expression | 5.142073e-01 | 0.289 |
| R-HSA-9734779 | Developmental Cell Lineages of the Integumentary System | 5.142073e-01 | 0.289 |
| R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 5.171745e-01 | 0.286 |
| R-HSA-73776 | RNA Polymerase II Promoter Escape | 5.194211e-01 | 0.284 |
| R-HSA-9710421 | Defective pyroptosis | 5.194211e-01 | 0.284 |
| R-HSA-5387390 | Hh mutants abrogate ligand secretion | 5.194211e-01 | 0.284 |
| R-HSA-8854214 | TBC/RABGAPs | 5.194211e-01 | 0.284 |
| R-HSA-9907900 | Proteasome assembly | 5.262876e-01 | 0.279 |
| R-HSA-2172127 | DAP12 interactions | 5.262876e-01 | 0.279 |
| R-HSA-3214858 | RMTs methylate histone arginines | 5.262876e-01 | 0.279 |
| R-HSA-375280 | Amine ligand-binding receptors | 5.262876e-01 | 0.279 |
| R-HSA-373752 | Netrin-1 signaling | 5.262876e-01 | 0.279 |
| R-HSA-9678108 | SARS-CoV-1 Infection | 5.276113e-01 | 0.278 |
| R-HSA-927802 | Nonsense-Mediated Decay (NMD) | 5.317294e-01 | 0.274 |
| R-HSA-975957 | Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 5.317294e-01 | 0.274 |
| R-HSA-76042 | RNA Polymerase II Transcription Initiation And Promoter Clearance | 5.330565e-01 | 0.273 |
| R-HSA-774815 | Nucleosome assembly | 5.330565e-01 | 0.273 |
| R-HSA-606279 | Deposition of new CENPA-containing nucleosomes at the centromere | 5.330565e-01 | 0.273 |
| R-HSA-168333 | NEP/NS2 Interacts with the Cellular Export Machinery | 5.330565e-01 | 0.273 |
| R-HSA-4608870 | Asymmetric localization of PCP proteins | 5.330565e-01 | 0.273 |
| R-HSA-6783310 | Fanconi Anemia Pathway | 5.330565e-01 | 0.273 |
| R-HSA-5678895 | Defective CFTR causes cystic fibrosis | 5.330565e-01 | 0.273 |
| R-HSA-5607761 | Dectin-1 mediated noncanonical NF-kB signaling | 5.330565e-01 | 0.273 |
| R-HSA-9824272 | Somitogenesis | 5.330565e-01 | 0.273 |
| R-HSA-1489509 | DAG and IP3 signaling | 5.330565e-01 | 0.273 |
| R-HSA-1912422 | Pre-NOTCH Expression and Processing | 5.360425e-01 | 0.271 |
| R-HSA-6781823 | Formation of TC-NER Pre-Incision Complex | 5.397291e-01 | 0.268 |
| R-HSA-174084 | Autodegradation of Cdh1 by Cdh1:APC/C | 5.397291e-01 | 0.268 |
| R-HSA-168274 | Export of Viral Ribonucleoproteins from Nucleus | 5.397291e-01 | 0.268 |
| R-HSA-75153 | Apoptotic execution phase | 5.397291e-01 | 0.268 |
| R-HSA-9675135 | Diseases of DNA repair | 5.397291e-01 | 0.268 |
| R-HSA-168255 | Influenza Infection | 5.413317e-01 | 0.267 |
| R-HSA-174154 | APC/C:Cdc20 mediated degradation of Securin | 5.463067e-01 | 0.263 |
| R-HSA-9031628 | NGF-stimulated transcription | 5.527907e-01 | 0.257 |
| R-HSA-2029485 | Role of phospholipids in phagocytosis | 5.530215e-01 | 0.257 |
| R-HSA-72737 | Cap-dependent Translation Initiation | 5.571975e-01 | 0.254 |
| R-HSA-72613 | Eukaryotic Translation Initiation | 5.571975e-01 | 0.254 |
| R-HSA-373760 | L1CAM interactions | 5.571975e-01 | 0.254 |
| R-HSA-73893 | DNA Damage Bypass | 5.591825e-01 | 0.252 |
| R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription | 5.591825e-01 | 0.252 |
| R-HSA-9007101 | Rab regulation of trafficking | 5.613458e-01 | 0.251 |
| R-HSA-5658442 | Regulation of RAS by GAPs | 5.654833e-01 | 0.248 |
| R-HSA-71291 | Metabolism of amino acids and derivatives | 5.691403e-01 | 0.245 |
| R-HSA-1280218 | Adaptive Immune System | 5.698844e-01 | 0.244 |
| R-HSA-3371571 | HSF1-dependent transactivation | 5.716944e-01 | 0.243 |
| R-HSA-1169091 | Activation of NF-kappaB in B cells | 5.716944e-01 | 0.243 |
| R-HSA-1234176 | Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 5.716944e-01 | 0.243 |
| R-HSA-70895 | Branched-chain amino acid catabolism | 5.716944e-01 | 0.243 |
| R-HSA-5358346 | Hedgehog ligand biogenesis | 5.716944e-01 | 0.243 |
| R-HSA-9635486 | Infection with Mycobacterium tuberculosis | 5.776615e-01 | 0.238 |
| R-HSA-72187 | mRNA 3'-end processing | 5.778171e-01 | 0.238 |
| R-HSA-5617833 | Cilium Assembly | 5.778545e-01 | 0.238 |
| R-HSA-432722 | Golgi Associated Vesicle Biogenesis | 5.838527e-01 | 0.234 |
| R-HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins ... | 5.838527e-01 | 0.234 |
| R-HSA-9639288 | Amino acids regulate mTORC1 | 5.838527e-01 | 0.234 |
| R-HSA-6809371 | Formation of the cornified envelope | 5.896055e-01 | 0.229 |
| R-HSA-9754678 | SARS-CoV-2 modulates host translation machinery | 5.898023e-01 | 0.229 |
| R-HSA-73929 | Base-Excision Repair, AP Site Formation | 5.898023e-01 | 0.229 |
| R-HSA-156588 | Glucuronidation | 5.898023e-01 | 0.229 |
| R-HSA-9012852 | Signaling by NOTCH3 | 5.956673e-01 | 0.225 |
| R-HSA-9609690 | HCMV Early Events | 5.969956e-01 | 0.224 |
| R-HSA-9851695 | Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 5.974285e-01 | 0.224 |
| R-HSA-9841922 | MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesi... | 5.974285e-01 | 0.224 |
| R-HSA-9818564 | Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 5.974285e-01 | 0.224 |
| R-HSA-9664323 | FCGR3A-mediated IL10 synthesis | 6.012980e-01 | 0.221 |
| R-HSA-5578775 | Ion homeostasis | 6.014487e-01 | 0.221 |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex | 6.127658e-01 | 0.213 |
| R-HSA-191859 | snRNP Assembly | 6.183038e-01 | 0.209 |
| R-HSA-194441 | Metabolism of non-coding RNA | 6.183038e-01 | 0.209 |
| R-HSA-376176 | Signaling by ROBO receptors | 6.186044e-01 | 0.209 |
| R-HSA-72203 | Processing of Capped Intron-Containing Pre-mRNA | 6.230821e-01 | 0.205 |
| R-HSA-2644602 | Signaling by NOTCH1 PEST Domain Mutants in Cancer | 6.237629e-01 | 0.205 |
| R-HSA-2894862 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 6.237629e-01 | 0.205 |
| R-HSA-2644606 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | 6.237629e-01 | 0.205 |
| R-HSA-2894858 | Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 6.237629e-01 | 0.205 |
| R-HSA-2644603 | Signaling by NOTCH1 in Cancer | 6.237629e-01 | 0.205 |
| R-HSA-9764725 | Negative Regulation of CDH1 Gene Transcription | 6.237629e-01 | 0.205 |
| R-HSA-351202 | Metabolism of polyamines | 6.237629e-01 | 0.205 |
| R-HSA-1227986 | Signaling by ERBB2 | 6.237629e-01 | 0.205 |
| R-HSA-9843745 | Adipogenesis | 6.239281e-01 | 0.205 |
| R-HSA-597592 | Post-translational protein modification | 6.250795e-01 | 0.204 |
| R-HSA-5357801 | Programmed Cell Death | 6.276232e-01 | 0.202 |
| R-HSA-73856 | RNA Polymerase II Transcription Termination | 6.291443e-01 | 0.201 |
| R-HSA-168325 | Viral Messenger RNA Synthesis | 6.291443e-01 | 0.201 |
| R-HSA-8939902 | Regulation of RUNX2 expression and activity | 6.291443e-01 | 0.201 |
| R-HSA-6784531 | tRNA processing in the nucleus | 6.344491e-01 | 0.198 |
| R-HSA-186797 | Signaling by PDGF | 6.344491e-01 | 0.198 |
| R-HSA-9707616 | Heme signaling | 6.344491e-01 | 0.198 |
| R-HSA-2426168 | Activation of gene expression by SREBF (SREBP) | 6.396782e-01 | 0.194 |
| R-HSA-5690714 | CD22 mediated BCR regulation | 6.448329e-01 | 0.191 |
| R-HSA-936837 | Ion transport by P-type ATPases | 6.448329e-01 | 0.191 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 6.455565e-01 | 0.190 |
| R-HSA-5653656 | Vesicle-mediated transport | 6.467211e-01 | 0.189 |
| R-HSA-1234174 | Cellular response to hypoxia | 6.499142e-01 | 0.187 |
| R-HSA-9948299 | Ribosome-associated quality control | 6.525450e-01 | 0.185 |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | 6.549231e-01 | 0.184 |
| R-HSA-381119 | Unfolded Protein Response (UPR) | 6.559981e-01 | 0.183 |
| R-HSA-5685942 | HDR through Homologous Recombination (HRR) | 6.598606e-01 | 0.181 |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet fun... | 6.647278e-01 | 0.177 |
| R-HSA-167172 | Transcription of the HIV genome | 6.647278e-01 | 0.177 |
| R-HSA-5218859 | Regulated Necrosis | 6.647278e-01 | 0.177 |
| R-HSA-168256 | Immune System | 6.665688e-01 | 0.176 |
| R-HSA-162599 | Late Phase of HIV Life Cycle | 6.695378e-01 | 0.174 |
| R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 6.695378e-01 | 0.174 |
| R-HSA-8951664 | Neddylation | 6.732297e-01 | 0.172 |
| R-HSA-1168372 | Downstream signaling events of B Cell Receptor (BCR) | 6.742551e-01 | 0.171 |
| R-HSA-204005 | COPII-mediated vesicle transport | 6.742551e-01 | 0.171 |
| R-HSA-195253 | Degradation of beta-catenin by the destruction complex | 6.742551e-01 | 0.171 |
| R-HSA-1834949 | Cytosolic sensors of pathogen-associated DNA | 6.742551e-01 | 0.171 |
| R-HSA-5620920 | Cargo trafficking to the periciliary membrane | 6.789171e-01 | 0.168 |
| R-HSA-5632684 | Hedgehog 'on' state | 6.789171e-01 | 0.168 |
| R-HSA-9856649 | Transcriptional and post-translational regulation of MITF-M expression and activ... | 6.789171e-01 | 0.168 |
| R-HSA-199992 | trans-Golgi Network Vesicle Budding | 6.835128e-01 | 0.165 |
| R-HSA-198725 | Nuclear Events (kinase and transcription factor activation) | 6.835128e-01 | 0.165 |
| R-HSA-450531 | Regulation of mRNA stability by proteins that bind AU-rich elements | 6.835128e-01 | 0.165 |
| R-HSA-159236 | Transport of Mature mRNA derived from an Intron-Containing Transcript | 6.880429e-01 | 0.162 |
| R-HSA-5663084 | Diseases of carbohydrate metabolism | 6.880429e-01 | 0.162 |
| R-HSA-9705683 | SARS-CoV-2-host interactions | 6.918547e-01 | 0.160 |
| R-HSA-71403 | Citric acid cycle (TCA cycle) | 6.969104e-01 | 0.157 |
| R-HSA-1980143 | Signaling by NOTCH1 | 7.012496e-01 | 0.154 |
| R-HSA-9010553 | Regulation of expression of SLITs and ROBOs | 7.015089e-01 | 0.154 |
| R-HSA-9609507 | Protein localization | 7.045611e-01 | 0.152 |
| R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 7.075874e-01 | 0.150 |
| R-HSA-416482 | G alpha (12/13) signalling events | 7.097432e-01 | 0.149 |
| R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | 7.097432e-01 | 0.149 |
| R-HSA-5619084 | ABC transporter disorders | 7.097432e-01 | 0.149 |
| R-HSA-4086400 | PCP/CE pathway | 7.097432e-01 | 0.149 |
| R-HSA-216083 | Integrin cell surface interactions | 7.097432e-01 | 0.149 |
| R-HSA-168273 | Influenza Viral RNA Transcription and Replication | 7.105879e-01 | 0.148 |
| R-HSA-1655829 | Regulation of cholesterol biosynthesis by SREBP (SREBF) | 7.138994e-01 | 0.146 |
| R-HSA-202733 | Cell surface interactions at the vascular wall | 7.146189e-01 | 0.146 |
| R-HSA-6806834 | Signaling by MET | 7.179964e-01 | 0.144 |
| R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 7.194358e-01 | 0.143 |
| R-HSA-977225 | Amyloid fiber formation | 7.220349e-01 | 0.141 |
| R-HSA-72202 | Transport of Mature Transcript to Cytoplasm | 7.260159e-01 | 0.139 |
| R-HSA-5668541 | TNFR2 non-canonical NF-kB pathway | 7.299401e-01 | 0.137 |
| R-HSA-109581 | Apoptosis | 7.308792e-01 | 0.136 |
| R-HSA-141444 | Amplification of signal from unattached kinetochores via a MAD2 inhibitory si... | 7.413800e-01 | 0.130 |
| R-HSA-141424 | Amplification of signal from the kinetochores | 7.413800e-01 | 0.130 |
| R-HSA-8876198 | RAB GEFs exchange GTP for GDP on RABs | 7.413800e-01 | 0.130 |
| R-HSA-163841 | Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | 7.450851e-01 | 0.128 |
| R-HSA-9609646 | HCMV Infection | 7.451882e-01 | 0.128 |
| R-HSA-438064 | Post NMDA receptor activation events | 7.487372e-01 | 0.126 |
| R-HSA-70268 | Pyruvate metabolism | 7.487372e-01 | 0.126 |
| R-HSA-156902 | Peptide chain elongation | 7.523373e-01 | 0.124 |
| R-HSA-9645723 | Diseases of programmed cell death | 7.523373e-01 | 0.124 |
| R-HSA-1236974 | ER-Phagosome pathway | 7.558861e-01 | 0.122 |
| R-HSA-9954714 | PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | 7.628324e-01 | 0.118 |
| R-HSA-9664433 | Leishmania parasite growth and survival | 7.628621e-01 | 0.118 |
| R-HSA-9662851 | Anti-inflammatory response favouring Leishmania parasite infection | 7.628621e-01 | 0.118 |
| R-HSA-975956 | Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 7.662313e-01 | 0.116 |
| R-HSA-156842 | Eukaryotic Translation Elongation | 7.695818e-01 | 0.114 |
| R-HSA-2029481 | FCGR activation | 7.728845e-01 | 0.112 |
| R-HSA-983695 | Antigen activates B Cell Receptor (BCR) leading to generation of second messenge... | 7.728845e-01 | 0.112 |
| R-HSA-72766 | Translation | 7.752402e-01 | 0.111 |
| R-HSA-9954716 | ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ri... | 7.793491e-01 | 0.108 |
| R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 7.793491e-01 | 0.108 |
| R-HSA-72764 | Eukaryotic Translation Termination | 7.825123e-01 | 0.107 |
| R-HSA-9954709 | Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | 7.825123e-01 | 0.107 |
| R-HSA-5607764 | CLEC7A (Dectin-1) signaling | 7.856304e-01 | 0.105 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 7.869561e-01 | 0.104 |
| R-HSA-8957275 | Post-translational protein phosphorylation | 7.917337e-01 | 0.101 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | 7.947341e-01 | 0.100 |
| R-HSA-69618 | Mitotic Spindle Checkpoint | 7.976639e-01 | 0.098 |
| R-HSA-5610787 | Hedgehog 'off' state | 7.976639e-01 | 0.098 |
| R-HSA-70171 | Glycolysis | 7.976639e-01 | 0.098 |
| R-HSA-382556 | ABC-family proteins mediated transport | 7.976639e-01 | 0.098 |
| R-HSA-983712 | Ion channel transport | 8.003606e-01 | 0.097 |
| R-HSA-2408557 | Selenocysteine synthesis | 8.005657e-01 | 0.097 |
| R-HSA-9020702 | Interleukin-1 signaling | 8.005657e-01 | 0.097 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 8.034261e-01 | 0.095 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 8.034261e-01 | 0.095 |
| R-HSA-192823 | Viral mRNA Translation | 8.062455e-01 | 0.094 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 8.067795e-01 | 0.093 |
| R-HSA-72163 | mRNA Splicing - Major Pathway | 8.109566e-01 | 0.091 |
| R-HSA-5619507 | Activation of HOX genes during differentiation | 8.117643e-01 | 0.091 |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogen... | 8.117643e-01 | 0.091 |
| R-HSA-163125 | Post-translational modification: synthesis of GPI-anchored proteins | 8.117643e-01 | 0.091 |
| R-HSA-9833110 | RSV-host interactions | 8.117643e-01 | 0.091 |
| R-HSA-418346 | Platelet homeostasis | 8.171265e-01 | 0.088 |
| R-HSA-1799339 | SRP-dependent cotranslational protein targeting to membrane | 8.197503e-01 | 0.086 |
| R-HSA-109582 | Hemostasis | 8.199212e-01 | 0.086 |
| R-HSA-1236975 | Antigen processing-Cross presentation | 8.223366e-01 | 0.085 |
| R-HSA-2672351 | Stimuli-sensing channels | 8.223366e-01 | 0.085 |
| R-HSA-9648025 | EML4 and NUDC in mitotic spindle formation | 8.248859e-01 | 0.084 |
| R-HSA-2454202 | Fc epsilon receptor (FCERI) signaling | 8.287757e-01 | 0.082 |
| R-HSA-1483206 | Glycerophospholipid biosynthesis | 8.287757e-01 | 0.082 |
| R-HSA-2871796 | FCERI mediated MAPK activation | 8.323175e-01 | 0.080 |
| R-HSA-72172 | mRNA Splicing | 8.325252e-01 | 0.080 |
| R-HSA-6805567 | Keratinization | 8.362008e-01 | 0.078 |
| R-HSA-9679506 | SARS-CoV Infections | 8.365649e-01 | 0.078 |
| R-HSA-392499 | Metabolism of proteins | 8.376756e-01 | 0.077 |
| R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-l... | 8.394350e-01 | 0.076 |
| R-HSA-2871809 | FCERI mediated Ca+2 mobilization | 8.440121e-01 | 0.074 |
| R-HSA-9824446 | Viral Infection Pathways | 8.456445e-01 | 0.073 |
| R-HSA-70326 | Glucose metabolism | 8.484592e-01 | 0.071 |
| R-HSA-2980736 | Peptide hormone metabolism | 8.484592e-01 | 0.071 |
| R-HSA-5663205 | Infectious disease | 8.613147e-01 | 0.065 |
| R-HSA-114608 | Platelet degranulation | 8.707551e-01 | 0.060 |
| R-HSA-198933 | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 8.735253e-01 | 0.059 |
| R-HSA-196849 | Metabolism of water-soluble vitamins and cofactors | 8.749562e-01 | 0.058 |
| R-HSA-5576891 | Cardiac conduction | 8.797788e-01 | 0.056 |
| R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 8.832100e-01 | 0.054 |
| R-HSA-15869 | Metabolism of nucleotides | 8.832338e-01 | 0.054 |
| R-HSA-8939211 | ESR-mediated signaling | 8.845634e-01 | 0.053 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 8.897827e-01 | 0.051 |
| R-HSA-163685 | Integration of energy metabolism | 8.897827e-01 | 0.051 |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 8.913675e-01 | 0.050 |
| R-HSA-1428517 | Aerobic respiration and respiratory electron transport | 8.923108e-01 | 0.049 |
| R-HSA-5358351 | Signaling by Hedgehog | 8.929296e-01 | 0.049 |
| R-HSA-5619115 | Disorders of transmembrane transporters | 8.971110e-01 | 0.047 |
| R-HSA-9694516 | SARS-CoV-2 Infection | 9.006461e-01 | 0.045 |
| R-HSA-2871837 | FCERI mediated NF-kB activation | 9.032557e-01 | 0.044 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 9.073717e-01 | 0.042 |
| R-HSA-9679191 | Potential therapeutics for SARS | 9.113133e-01 | 0.040 |
| R-HSA-71387 | Metabolism of carbohydrates and carbohydrate derivatives | 9.120974e-01 | 0.040 |
| R-HSA-9734767 | Developmental Cell Lineages | 9.145839e-01 | 0.039 |
| R-HSA-416476 | G alpha (q) signalling events | 9.155783e-01 | 0.038 |
| R-HSA-1989781 | PPARA activates gene expression | 9.175150e-01 | 0.037 |
| R-HSA-400206 | Regulation of lipid metabolism by PPARalpha | 9.198730e-01 | 0.036 |
| R-HSA-877300 | Interferon gamma signaling | 9.221639e-01 | 0.035 |
| R-HSA-168249 | Innate Immune System | 9.237740e-01 | 0.034 |
| R-HSA-1643685 | Disease | 9.303090e-01 | 0.031 |
| R-HSA-5619102 | SLC transporter disorders | 9.306934e-01 | 0.031 |
| R-HSA-72306 | tRNA processing | 9.346024e-01 | 0.029 |
| R-HSA-418555 | G alpha (s) signalling events | 9.355449e-01 | 0.029 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 9.355449e-01 | 0.029 |
| R-HSA-9824439 | Bacterial Infection Pathways | 9.355991e-01 | 0.029 |
| R-HSA-195721 | Signaling by WNT | 9.435895e-01 | 0.025 |
| R-HSA-948021 | Transport to the Golgi and subsequent modification | 9.589200e-01 | 0.018 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 9.649956e-01 | 0.015 |
| R-HSA-112316 | Neuronal System | 9.723642e-01 | 0.012 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 9.745051e-01 | 0.011 |
| R-HSA-196854 | Metabolism of vitamins and cofactors | 9.748199e-01 | 0.011 |
| R-HSA-156580 | Phase II - Conjugation of compounds | 9.763785e-01 | 0.010 |
| R-HSA-211945 | Phase I - Functionalization of compounds | 9.866322e-01 | 0.006 |
| R-HSA-112315 | Transmission across Chemical Synapses | 9.930814e-01 | 0.003 |
| R-HSA-8957322 | Metabolism of steroids | 9.931821e-01 | 0.003 |
| R-HSA-211859 | Biological oxidations | 9.967624e-01 | 0.001 |
| R-HSA-373076 | Class A/1 (Rhodopsin-like receptors) | 9.975976e-01 | 0.001 |
| R-HSA-446203 | Asparagine N-linked glycosylation | 9.984099e-01 | 0.001 |
| R-HSA-5668914 | Diseases of metabolism | 9.985230e-01 | 0.001 |
| R-HSA-382551 | Transport of small molecules | 9.989357e-01 | 0.000 |
| R-HSA-388396 | GPCR downstream signalling | 9.992948e-01 | 0.000 |
| R-HSA-372790 | Signaling by GPCR | 9.997564e-01 | 0.000 |
| R-HSA-500792 | GPCR ligand binding | 9.998664e-01 | 0.000 |
| R-HSA-556833 | Metabolism of lipids | 9.999895e-01 | 0.000 |
| R-HSA-1430728 | Metabolism | 9.999950e-01 | 0.000 |
| R-HSA-9709957 | Sensory Perception | 9.999985e-01 | 0.000 |
Download
| kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
|---|---|---|---|---|
CLK3 |
0.880 | 0.319 | 1 | 0.886 |
COT |
0.878 | 0.148 | 2 | 0.871 |
PIM3 |
0.876 | 0.252 | -3 | 0.873 |
MOS |
0.873 | 0.178 | 1 | 0.912 |
NDR2 |
0.871 | 0.177 | -3 | 0.870 |
RSK2 |
0.869 | 0.242 | -3 | 0.829 |
CDKL1 |
0.869 | 0.219 | -3 | 0.844 |
CDC7 |
0.868 | 0.045 | 1 | 0.869 |
CDKL5 |
0.867 | 0.230 | -3 | 0.839 |
MTOR |
0.867 | 0.041 | 1 | 0.843 |
PRPK |
0.867 | -0.026 | -1 | 0.865 |
NLK |
0.867 | 0.160 | 1 | 0.896 |
SRPK1 |
0.867 | 0.231 | -3 | 0.810 |
CAMK1B |
0.867 | 0.151 | -3 | 0.884 |
HIPK4 |
0.867 | 0.248 | 1 | 0.841 |
SKMLCK |
0.866 | 0.225 | -2 | 0.915 |
PRKD1 |
0.866 | 0.206 | -3 | 0.855 |
PKN3 |
0.864 | 0.165 | -3 | 0.857 |
ERK5 |
0.864 | 0.131 | 1 | 0.874 |
PIM1 |
0.864 | 0.248 | -3 | 0.837 |
RAF1 |
0.864 | 0.002 | 1 | 0.873 |
P90RSK |
0.863 | 0.196 | -3 | 0.825 |
KIS |
0.862 | 0.169 | 1 | 0.774 |
PRKD2 |
0.862 | 0.200 | -3 | 0.828 |
CAMLCK |
0.862 | 0.179 | -2 | 0.888 |
NDR1 |
0.862 | 0.129 | -3 | 0.870 |
IKKB |
0.861 | -0.057 | -2 | 0.729 |
NUAK2 |
0.861 | 0.144 | -3 | 0.873 |
WNK1 |
0.861 | 0.127 | -2 | 0.918 |
DSTYK |
0.860 | 0.007 | 2 | 0.896 |
ICK |
0.860 | 0.213 | -3 | 0.867 |
RSK3 |
0.860 | 0.184 | -3 | 0.821 |
DAPK2 |
0.860 | 0.178 | -3 | 0.883 |
DYRK2 |
0.859 | 0.235 | 1 | 0.778 |
PKN2 |
0.859 | 0.155 | -3 | 0.868 |
TBK1 |
0.859 | -0.040 | 1 | 0.770 |
ATR |
0.859 | -0.002 | 1 | 0.836 |
AURC |
0.859 | 0.213 | -2 | 0.744 |
GCN2 |
0.859 | -0.134 | 2 | 0.822 |
MST4 |
0.858 | 0.113 | 2 | 0.868 |
PDHK4 |
0.858 | -0.203 | 1 | 0.883 |
NIK |
0.858 | 0.111 | -3 | 0.889 |
BMPR2 |
0.858 | -0.120 | -2 | 0.873 |
P70S6KB |
0.858 | 0.170 | -3 | 0.843 |
GRK1 |
0.857 | 0.136 | -2 | 0.783 |
SRPK2 |
0.857 | 0.208 | -3 | 0.743 |
MAPKAPK2 |
0.857 | 0.176 | -3 | 0.795 |
NEK6 |
0.856 | 0.014 | -2 | 0.850 |
PKCD |
0.856 | 0.176 | 2 | 0.818 |
AMPKA1 |
0.856 | 0.121 | -3 | 0.882 |
CAMK2G |
0.856 | -0.068 | 2 | 0.786 |
PDHK1 |
0.856 | -0.123 | 1 | 0.866 |
CLK2 |
0.855 | 0.302 | -3 | 0.812 |
MAPKAPK3 |
0.855 | 0.119 | -3 | 0.827 |
PKACG |
0.855 | 0.155 | -2 | 0.812 |
GRK5 |
0.855 | -0.059 | -3 | 0.834 |
IKKE |
0.854 | -0.075 | 1 | 0.763 |
HIPK2 |
0.854 | 0.262 | 1 | 0.697 |
ULK2 |
0.854 | -0.138 | 2 | 0.810 |
SRPK3 |
0.853 | 0.171 | -3 | 0.779 |
CLK4 |
0.853 | 0.230 | -3 | 0.820 |
MARK4 |
0.853 | 0.049 | 4 | 0.855 |
TSSK1 |
0.853 | 0.145 | -3 | 0.895 |
TGFBR2 |
0.852 | -0.028 | -2 | 0.789 |
RSK4 |
0.852 | 0.221 | -3 | 0.801 |
PKACB |
0.852 | 0.229 | -2 | 0.759 |
HIPK1 |
0.852 | 0.257 | 1 | 0.794 |
LATS2 |
0.852 | 0.060 | -5 | 0.762 |
CAMK2D |
0.852 | 0.056 | -3 | 0.863 |
CLK1 |
0.852 | 0.234 | -3 | 0.804 |
TSSK2 |
0.851 | 0.104 | -5 | 0.882 |
LATS1 |
0.851 | 0.195 | -3 | 0.873 |
RIPK3 |
0.851 | -0.052 | 3 | 0.700 |
HUNK |
0.851 | -0.062 | 2 | 0.823 |
GRK6 |
0.851 | 0.015 | 1 | 0.873 |
AMPKA2 |
0.851 | 0.123 | -3 | 0.862 |
CDK8 |
0.851 | 0.124 | 1 | 0.741 |
SGK3 |
0.851 | 0.229 | -3 | 0.825 |
BCKDK |
0.850 | -0.090 | -1 | 0.795 |
MLK1 |
0.850 | -0.061 | 2 | 0.853 |
GRK7 |
0.850 | 0.163 | 1 | 0.824 |
BMPR1B |
0.850 | 0.136 | 1 | 0.828 |
NEK7 |
0.850 | -0.122 | -3 | 0.817 |
CDK18 |
0.849 | 0.193 | 1 | 0.703 |
FAM20C |
0.849 | 0.122 | 2 | 0.614 |
CAMK2B |
0.849 | 0.116 | 2 | 0.747 |
MSK2 |
0.848 | 0.132 | -3 | 0.796 |
P38A |
0.848 | 0.185 | 1 | 0.795 |
MSK1 |
0.848 | 0.186 | -3 | 0.804 |
PAK1 |
0.848 | 0.118 | -2 | 0.845 |
IKKA |
0.848 | -0.009 | -2 | 0.710 |
PKCA |
0.848 | 0.172 | 2 | 0.780 |
CDK5 |
0.848 | 0.175 | 1 | 0.785 |
AURB |
0.847 | 0.164 | -2 | 0.737 |
WNK3 |
0.847 | -0.128 | 1 | 0.837 |
MNK2 |
0.847 | 0.131 | -2 | 0.848 |
PRKD3 |
0.847 | 0.148 | -3 | 0.800 |
PRKX |
0.847 | 0.239 | -3 | 0.757 |
CAMK2A |
0.847 | 0.120 | 2 | 0.763 |
DYRK1A |
0.847 | 0.221 | 1 | 0.810 |
TGFBR1 |
0.847 | 0.083 | -2 | 0.801 |
CDK1 |
0.847 | 0.153 | 1 | 0.728 |
PKCB |
0.847 | 0.138 | 2 | 0.788 |
CDK19 |
0.847 | 0.133 | 1 | 0.706 |
CHAK2 |
0.846 | -0.073 | -1 | 0.796 |
ALK4 |
0.846 | 0.039 | -2 | 0.828 |
CDK7 |
0.846 | 0.117 | 1 | 0.763 |
PIM2 |
0.846 | 0.220 | -3 | 0.806 |
PKG2 |
0.846 | 0.180 | -2 | 0.759 |
CAMK4 |
0.846 | 0.042 | -3 | 0.849 |
NIM1 |
0.846 | 0.029 | 3 | 0.746 |
AKT2 |
0.846 | 0.203 | -3 | 0.759 |
PKCG |
0.845 | 0.117 | 2 | 0.779 |
MASTL |
0.845 | -0.194 | -2 | 0.813 |
CDK13 |
0.844 | 0.123 | 1 | 0.738 |
JNK2 |
0.844 | 0.173 | 1 | 0.710 |
MYLK4 |
0.844 | 0.137 | -2 | 0.833 |
IRE1 |
0.844 | -0.005 | 1 | 0.809 |
P38B |
0.844 | 0.180 | 1 | 0.729 |
AURA |
0.844 | 0.153 | -2 | 0.705 |
PAK3 |
0.844 | 0.070 | -2 | 0.835 |
ANKRD3 |
0.844 | -0.073 | 1 | 0.874 |
HIPK3 |
0.844 | 0.215 | 1 | 0.791 |
MELK |
0.843 | 0.083 | -3 | 0.848 |
JNK3 |
0.843 | 0.148 | 1 | 0.743 |
ERK1 |
0.843 | 0.155 | 1 | 0.718 |
NEK9 |
0.843 | -0.104 | 2 | 0.869 |
QSK |
0.843 | 0.085 | 4 | 0.831 |
PKR |
0.843 | 0.066 | 1 | 0.863 |
MLK3 |
0.842 | 0.035 | 2 | 0.786 |
DYRK4 |
0.842 | 0.212 | 1 | 0.711 |
P38G |
0.842 | 0.165 | 1 | 0.644 |
PAK6 |
0.842 | 0.143 | -2 | 0.757 |
MNK1 |
0.842 | 0.121 | -2 | 0.847 |
ATM |
0.842 | -0.031 | 1 | 0.767 |
DLK |
0.842 | -0.164 | 1 | 0.846 |
MLK2 |
0.841 | -0.074 | 2 | 0.845 |
GRK4 |
0.841 | -0.117 | -2 | 0.817 |
NUAK1 |
0.841 | 0.049 | -3 | 0.836 |
RIPK1 |
0.841 | -0.135 | 1 | 0.823 |
ULK1 |
0.841 | -0.220 | -3 | 0.777 |
PKCH |
0.840 | 0.094 | 2 | 0.779 |
CDK12 |
0.840 | 0.132 | 1 | 0.710 |
DYRK3 |
0.839 | 0.228 | 1 | 0.790 |
PHKG1 |
0.839 | 0.049 | -3 | 0.860 |
CDK14 |
0.839 | 0.188 | 1 | 0.749 |
CDK17 |
0.839 | 0.145 | 1 | 0.655 |
PKCZ |
0.839 | 0.081 | 2 | 0.825 |
VRK2 |
0.839 | -0.063 | 1 | 0.892 |
PRP4 |
0.839 | 0.157 | -3 | 0.787 |
ALK2 |
0.838 | 0.052 | -2 | 0.804 |
QIK |
0.838 | -0.019 | -3 | 0.853 |
PKACA |
0.838 | 0.201 | -2 | 0.716 |
PLK1 |
0.838 | -0.066 | -2 | 0.776 |
CDK3 |
0.838 | 0.158 | 1 | 0.674 |
SIK |
0.838 | 0.076 | -3 | 0.807 |
PAK2 |
0.838 | 0.055 | -2 | 0.825 |
DYRK1B |
0.838 | 0.189 | 1 | 0.747 |
BRSK1 |
0.838 | 0.051 | -3 | 0.838 |
IRE2 |
0.837 | -0.003 | 2 | 0.797 |
NEK2 |
0.837 | -0.002 | 2 | 0.857 |
YSK4 |
0.837 | -0.051 | 1 | 0.799 |
TTBK2 |
0.836 | -0.195 | 2 | 0.721 |
MEK1 |
0.836 | -0.148 | 2 | 0.842 |
ACVR2A |
0.836 | -0.004 | -2 | 0.771 |
ACVR2B |
0.836 | 0.009 | -2 | 0.782 |
CDK2 |
0.836 | 0.059 | 1 | 0.811 |
MARK3 |
0.836 | 0.049 | 4 | 0.798 |
CDK9 |
0.836 | 0.096 | 1 | 0.744 |
P38D |
0.835 | 0.181 | 1 | 0.651 |
DCAMKL1 |
0.835 | 0.106 | -3 | 0.837 |
AKT1 |
0.835 | 0.197 | -3 | 0.778 |
DNAPK |
0.834 | 0.008 | 1 | 0.721 |
CHK1 |
0.833 | 0.033 | -3 | 0.852 |
CDK10 |
0.833 | 0.194 | 1 | 0.734 |
MPSK1 |
0.833 | 0.193 | 1 | 0.847 |
MAK |
0.833 | 0.287 | -2 | 0.799 |
ERK2 |
0.833 | 0.084 | 1 | 0.754 |
SMMLCK |
0.832 | 0.119 | -3 | 0.853 |
CDK16 |
0.832 | 0.168 | 1 | 0.673 |
MARK2 |
0.832 | 0.018 | 4 | 0.757 |
MLK4 |
0.832 | -0.046 | 2 | 0.768 |
CAMK1G |
0.832 | 0.063 | -3 | 0.809 |
DRAK1 |
0.831 | -0.021 | 1 | 0.800 |
BRSK2 |
0.831 | -0.023 | -3 | 0.852 |
PASK |
0.831 | 0.102 | -3 | 0.875 |
WNK4 |
0.831 | 0.010 | -2 | 0.906 |
MST3 |
0.831 | 0.091 | 2 | 0.868 |
P70S6K |
0.830 | 0.126 | -3 | 0.769 |
BMPR1A |
0.830 | 0.076 | 1 | 0.804 |
DAPK3 |
0.830 | 0.179 | -3 | 0.845 |
TLK2 |
0.830 | -0.087 | 1 | 0.806 |
GRK2 |
0.829 | -0.054 | -2 | 0.715 |
SMG1 |
0.829 | -0.104 | 1 | 0.781 |
MAPKAPK5 |
0.828 | -0.024 | -3 | 0.770 |
PKCT |
0.828 | 0.097 | 2 | 0.781 |
SGK1 |
0.828 | 0.217 | -3 | 0.695 |
BRAF |
0.827 | -0.072 | -4 | 0.827 |
MARK1 |
0.827 | -0.007 | 4 | 0.821 |
PLK3 |
0.827 | -0.110 | 2 | 0.750 |
PDHK3_TYR |
0.827 | 0.246 | 4 | 0.914 |
TAO3 |
0.827 | 0.040 | 1 | 0.826 |
CHAK1 |
0.827 | -0.164 | 2 | 0.795 |
PERK |
0.827 | -0.126 | -2 | 0.813 |
PHKG2 |
0.826 | 0.049 | -3 | 0.836 |
HRI |
0.826 | -0.151 | -2 | 0.835 |
GAK |
0.826 | 0.156 | 1 | 0.917 |
SNRK |
0.826 | -0.140 | 2 | 0.708 |
ERK7 |
0.826 | 0.163 | 2 | 0.639 |
NEK5 |
0.826 | -0.036 | 1 | 0.848 |
MEK5 |
0.825 | -0.210 | 2 | 0.841 |
CAMK1D |
0.825 | 0.117 | -3 | 0.760 |
MEKK1 |
0.825 | -0.105 | 1 | 0.823 |
MEKK2 |
0.825 | -0.069 | 2 | 0.833 |
PKCE |
0.825 | 0.147 | 2 | 0.774 |
SSTK |
0.825 | 0.038 | 4 | 0.837 |
AKT3 |
0.825 | 0.195 | -3 | 0.709 |
MEKK3 |
0.824 | -0.157 | 1 | 0.825 |
DAPK1 |
0.824 | 0.157 | -3 | 0.829 |
DCAMKL2 |
0.824 | 0.018 | -3 | 0.850 |
CK1E |
0.824 | -0.029 | -3 | 0.520 |
GSK3A |
0.823 | 0.080 | 4 | 0.459 |
ZAK |
0.823 | -0.132 | 1 | 0.785 |
CK2A2 |
0.822 | 0.121 | 1 | 0.758 |
PINK1 |
0.822 | -0.145 | 1 | 0.877 |
IRAK4 |
0.822 | -0.067 | 1 | 0.801 |
PKCI |
0.822 | 0.081 | 2 | 0.803 |
PLK4 |
0.822 | -0.132 | 2 | 0.648 |
ROCK2 |
0.820 | 0.203 | -3 | 0.839 |
JNK1 |
0.820 | 0.103 | 1 | 0.707 |
MOK |
0.820 | 0.218 | 1 | 0.804 |
TLK1 |
0.820 | -0.142 | -2 | 0.822 |
PAK5 |
0.820 | 0.082 | -2 | 0.702 |
TAO2 |
0.820 | -0.013 | 2 | 0.870 |
GCK |
0.820 | 0.074 | 1 | 0.845 |
PDK1 |
0.819 | -0.000 | 1 | 0.819 |
MAP2K4_TYR |
0.819 | 0.086 | -1 | 0.894 |
PKN1 |
0.819 | 0.119 | -3 | 0.784 |
CDK6 |
0.819 | 0.132 | 1 | 0.725 |
MRCKB |
0.819 | 0.169 | -3 | 0.799 |
GSK3B |
0.819 | 0.011 | 4 | 0.450 |
TESK1_TYR |
0.818 | 0.034 | 3 | 0.846 |
PKMYT1_TYR |
0.818 | 0.081 | 3 | 0.816 |
EEF2K |
0.818 | 0.031 | 3 | 0.784 |
BUB1 |
0.818 | 0.187 | -5 | 0.844 |
MRCKA |
0.818 | 0.153 | -3 | 0.812 |
CHK2 |
0.817 | 0.122 | -3 | 0.714 |
MAP2K6_TYR |
0.817 | 0.062 | -1 | 0.889 |
PDHK4_TYR |
0.817 | 0.065 | 2 | 0.858 |
GRK3 |
0.817 | -0.044 | -2 | 0.675 |
TNIK |
0.816 | 0.078 | 3 | 0.817 |
NEK8 |
0.816 | -0.109 | 2 | 0.855 |
CDK4 |
0.816 | 0.126 | 1 | 0.701 |
CK1D |
0.816 | -0.026 | -3 | 0.468 |
PAK4 |
0.816 | 0.088 | -2 | 0.710 |
CAMK1A |
0.815 | 0.130 | -3 | 0.732 |
BMPR2_TYR |
0.815 | 0.035 | -1 | 0.884 |
NEK11 |
0.815 | -0.153 | 1 | 0.820 |
DMPK1 |
0.815 | 0.215 | -3 | 0.821 |
MAP2K7_TYR |
0.815 | -0.082 | 2 | 0.856 |
HPK1 |
0.814 | 0.063 | 1 | 0.826 |
PDHK1_TYR |
0.814 | 0.002 | -1 | 0.898 |
MEKK6 |
0.813 | -0.041 | 1 | 0.811 |
LIMK2_TYR |
0.813 | 0.071 | -3 | 0.891 |
CK1A2 |
0.813 | -0.036 | -3 | 0.473 |
LKB1 |
0.813 | -0.085 | -3 | 0.826 |
HGK |
0.813 | 0.006 | 3 | 0.813 |
MST2 |
0.813 | -0.048 | 1 | 0.840 |
CK1G1 |
0.812 | -0.074 | -3 | 0.516 |
MINK |
0.812 | 0.007 | 1 | 0.817 |
LRRK2 |
0.812 | -0.051 | 2 | 0.875 |
KHS1 |
0.812 | 0.106 | 1 | 0.814 |
PINK1_TYR |
0.812 | -0.092 | 1 | 0.868 |
KHS2 |
0.812 | 0.126 | 1 | 0.831 |
MAP3K15 |
0.811 | -0.055 | 1 | 0.777 |
NEK4 |
0.811 | -0.080 | 1 | 0.812 |
CK2A1 |
0.811 | 0.091 | 1 | 0.736 |
EPHA6 |
0.811 | 0.064 | -1 | 0.878 |
SBK |
0.810 | 0.145 | -3 | 0.659 |
PBK |
0.810 | 0.146 | 1 | 0.857 |
TAK1 |
0.810 | -0.066 | 1 | 0.843 |
CAMKK1 |
0.810 | -0.224 | -2 | 0.722 |
EPHB4 |
0.810 | 0.066 | -1 | 0.860 |
CAMKK2 |
0.809 | -0.173 | -2 | 0.728 |
NEK1 |
0.809 | -0.024 | 1 | 0.819 |
VRK1 |
0.809 | -0.070 | 2 | 0.854 |
RET |
0.809 | -0.026 | 1 | 0.822 |
LOK |
0.808 | -0.008 | -2 | 0.776 |
TTBK1 |
0.807 | -0.238 | 2 | 0.631 |
ABL2 |
0.807 | 0.068 | -1 | 0.826 |
ROCK1 |
0.807 | 0.173 | -3 | 0.812 |
LIMK1_TYR |
0.806 | -0.092 | 2 | 0.866 |
MST1R |
0.806 | -0.052 | 3 | 0.778 |
YES1 |
0.806 | 0.034 | -1 | 0.862 |
CRIK |
0.805 | 0.180 | -3 | 0.777 |
IRAK1 |
0.805 | -0.305 | -1 | 0.734 |
ROS1 |
0.805 | -0.034 | 3 | 0.720 |
FGR |
0.805 | 0.013 | 1 | 0.895 |
TYK2 |
0.804 | -0.103 | 1 | 0.818 |
ABL1 |
0.803 | 0.045 | -1 | 0.821 |
PKG1 |
0.803 | 0.107 | -2 | 0.691 |
YSK1 |
0.803 | -0.016 | 2 | 0.850 |
TXK |
0.803 | 0.075 | 1 | 0.864 |
TYRO3 |
0.803 | -0.091 | 3 | 0.756 |
MST1 |
0.803 | -0.101 | 1 | 0.821 |
LCK |
0.802 | 0.083 | -1 | 0.841 |
PLK2 |
0.802 | -0.071 | -3 | 0.744 |
JAK2 |
0.802 | -0.090 | 1 | 0.808 |
BLK |
0.802 | 0.112 | -1 | 0.852 |
DDR1 |
0.802 | -0.097 | 4 | 0.862 |
CSF1R |
0.801 | -0.070 | 3 | 0.743 |
HCK |
0.800 | -0.003 | -1 | 0.842 |
SLK |
0.800 | -0.072 | -2 | 0.715 |
MEK2 |
0.799 | -0.241 | 2 | 0.823 |
FER |
0.799 | -0.112 | 1 | 0.894 |
TNK2 |
0.798 | 0.004 | 3 | 0.736 |
HASPIN |
0.798 | 0.026 | -1 | 0.667 |
INSRR |
0.798 | -0.059 | 3 | 0.706 |
OSR1 |
0.797 | -0.032 | 2 | 0.825 |
JAK3 |
0.797 | -0.091 | 1 | 0.793 |
EPHA4 |
0.797 | -0.043 | 2 | 0.744 |
TNNI3K_TYR |
0.796 | 0.034 | 1 | 0.808 |
TTK |
0.796 | -0.026 | -2 | 0.807 |
BIKE |
0.796 | 0.144 | 1 | 0.822 |
EPHB1 |
0.796 | -0.044 | 1 | 0.856 |
KDR |
0.795 | -0.040 | 3 | 0.709 |
EPHB2 |
0.795 | -0.011 | -1 | 0.840 |
EPHB3 |
0.795 | -0.037 | -1 | 0.842 |
TNK1 |
0.795 | -0.022 | 3 | 0.742 |
FYN |
0.794 | 0.057 | -1 | 0.828 |
SRMS |
0.794 | -0.078 | 1 | 0.871 |
MYO3B |
0.794 | 0.034 | 2 | 0.859 |
RIPK2 |
0.794 | -0.281 | 1 | 0.746 |
JAK1 |
0.794 | -0.014 | 1 | 0.759 |
FGFR2 |
0.793 | -0.116 | 3 | 0.759 |
ITK |
0.792 | -0.078 | -1 | 0.804 |
MERTK |
0.792 | -0.052 | 3 | 0.739 |
KIT |
0.792 | -0.131 | 3 | 0.750 |
PDGFRB |
0.792 | -0.150 | 3 | 0.760 |
NEK3 |
0.791 | -0.139 | 1 | 0.765 |
MET |
0.791 | -0.076 | 3 | 0.754 |
FLT3 |
0.791 | -0.129 | 3 | 0.755 |
STK33 |
0.791 | -0.229 | 2 | 0.618 |
TEC |
0.791 | -0.044 | -1 | 0.758 |
BMX |
0.790 | -0.046 | -1 | 0.737 |
AXL |
0.789 | -0.112 | 3 | 0.740 |
DDR2 |
0.788 | 0.039 | 3 | 0.688 |
ALK |
0.788 | -0.097 | 3 | 0.670 |
EPHA7 |
0.788 | -0.047 | 2 | 0.758 |
MYO3A |
0.788 | -0.037 | 1 | 0.806 |
WEE1_TYR |
0.788 | -0.071 | -1 | 0.738 |
FGFR1 |
0.788 | -0.148 | 3 | 0.729 |
ASK1 |
0.788 | -0.137 | 1 | 0.763 |
TAO1 |
0.787 | -0.049 | 1 | 0.743 |
NEK10_TYR |
0.787 | -0.125 | 1 | 0.692 |
LTK |
0.787 | -0.102 | 3 | 0.691 |
TEK |
0.786 | -0.187 | 3 | 0.697 |
FRK |
0.785 | -0.071 | -1 | 0.847 |
EPHA1 |
0.785 | -0.074 | 3 | 0.735 |
EPHA3 |
0.785 | -0.111 | 2 | 0.722 |
ALPHAK3 |
0.785 | -0.089 | -1 | 0.795 |
BTK |
0.784 | -0.193 | -1 | 0.763 |
FLT1 |
0.784 | -0.100 | -1 | 0.856 |
PDGFRA |
0.784 | -0.215 | 3 | 0.755 |
PTK2B |
0.784 | -0.028 | -1 | 0.792 |
LYN |
0.783 | -0.075 | 3 | 0.676 |
NTRK1 |
0.783 | -0.181 | -1 | 0.835 |
AAK1 |
0.783 | 0.196 | 1 | 0.730 |
SRC |
0.783 | -0.027 | -1 | 0.835 |
PTK6 |
0.783 | -0.203 | -1 | 0.744 |
FGFR3 |
0.783 | -0.137 | 3 | 0.734 |
ERBB2 |
0.782 | -0.165 | 1 | 0.798 |
INSR |
0.782 | -0.131 | 3 | 0.691 |
EPHA5 |
0.781 | -0.052 | 2 | 0.732 |
YANK3 |
0.780 | -0.099 | 2 | 0.379 |
PTK2 |
0.780 | 0.028 | -1 | 0.822 |
NTRK2 |
0.779 | -0.205 | 3 | 0.717 |
NTRK3 |
0.778 | -0.144 | -1 | 0.792 |
EPHA8 |
0.778 | -0.087 | -1 | 0.828 |
FLT4 |
0.777 | -0.199 | 3 | 0.702 |
EGFR |
0.776 | -0.073 | 1 | 0.703 |
MATK |
0.776 | -0.138 | -1 | 0.745 |
CK1A |
0.775 | -0.074 | -3 | 0.381 |
SYK |
0.775 | 0.001 | -1 | 0.808 |
CSK |
0.773 | -0.168 | 2 | 0.760 |
FGFR4 |
0.772 | -0.116 | -1 | 0.801 |
STLK3 |
0.771 | -0.234 | 1 | 0.755 |
IGF1R |
0.768 | -0.136 | 3 | 0.635 |
EPHA2 |
0.768 | -0.086 | -1 | 0.803 |
MUSK |
0.766 | -0.126 | 1 | 0.706 |
ERBB4 |
0.763 | -0.071 | 1 | 0.725 |
CK1G3 |
0.756 | -0.081 | -3 | 0.336 |
FES |
0.754 | -0.158 | -1 | 0.722 |
ZAP70 |
0.753 | -0.037 | -1 | 0.722 |
YANK2 |
0.742 | -0.154 | 2 | 0.398 |
CK1G2 |
0.738 | -0.086 | -3 | 0.431 |